var title_f8_8_8320="Sonogram abn ut bleeding2";
var content_f8_8_8320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long axis sonographic view of a patient with abnormal uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrial echo is not well visualized and there is an area of acoustic shadowing in the posterior portion of the myometrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8320=[""].join("\n");
var outline_f8_8_8320=null;
var title_f8_8_8321="Patient information: Choosing treatment for early-stage breast cancer (The Basics)";
var content_f8_8_8321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15988496\">",
"    <span class=\"h1\">",
"     What are the treatment choices for early-stage breast cancer?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only your doctor can tell you what your treatment choices are. That's because every woman and every cancer is different. But, in general, women with early-stage breast cancer need 2 types of treatment. They need treatment directly to the breast, which is called &ldquo;local treatment,&rdquo; and they need treatment to the whole body, which is called &ldquo;systemic treatment.&rdquo; Local treatment is surgery and radiation. Systemic treatment is chemotherapy, hormone therapy, or both.",
"   </p>",
"   <p>",
"    For surgery, women can often choose between these 2 options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mastectomy",
"      </strong>",
"      &ndash; Surgery to remove the whole breast. Most women who have a mastectomy can also have surgery to reconstruct the breast that is removed.",
"     </li>",
"     <li>",
"      <strong>",
"       Breast-conserving therapy (also called &ldquo;lumpectomy&rdquo;)",
"      </strong>",
"      &ndash; Surgery to remove the cancer and a section of healthy tissue",
"      <strong>",
"      </strong>",
"      around it (called a &ldquo;margin&rdquo;). Women who choose this option keep their breast. But they usually must have radiation therapy after surgery to kill any cancer cells that might still be in the breast area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the same time as they have lumpectomy or mastectomy, most women also have surgery to remove lymph nodes under the arm. Lymph nodes are bean-shaped organs that filter and trap cancer cells (",
"    <a class=\"graphic graphic_figure graphicRef86801 \" href=\"UTD.htm?40/2/40997\">",
"     figure 1",
"    </a>",
"    ). Depending on what kind of cancer a woman has and how far it has spread, she might also need systemic treatment with medicines that can slow or prevent the growth of cancer. This article will focus on the choice of surgery a woman has, not on systemic treatments or on lymph node surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988503\">",
"    <span class=\"h1\">",
"     Will my choice of surgery affect how long I live?",
"    </span>",
"    &nbsp;&mdash;&nbsp;No. Studies show that women who choose lumpectomy live just as long as those who choose mastectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988510\">",
"    <span class=\"h1\">",
"     Will my choice of surgery affect the chances that cancer will come back?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. Women who choose lumpectomy have a slightly higher chance of having their cancer come back. But if cancer comes back, it can usually be treated successfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988517\">",
"    <span class=\"h1\">",
"     Is lumpectomy always an option?",
"    </span>",
"    &nbsp;&mdash;&nbsp;No. Lumpectomy is not an option for some women. For example, lumpectomy is sometimes not an option for women who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have more than 1 tumor in different areas of the same breast",
"     </li>",
"     <li>",
"      Have cancer that has spread throughout the breast tissue and the surgeon can&rsquo;t get all the cancer out with a margin of normal tissue around it",
"     </li>",
"     <li>",
"      Cannot have radiation therapy, for example because they are pregnant or have certain forms of skin cancer",
"     </li>",
"     <li>",
"      Already had radiation to the area. (Radiation can only be given to an area of the body once.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988524\">",
"    <span class=\"h1\">",
"     How do I decide between the 2 surgery options?",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, make sure you understand all the facts about the different treatment options (",
"    <a class=\"graphic graphic_table graphicRef61056 \" href=\"UTD.htm?25/32/26124\">",
"     table 1",
"    </a>",
"    ). Ask your doctor any questions you might have. Then think about how you feel about these issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       The way you will look &ndash;",
"      </strong>",
"      Is it important to you to keep your own breast? How would you feel if your chest was flat and you had to wear a plastic breast in your bra? Ask to see pictures of women who have had the different kinds of surgery. Remember, women who choose mastectomy can have their breast reconstructed if they want (",
"      <a class=\"graphic graphic_figure graphicRef73172 \" href=\"UTD.htm?9/12/9412\">",
"       figure 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       The risk that cancer will come back",
"      </strong>",
"      &ndash; Women who choose lumpectomy live just as long as women who choose mastectomy. But women who choose lumpectomy have a slightly higher risk of cancer returning in the breast. Women whose cancer comes back after lumpectomy go on to have a mastectomy.",
"     </li>",
"     <li>",
"      <strong>",
"       The time involved and the side effects of radiation &ndash;",
"      </strong>",
"      After lumpectomy, most women must have radiation therapy. This usually involves getting treatments 5 days a week for 3 to 6 weeks, depending on the woman&rsquo;s age and other factors. This type of radiation will not make you sick or make your hair fall out. But it will tan and possibly even burn the skin on your chest. This burn is like a sunburn and goes away fairly quickly. Toward the end of treatment, radiation can make you feel a little tired, but this is not very common and usually doesn&rsquo;t last long.",
"     </li>",
"     <li>",
"      <strong>",
"       Recovery from surgery &nbsp;",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women who have lumpectomy go home from the hospital the same day as their surgery. For a week or 2 after surgery, they must rest and avoid sports, swimming and heavy lifting.",
"     </li>",
"     <li>",
"      Women who have mastectomy stay in the hospital for 1 to 2 days after surgery. If they also have breast reconstruction, they might stay a day or 2 longer. They go home with drains that must be emptied twice a day. After about 2 weeks, the surgeon takes the drains out in the office. If more fluid or blood builds up after the drains come out, the doctor will drain it with a needle in the office. During the draining process and for a few weeks more, women who have a mastectomy must rest and avoid sports, swimming, or heavy lifting. Even after they recover, women who have mastectomy will not have normal feeling in the chest. Women who have mastectomy can have the breast that was removed reconstructed right away or later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regardless of which surgery you have, you will probably need to have biopsies of your lymph nodes. This part of the surgery usually does not cause problems. But in some cases it can cause arm swelling, pain, or stiffness; shoulder pain or stiffness; or a nerve injury. If any of these happen to you, you might need to do special exercises or have physical therapy (work with an exercise expert) to get back to normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988531\">",
"    <span class=\"h1\">",
"     How do I work with my doctor to make a decision?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tell your doctor how you feel about the different treatment options. If there is something specific that worries you, tell your doctor about that, too. Then listen to what your doctor has to say about his or her experiences with women who had situations similar to yours. Together you can decide which treatment option is right for you. When you choose your treatment, you can find out more details about that option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15988644\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"     Patient information: Breast cancer (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"     Patient information: Breast reconstruction after mastectomy (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"     Patient information: Breast cancer screening (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"     Patient information: Common breast problems (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"     Patient information: Cancer screening (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"     Patient information: Breast biopsy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=see_link\">",
"     Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"     Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"     Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"     Patient information: Breast cancer screening (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"     Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"     Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"     Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16242 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-112.133.201.70-F3D586363C-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8321=[""].join("\n");
var outline_f8_8_8321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988496\">",
"      What are the treatment choices for early-stage breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988503\">",
"      Will my choice of surgery affect how long I live?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988510\">",
"      Will my choice of surgery affect the chances that cancer will come back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988517\">",
"      Is lumpectomy always an option?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988524\">",
"      How do I decide between the 2 surgery options?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988531\">",
"      How do I work with my doctor to make a decision?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15988644\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     FIGURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40997\" title=\"figure 1\">",
"      Lymphatic system female PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/12/9412\" title=\"figure 2\">",
"      Lumpectomy mastectomy PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     TABLES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/32/26124\" title=\"table 1\">",
"      Choosing between mastectomy and lumpectomy PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=related_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=related_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=related_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=related_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8322="X-linked ichthyosis";
var content_f8_8_8322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-linked ichthyosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    X-linked ichthyosis: legs, infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8322=[""].join("\n");
var outline_f8_8_8322=null;
var title_f8_8_8323="Schematic PSAX VSDs";
var content_f8_8_8323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic illustration of a parasternal short-axis echocardiographic view showing ventricular septal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 415px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGfAcIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqlq+q6foti97q99a2Non3prmVY0HpySBQBdorzWD4oSeIWdPh94a1PX48gLqMwFnYHnBIlk+ZtpzkKhPHFRHwf468SE/8Jf4xGl2bcGw8NRmHI7ZuHzJ9QAAaAO31/wAUaD4dVTr2tadpu4EqLq5SNnx12gnJ/CuQl+LOn3YX/hFtA8S+I1kyqT2OnOtuW9DNJtUfUZrV8NfDHwf4cmNxp+h2z3zMHa8u83E5b+9vkJIP0xXZUAeZjWfipqwDaf4W0DQYyeurag1y+PXbCMD6FqUeE/iJfMTqfxEis426w6ZpES4+jyFj+lel1DdXVvaIj3c8UCO6xK0rhQzsQFUZ7kkADuTQB52nwrmkbff+P/HVwx6iPUxAv5Ig/nV6P4YaYq4l1zxdN7ya/dc/k4rvKa7rGjPIwVFGWZjgAepoA4f/AIVjow+5qfihD6rr95/8cqvP8LLOT/U+KvG9uf8Apnr05/8AQia7yyu7e+tIrqyuIrm2lXdHLC4dHHqCOCKmoA80Hwuv4G3WXxG8boewnvY5x/49HQ3g74hW5/0D4mNIg6Je6LBJn6spU1uX3xI8KWupPp0eqfb79Ad9vptvLeumDghhCrbT7HFRJ8TfDKTQx6lcX2kGZtkbatp1xZRk4zjzJUVM/jQBkPF8XLEgQ3PgvVox1M0VxayH/vkstB8YeP7BwuqfDhrmNfvT6Zq0MoP0RwrV6UCGAKkEHkEd6WgDzqH4taXGrvrmgeLNDhT702oaNN5Y/wCBxhx+NbWj/EbwZrBjXT/FGjySyHCwtdokpPpsYhv0rq6xNe8J+HvEAP8Abmh6bqDEY33FsjsB7MRkfhQBtKwZQykFT0IOc0teZn4NaDZMH8K6jr/hhgd23S9RdYmb1aN9yn6YFOh0r4o6JKgs/EGg+JLQHLLqlq1nPj0Dw7lJ9ytAHpVFebTfEy80NU/4TXwZrukR8mS8tVW/tI1H8TPEdyj6oDXV+FfGPh3xbb+d4c1my1ABdzJFIPMQf7SH5l/ECgDeooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKgvry20+0lu7+4htrWFd0k0zhEQepY8AUAT1leJPEOkeGdLk1HX9Qt7CzTrJM2Mn0UdWPsMk1wl34613xbO1l8L9PjmtMlZfEWoKyWcZBwfJX7054IyPlBxkkGtXw18M9K0+9j1XxBPceJvEIO7+0dUIk8psg/uY/uQqG5AUZGcZoAyYfFvjHxo4XwVoo0XR3BH9ta5EQ7gj70NsCCexBcgH0q9pnwo0Y6kuq+K7m98WasOVm1dhJFCT1EUAAjQEgHGDj1rs9a1vStCthca3qdlp0BOBJdTrEpPoCxGTXF3/jvWLydbvwj4avNV0K0/eXlzKjQSXKHjFmr481h97JwpAwpJYEAHoagKAFAAHAA7VXudQtLW6tLa5uYori7dkt43YBpWVSxCjvhQT+FcxH8TPBnlk3XiPTbCZfv21/MLWeM+jRSbXU/UVz91YRfE/xTY3F3ptyvhHSElaKS6R4Gv7mRQoeNSA4jjUsRJxlmG3O3NAHqFFcRc/DfTpZAYdc8XWyD/lnD4gu9v8A49ITU3/CudBkhWO+l1vUFHUXutXkyn6q0u0/lQBf8SeNPD3hxhFquqW6XbHEdnGfNuJSegSJcuxPsK5iXRb34k3MEvi7R/7P8K2zGa20u6wbi7kKsoknAyI1UOSqA7t2CSMAV2WieGdC0FnbRNG03T3f772tskbP/vFRk/jWvQBxVp4Cl07fHpPjDxVZWh+5bG5huljGMYVriKRwPbdUQ+GWkXchfxJqGt+JB5glEWq3peAEdP3CBIiPYoa7qigDiF+H8el3c1x4O1i/8OrMd0llbLHLZs3dhDIpCE9/LK5xzTbvwFPre2Pxd4l1TVrEHLafEEs7aXjpIIwHcd9pcr6g13NFAFXS9NsdJso7PS7O2srSLhILeJY0XvwoAAqW7toLy1ltryGKe3lUpJFKoZHU8EEHgg+lS0UAcIvgi98OGWX4f6p/Z0TZP9kXwaewzkk7FyHhyWP3Dt/2DTU+Ig0j9z460e90GZet0sbXVi/us6D5fo4U13tFAHBT/FXw1OjReG7iXxHqTDEVnpcTTFmPTc4GyMerMQAKrWeo+PtARbzxDp1vr1nc5llt9JULc6eT0jUMQJ0AwM5D5zwRjHoqqFGFAA9qWgDh1+J/h4J+/h163n7wS6HeeYD6YERH5Gom8W+I9bHleE/Ct3Arcf2hrw+ywp/tCHPmv9MJ9RXe0UAcG2veM9CYnxB4dg1izH/L3oDnzAPVraU7v++Hc+1ZUmjfDT4m3ckq21qdcgbc7Rh7HUIGA4LgbZOMjG4EV6jWL4h8LaH4i2NrGm29xNH/AKq427J4ec5jlXDofdSKAOP/AOEX8deGoMeE/Faa3bouFsvE0fmv1ySLmPa+eoG4MBTbT4rwabdR2XxB0S/8J3bnYs9ziaykb0W4T5f++sYqbTtWu/A2s3ekeILnWNS0EwxT6fqctlLcvESXEkM80anO3ajB3AOHwScZrorLxT4R8Tq2nWmtaHqvngq1otzFMXHcGPJJ+hFAG/aXMF5bR3FpPFPbyDcksThlYeoI4IqWvN9S+F0NjO998PtWuvCV+WLtDajzLGY/7ds3yewK7cZPWoLb4hax4YlFp8TtEawjXAGuaarz6e4JwC/G+E5IHzjHU5AoA9Poqvp19aalZRXmnXUF3aSjdHPBIJEceoYcGrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTZHWONnkZURQWZmOAAOpJryu78Xa58QL+fTPhpNHZ6NA/lXniaWPzE3A/NHaoeJG/2z8oGcfwkgHReNviDYeHLyLSLC2m1rxPcj/RtIsyPMb0aRukSerN2ycHFYtt8P9S8V38Wp/FC8hv4oyJLbw/agixtnHQvk5nfHdvlGWABBGOr8GeDNG8I28y6VA73lyd93f3DmW5u37vJIeSScnAwAScAVoeINd0/w/awXGqz+Uk9xHawqFLtLLI21UVQCSSfTsCegNAGjFGkMSRxIqRoAqqowFA6ACsP4gLI3gPxIsEzwSnTbkJLGxVo28psMCOhHXNb1cb8Wbzy/Bl3pcJzf66f7ItEGcmScFC3A6IheQn0Q0AVPhz4K8L2mhaLrFnoFimoz2kVwbqSPzZgzoCf3j5bue9d7UNjaxWVlb2luu2CCNYo19FUYA/IVNQA1o0ZgzIpYdCRzTqKKACiiigAooooAKKKKACiisvVdag025hgkhuJZZRlREobPOMdaANSisqx1y2u737IYri3uMZCTptJ7+tSaXq8GozXEUSSxyQHDrIAD3HYn0oA0aKzrLV4LzUbizgSUvBne5A28HHXP9K0aACiiigAooooAKKKKACsfXfDGheIECa5o2n6gF+6bm3SQr9CRkfhWxRQBwX/AAro6VH/AMUX4j1nQCqlUtzMb20HOf8AUz7sD/cZKkuta8W6Eu3W/D8OvWHIkvNFO2Xb72khJPvskc+1dzRQB4zovhzSLu4n1z4L+ILfSL0Nm80l1Y2Urf3ZrY4eBug3KAQM8c103hv4jLLraeHvGWmSeG/EL58iKaQPbXgBxmCbgMeR8pwwzjnBrd8R+DNH127jv5oZLTV4lIh1Oycw3MXGOHH3h/stuU9wa4nxXFc2OlyaX8UrCHxN4Sdiw1mC3KzWpAyGuIk5XGWHnRYA7quc0Aes0V4/DquufDuCC8W5n8X/AA7kjEiX0bCa906PH3iV/wBfCBzu+8ATnIUZ9U0bVLHW9LttS0m6iu7G5QSRTRnKsD/np1HegC5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk+KPEOleFtGm1XXbxLSxiwC7AkkngKqjJYn0AJrO8e+NdM8F6bFPf8Am3F7dP5Nlp9su+4vJeyRqOTyRk9BkeoB57wz4K1LVtftvFnxDljuNWh+aw0mI7rXS8+n/PSXGMueh6dAaAM2LQ9b+KN2l54xtbnRvB0bB7XQmfbPfdxJd7T8qjgiId+vTn1W1t4bS2itrSGOC3iUJHFGoVUUDAAA4AHpUtc34r8ZaZ4auILO5jv7zU7mJ5baxsLSS4mmCEA42jCjLAZYqOetAGTd+ONSPiXxBoujeFL3VZtK8hRNFdwRRM0kYcB/MZWXGeqq/wBOgrKvfh1qviYNq/irWFi8SxMkml/YlLWuksjq42K2PNZio3u2Cy/KAorpfh7o17p1jqGo60ix6zrN21/dRKwYW+VVI4dw4bYiIpPQkMR1rqqAODTWfiFbeXa3HhLSL2fGGvbfVzFAT6lGjLr9Bu+pq34X8K3kesHxF4svItQ8QNEYoVhUrbWEbctHAp5JOBukb5mwOg4rsaKACiiigAooooAKKKKACiiigAooooAK5HxT5v8AwkmlfZ9nncbPMztzu747V11VbjT7W5u4bmaLdPD9xtxGOc9AcUAcxpEjXfiuR9WKx3sK7Y41XCng9CfY5pusStoPiWS8RcxXMTHH+1j/ABAP41011pdndXUdzPDmePG11YqRjp0NO1HTbTUVRbyLzAhJX5iMfkaAMjwTaGHS2uZMmW5beSeuB0/qfxroqZDEkMSRRLtjRQqgdgKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwGq+GNT8NX9xrXgBIj5zebfaC7CO3vG7vEekMxHf7rYG4fxVytrZSxXVz4y+EzNvacjXPC9x+6Eso/1gCn/U3I/wC+W4PI+97TXF+LfDN3Hqw8U+EisPiGFAtxbk7YtUiXpDL2Df3JOqk85XigDV8GeLdJ8YaW17o8zkxuYri2mQxzW0o6xyIeVYfl6Ejmt+vI7izbXynxB+Gqrb+JYgbfUtLuR5QvdnD2s4/5ZzKfuufbOVII7nwF4usfGegjULFJbeaORre7s51Ky2k6/ficHoRQB0dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyPxC8aw+E7a1t7a1l1PX9RYxadpkH37hx1JP8ACi5yzHgCrHj/AMVx+FNGSaK2e+1W7kFrp1hGcPdTt91c9lHVmPAAPtWb8N/BtxojXeueJLhdQ8XaoAb26/ghUcrbwj+GNf8Ax4jJ7AAEXgXwPLZ6ifFHi+WPU/Gdwm17gZ8mzjPSC3U8KoHBb7zEsSeTXe0EgAknAHJNcJpHxN03WNPtbrTNF8T3H2lBJEg0iZQynoRKwEWCMEHfjB60Ad3XD6B5Ws/FDxDq8DiSDSrWLREYEEedkzTgY9A8Cn3Vh2qK9vvHHiAPZ6Xo6eF7aQbX1HULiKe4RT1MUMRZd3oXfA9D0rqfDOh2XhvQ7XStMR1trdSA0jbndiSWd27szEsT3JNAGpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAef8AjS1k8I6rJ420a2aSEhV161izme3UYFwq95Yhz/tJuHULjP8AG2mXunXsXxE+H4W8uHhRtSsICCmr2gGVZcdZVU5RhyRxyOD6hXn/AITEXgzxbceEjmPStQ8zUNFBwFj5zPar/uk+Yo/uyED7lAHXeG9asfEehWOsaTMJrG8iEsT98HqCOxByCOxBFaVeSahn4V+OJdVBYeCPENx/pw/h02+c4E3tHIcBuwbByBgV63QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2R0ijaSRlRFBZmY4AA6kmnV5t8ar25vbPR/BelTNFf+J7k2skifeis0G64cf8A+X/gVAFT4b20vjjxLL8RdVjkSzCvaeHrSQf6m2zh7gg9HlIPYYXAywINeqVDZWsFjZwWlnEkNtBGsUUSDCoijAUD0AAFc78Q/CEXjTQJNOk1LUNOfkxzWk7IM+kiA7ZF9Vb8COtAGH4t1eTxjd3fg3wxM5jYeTrOqQ4KWUR+9CjdGmdSVwPuA7jyAD6BbwxW1vFBbxrHDEoREUYCqBgAD0xXKfCueP/hFF0/+z7LTbzS55LC8tLFNkKSoc7kHo6skg74cZJOa6+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimLLG0jIsiM6/eUHJH1FAD6KKKACiiigAooooAKKKKACiiigAorjdY1HxJc+L9R0vQbrS7aCx022vCLnT3uZJnlkuF2qRcRKoAgGM92PIrlPh/4x8W+N59VjsLqws10y4e0uJLzQcKJ1I3RjZqLEkZznG33oA9dorF8EarPr3gvQNXvEiS51DT7e7lWIEIHkjViFBJOMk4yTW1QAUUUUAFFFFABXI/FDRJ9X8LST6ZIkGtaXIupadM7bVWeLJCscj5HXcjZONrmuuryldOh+KXjDXf7VuZLjwdoVyNMj0tZHSO7vY9rzSzABSyozIiqSykozd+QBk3xP8HeNfCD2Zs9V1kahZqLrT9P06a5aIyICULquwMpP94YIzWR8PvifeeH9AttK8f6D4rtjZb4V1qfS5GimhX/VvLt3MrlcAj5uRndycdRP46itb+68NfDvwvPrlxpeIJhatHaWFowIBiMzcb1BBKIrEdOoONKXWPHlmEluPCek3sOfnj0/WCZlHsJYY1Y+24UAdF4e8Q6P4jsReaDqdpqFsQMvbyh9uezAcqfY4NaleZWVv4P8b6tNLb2174f8X2ybpQqtYahCD/EwHEqe53pzV6z8Sar4U1O30nx1IlxZ3LCOy8QRxiOOVz0iuEHEUnow+R+20/LQB39FFFABRRRQAUUUUAFFFFABRRRQAV5h4NH/AAkfxh8XeIW+e10eOPQLJu28fvLg/UMVXPoK9MmlSCGSWVgkcalmY9AByTXB/AyCT/hXNlqdygS81qafV58DALXEjSD/AMdKj8KAO/qjrmrWGhaTdapq9ylrYWqeZNM+cKPw5P0HWr1Iyh1KsAVIwQRwaAON+F0jalpmq+IiuyHX79r+3jJGVhEccMZbBIyywq5Hbfg8g12dcD4Ehj0rx/410TTyiaXGLO/ito1CpbSzrIJVUDoGMSvj1dj3rvqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqO5nitbeW4uZFigiQvJI5wFUDJJPoBUlc78R7d7r4eeKLeI4kl0u6jUj1MLAUAcGv9ofEiM3+rXFzZeE5vmstMt5Ghe7iI+WW4dSGwwORECABjdk9J7r4c+F3t0Ww0m30m6j+aG90xBbXELY+8siAHP1yD3BrS0XU/tHg3TdTs7KW4E1lDPHawFA5DIpCrvZV6HuR0rnvDnxQ0bW/Cd/4mNrqFholnnfc3ax/OQcFVVHZs5I6gZyMZr8TxmZZpjq8sRGTXLKySezb0SV93+NmenGEIqx03hPxZeWOpQ+HPGci/2lIxSw1MIEi1IAZxgcRzAdU4BxleMgegV4xc63pvjHS7Ox1XQNbtdP1YqbO7mjjA3YLpIrRuzRMMAqWCnOPcVv6B44m0KaHRfiBItvcA+Xa62Rstb4Y43t0hlwOUY4J+6TnA/Qsgz94tLDYy0ay9LS9Ol+6/4ZcdWly+9HY9IopFIZQVIIPII70tfVGAUUUUAFFFFABRRRQByVm7R/E7xK6RtKy6JppCJgMx86/4GSBk+5ArlPgRoeveH5/F0ev6Hdacmp6vPqdvJJPbyKUcjCHy5GIfjnjHvW98Tf8AhCNPtl1Xxjo2kajdhPKgW5s4p5pACTsUsCQAWJ9Bn3qHwp4M8Ga34c0/U5vA/hmB7uITeWumQEKDyBnZzxio9pFy5L6nQ8JWjQWIcbQbsn3fka3wn/5JZ4N/7Atl/wCiErqqitLaCztIbWzhigtoUWOKKJAqRoBgKoHAAAAAFS1ZzhRRRQAUUUUAFeL/AAp1y/0/9mOXXjKJtUt7PVL4ySDcHmWa4fJ9csK9orxzwrpRHwT8ceDtJsrlJ9Lk1fSYIphgybzJLCRnqGjniwT1zQB3nwv0c+H/AIdeGtLltVtLi30+FbiFcfLMUBlJxwSXLEnuSTXT1j+DdT/tvwhoeqlChvrCC62E52741bH61sUAYPi/wrp3iqwSG/WSK5gbzLS9t22XFpJ2eJ+qngcdD0II4rG8ManLqQv/AAd43S1udaggPnfutsOpWrHaJ1Q8c52uv8LZ7Fc9vXHfEzR7q60221zRIy3iDQna9s1Uczrj97bng8SJlf8Ae2ntQBS8GXl34a1w+DNbuJLiPY02iX0xy1zbrjdC57yxZHP8SkHqGrvq4fxyG17wLa+IvDWJ7+xWPWdMYA5l2ruMfHOJIy8Z/wB/2rq9F1K31nRrDU7Fi1rewJcxEjBKOoZcj6EUAXaKKKACiiigAooooAKKKKAOS+Ld4LD4XeLbgtsK6XcqpHZmjZV/UitDwHYPpXgfw7p8n+stNOt7dvqkSqf5VyH7Skhi+CPill6mKJfwM0YP869KiGIkHooFADqr6he22nWNxe388dvaW6NLLLI21UUDJJPpijUb2202wub6+mSC0to2mmlc8IijJJ+gFec2E4+LZtL9Q0fgWCYyRxSEb9VkRvlZ1/hhVhkK2GYgblAAyAbXwwt5Lmx1PxNd2z2954hujeeVKm144FURwKffy0VyOxdq7SiigAooooAKKKKACiiigAoor5p+NninUfDmuand2n2+9eTXVshbjVr6BEhXT7SUrGkE8aglpHOSDy1AH0tRXyR4i8dwX/ifVNO8JXOtDRF0O7u7fUX13Uml+0R2bT/Lm42YUlAQVPINfW9ABRRRQAUUUUAFcX8VNdt9O8K3+mQzI+uarbSWmnWakGWWV1KBgvXYpYFm6KASaf8AEzx1p/gfRVnuZrX+0blxBZ2886xK8jcBnYn5Y16s3YD1IB5T4dQaVdw3euW+q2+vazcuYr7U4nDguMExR/3I1yNqjjGCcnmvBz/O45RQ51Hmk9u3q32/M1pUvaOxvWUVv4b8NWlvid7bT7aOACGF5nKooUYRAWY8dADXi3wn0qWP4J6noHiDwzrFxKbgtPp72slvI8Tug3Rs4VWZQC+Ac/KOmRXv1Y+v+J9D8PIp1zVrKxLKWVJ5lV3A/ur1b8BX5Fg8bUjGVKEXKUpRlpe9437a9Xs77WPQlFbs8c8IeHtZ0Xx3oMXgq/8AFknhsBjqVvrcMkUMCY+VEEiqGbqPkBxhecGvdbu2gvLaS2vIYp7eVdrxSoHVx6EHgiuW/wCE7guFibR/D/ijVo5RlZLbSZUjI9d8oRf1rRTV9cdQy+BvEWD/AHpbFT+Rua9PF5dm2PlGr9Xkmla9rN63u9rvzttb1IjOnDS5UtPBdnpSt/wjGoaroG4lvLsbnMIJOTiCUPEPwUVLDF47spXNv4r06/i/hTUtIG4f8ChkjH/jtR33ifVLAA3XgfxWF7mGG3uMfhFMx/So4PiF4bN2LS+v20m9Khvs+rQSWT89MCULn8M10RxPEmXxu+e3mub807C5aM+xai1v4jW82Z9P8J30PpFc3Fsx/NJBUyeP9ctPNOteBdUWNBkSaZdQXgP/AAEtG/5Ka21IYAggg9CKWnR44zKm/f5Zeq/yaB4WD2K1n8SvCsxVb3Ujo8zKD5WsQvYNz2HnBQx/3Sa6+GWOeJJYXSSJxuV0OQw9QRXKXMEN1A8NzFHNC4w0cihlYehB61yp8DWmnzPc+Er698N3ZJfFg/8Aozt/t27ZjI+gB9xX0GC48oTfLi6bj5rVfdo/zMZYRr4WesVm+IJ9Sg0uVtEtIru/PEaSybEB9WPXA9B19utcHJ4+1bwjaed4/soJdMRgraxpQZkjBIAaaBvnTOeqGQZ9Kl+LPjSfTYYPD/h0PL4h1IBIwnDQq3G72Y9vTk9ufsaWYYfE0Pb0J80fLv29fU0wGDq4nExowim99drLdvyXU+evGs+sX3iHUJtbuftt1BJ5Ussbbo4zzhFI4AGCMD0NfXfhe2+xeGdJtcY8i0hix/uoB/SuT8M/DbTdP8CTaBfos0t6u+8mX7xk6gqfRT0/Pua74AAADgClg8NKk3OW7Pd4jzujmFOnh6CtGm2trJqySaXTrp2sLRRRXefJhRRRQAUUUUAFcDDKdA+Mdxav8lj4osRcRFp2Ob22ASQKhGAWgaI5BHEB4PWu+rk/iZoN5rnhoPoxVde0udNS0wsSFNxFkhGwy5WRS8ZycASE9qAK/wAJp9nhq50VxOsmgX9xpIWaPYwhjfNv2G4G3aA7u+c812leVWOsW8HirSfG2nwyw6H4njj0rU4ZLcpNa3sbskDSgKSCHL27ZIAby+SBXqtABRRRQBwfwp/4lkOu+FJOP7Cv3jt1P/PpL+9h/ABmT/tmaX4QD7Bo2reHigj/ALC1W5s4k3ZIgZvOh/Dy5UA/3aXVo30j4taHqMat9m1yzl0ufA4E0QaeFj/wEXA/KpbCGPSvi3qowFGu6ZDcrj+KS2cxyE++yaAf8B9qAO1ooooAKKKKACiiigAoopP4j9KAPNf2kYWn+CXilFGSIY3/AAWZGP8AKvSIG3QxsOhUGuY+K9p9u+GPiy22F2fSrnaoGSWETFf1Aq38Pb19T8A+Gr6X/WXWmW0zfVolJ/nQBv15x4t0+38E6vZ+K9Chis4Lm8htNZt4l2x3Mc0gjWYqOPMR3B3DkqWBzxj0evNfjTqLRwaJp1xY37aJLeR3mq31vavNHbW9u6y4bYCRuZVGeyhiaAPSqKjt5ormCKe3kSWGVQ6SIcqykZBB7gipKACisTxHZubW5vI729heOIkJFLtTI9qpeG7KW90uK7l1G/Mrh12+eSo6rnHX369aAOoork9A1aW307U0v5GkuLMk5kYkntjn3H61e8Gi5k01rm8nllaZsr5jk4UccZ6c5/SgDeooooAK8M8XaHa3/j+4uNW/tq3TTvEUOqxLB4fu76K8iFjaIVEkSFR80bqevQ8V7nRQB81+LvB/hqK1e48G2XiK0Sz0XUrK30tfDWpN9oluYZFB850+X5nHXI9wOntXxF1jWvD+hHVNEtLa8jtiWuoZQ27y/wC8pB7d8g8c9ueqpGUOpVwGUjBBGQRUzi5RaTsb4arGjVjOcVJLdPqux4lpnx9s3wNU0O4i9Wt5lk/HDBf516t4X16HxHpy31raX1tC2Cv2uHyyw9RzyPfpXims/CID4iCztZpbTSb6KSe1njXd5Ei8+Wfp1HTjvkGt1dW+IXgIBNZsx4k0dP8Al5hJMqL7nG7/AL6B+tedRrV4N+32XkfY5llmV4qEP7LaU5JOzk1ddlfS9001dHs1UNe1az0HRb7VdTlEVlZwtPK/oqjJx6nsB3Nct4X+KHhfxAFSO/Flcn/lheYjOfZs7T+Bz7V5/wDtU61v0XSPDNtcPG9/Kby48sjmGL7oI7gyMjDsfLNevg4fXKkaVF3cnY+OxeFr4OThiIOL81Y8N8ReJJ/Gnim+1nWEVdQkwI7dhn7NAPuRrnsMkkjqxY10/wAJfFb+F/Fk9kLW6votYixHa2qb5WuYx8pUZwAykgk8DapJABNefWmn6jrWqWmj29pJPrk77LKW3GN57kn+EAcsDxgE19d+CfCHh74UeF5NR1OaFtS8sfbtTkXMkrHH7uMYyFLYCxryTjgk19JxPDA1sseTVYXTt5NWd7v+9+DTvszhoOSn7RMSz8K+JvEcG/xRqbaFaudy6do0mJgODtluSM59REF/3jVaxvPBvhLUrjTvAfh3+2vEK5E401BLKjEk4uLuQ4XJB4dy3savwabrvjxxc+Ixd6F4aIzDo8UpiuroHvdOpyikf8sVPf5icYruNJ0uw0exjstJsraxtI/uQ20SxoueuAABXxeDy/DYGHJhoKK8v1e7+Z0ynKTvJnKwWvjvV1dr/UdJ8O27/dhsITeXKD3mkxHn/tkR71FJ8OFuZ2m1Dxf4yunPYaqbZR9FgWMfpXd1TbU7BWKtfWoYHBBlXIP512EnIw/Do2k/m6d4x8Y2zf3X1IXS/wDfM6SCmatovjGOxa1jvtC8T2LcSWutWfkySr3BkjzH/wCQfrXdxyJKgeJ1dG5DKcg06gDwiC18P6XqMULLrfw01WVzshZ1k0u4kbsud0B+70Xy354xXQX2t674UYt40sIZNKyca1pSO0KD/ptCcvEP9oFl9SK9QvbS2v7SW1vreG5tZlKSQzIHR1PUFTwR9a4e68I6p4aZrv4f3QWAD95oN9KzWci5yRCeTbt1xjKc8r3rxsyyDA5kn7aHvfzLR/f1+dzSFWUNmaFpdW97axXNnPFcW8q7o5YnDq49QRwRUjssaM7sFVQSWJwAK4C0tRLe3Fz4Eh/sHxHEplv/AAjqGIYrkA4MkYHCkngTR5RjjdznGT4s8VDWbIpfWeoaZ4ftto1OG5jMM15PjIsEz/D3kcZG3gE7q/OMXwbi6GJjSi7039rsvNd+3c9HDzeIkqdNXk9Eu7I9f8Vw3pg8R3kSyaNazFtAsXHzajcrx9scdRChzsHVj8393F/R4LjwXbL4g1m3Oq/EDXnZbCwdgGXI5LH+BVXlm6KuF6nmDQLVbCBfH/jW3Mlw5SHRNHgTlmx+6SKP6A7R0ABc+o67wtpF6Lq417xK0U3iO+AEhTlLSHqttEeyL1J/iYkntj6jF4vD8PYOKgve+xHv3lL+vJeXp4qpHCU5YHDu8n/Ekv8A0iPkuvd+R1ngrxVbeKLCZlhkstStH8m+0+cjzbWTGcHHVSOVYcMOR3A6KvLfFmlXsN1D4k8Moo8Q2K/6sNsW/g6tbyHuDyVJ+62CMZOe80nxDpeqeGodftryJdKkgNybiVgixoBli5P3duCGz0IOele5kOd083w/tFpNaSXZ915Pp9x85VpOm7GtRXncXxC1XXVjl8D+DtR1WwdhjUNQmXTbeRCgYPHvBldTnGRGB71KPFHjq3voVvfh4JbNgTJNp2twzOn/AACVYs/99V7hkd/RWD4d8WaRr80ltZXEkWoRIHlsLyF7a6iXj5mhkAfb8wG7G0noTW9QAUUUUAFFFFAHkvxD8PWWgw67dXGnNdeC/EGf+EgggTc9jKRgX8aYIOMKZMAsCiyDO1s9V8N9evNSsb3SdflifxJokwtL8ptAnBG6K4CqTtWVCGxxht64G3Fde6LIjI6hkYYKkZBHpXg/irT774W69a67bRi58PWpKwXROJLO2PMmnSnIDQn71ux+5KFjPyvkgHvNFUNB1jT9f0e11TR7qO7sLpN8UydCOhBB5BBBBBwQQQQCCKv0AcZ8Xo54/A13qlkiveaLJFq0IYkZ8hxI68f3oxIv/AqpePbmKK78FeLbJzLa29+kEkiN8jWt4oi3H1HmGBvwrvpY0lieOVQ8bgqykZBB6ivLfC2jNrvwm17wRdu5utLe50VJJ+qhPmtZOPSNoGB9qAPVKK574fa6fEvgrR9WkAFxcW6/aEH/ACzmX5ZU/wCAuGH4V0NABRRRQAUUUUAFIPvn6ClqOWRYlkkc4VF3E+wzSA868d6rq/iXxDL4F8JTizkECzazq2Axs4HyFijH/PZwCRnG1eRyQQ74Yw/8IZqNz4AuJZZLe2Q3mjTTHLTWjH54ycDLxyEg/wCyyGsz4Qata6X8L73xv4juDbtrd3Nqt075YoHfy4o0A5YbVjCqMkk4HWptZ1i38a3Fpa2Vrqnh3xhYlr/RTq9oYROVGHUEE7o2VtrpkMAc44pgeqVzHxJ1lNE8H38gTz7y6T7HZWwxuuLiQFY41HfJOT6KGPQGrXgzxLa+KtDS/tkeCZHaC6tJP9Zazrw8Tjsyn8xgjgiuc8TeEfEMni+XxL4f1XS57xLZYbS01q0kmitG5EhhaORdm8Y3Eq7fLjO04AB1XhLS20Pwro2kyOJHsbKG1Zx0YogUn9K1q4mbWvHVj9mNz4P02/jJAmOma1mRR3KpPDEp+m/8aNU8c6hplq1xc+AfF7xr1FslncP/AN8R3DMfwFAHVaxDJcaVdQwrukeMqozjJxVfwzazWWjQQXKbJVLZXIOMsT2rn7P4jadPAskui+LbZz1jl8O3pYfXbGw/Wnv8QtLUnGleKm+nh2+/rFQAniPQL241WSWwjzDcKPMO8AA55yCfYGuttYUtraKCMYSNQo+grnX8U3jxJJY+E/EV3G2eQtvAV+qzTI3f0qM+KdYxx4E8SfjPp/8A8lUAdXRXmWp/EjVbO6Fq/h6ytdQPI0261Qy3zrjO9YLOG4YpwfmOMYOexNbwb8S9VfxLeaJ4/wBGXQ53kjaynXPkhZVDRwysSQJD8yh8hHdJEGGT5gD1aiivDv2rdR12y8NeG4fDGp32n397qqWwa0uXgZ9yMApKkcZxQB7jRXyR8RPilrfiK58Az6BqV9Y20X2RdW+yzvDuup2IMLhSM4EDnB/vV2PxB8QeItA+JGs3XjDTPF934OSFRp0vh2eSKOAYBZ5fLdNzbuP3jY64BGKAPoUgEjI6dKWuC8HeKPP8EaNf6Bb654utLoSkXitbRzLiQ/LKJZY/mHK/KD9wnjIz076reLrbWI0DU2tQMjURJbeQfk3YwZfN6/L9zr7fNQBleJvh94a8Rln1DTIluG5+0QfupM+pI+9+Oa+dfFvgvwtc65e6Lb+KbP7XYSfZlh1hTCFIAbbHcfdBy3QbSTmvpSDX9Sksbqd/COuRSwlAlu8tkZJ9xOShFwVG3GTuZeoxnmvh/wAR6jd3Wr6/qP2VpYtS1C6lSJlDSRu8zBUYAkMOg4J/EV04DK6OMqSc248sW+ZdLW3t0/rY9KjnmMwsFTUuaH8skpL7ne3ysfTnwL+G48ERarrmuMq3syiOJpZllW3t1BZmWTJwrZBOT0QV0Phmwl8b6zbeL9bBOkQN5mgaew+VV7XkgPWRxyg/gQj+JiRm65oaad4V8GfDWyciK/UW97JGNpa0gQPcHjoZGKof+upr1SKNIYkjiRUjQBVVRgKB0AFczcnrJtvuzirVFVqOaio36LRL0HUUUUGQV55p1zZ2txqz31i10vmYVhGGCHLdSfu54/KvQ6xtM0KO0OoCaUTx3h+ZCm3A59/f9KAIPBNrJb6QXkcFZn3ooOcDGPz4roKydC0mTSRLGLszW7HKxsmCp+uf6VrUAFFFFAGB4u8Kab4oggF6JoL21YvZ39q/l3Fq5GC0bjpnuDlT3Brn9EuptSbUfC/jixttT1XSI4rxZo4hsv4iW8uZUP3JCY2Vk6Z6EqcDtdU1Gz0nT577U7qG0s4F3yzTOFRB6kmuK8Du1/rOqeMtVK2cWr+TZaXDOdjfZELGNiDgh5XkZtvUAoOuaTSasyozlBqUXZo5/wAGyv4v1J/GWqN+9HmWun2ByP7NjDbXV1PSdivzntgKDjr21c14ls4/CHje31aBvK0nxFOLW8iz8sd7t/dTAdBvCmNvVvL9Sa6Wvxbi3D4ijmU3XlzKWsX5dF8tvx6no4dpw0CvLE0jUbv4k3HgQLA/gy/dfEV4h5dQH+a3GQRsknVHIwMqZADzXqdYHgZjL8V/GTSnLQWGnRReyE3DH/x4n8q7OB5zWYuMXo4u/nt+pGKtyG54n8XT6frtvoGg6NPrOuTRLcNGJVgt7WEyBPMnlOSoPzkBVdj5ZGO9YlrL8XF1bzLq08BSaZvY/Z47q7SbbztHmmNlyOMnZzg8DPFz4epG3i/4h3EscQ1BtXiid1XDGFbOAxA+w3Ofqxru6/XjzzzKfUdK8aX1no+v2t/4T8a2h86xLmMTo2xWka0n+ZJoyMq6jqqsHQVq+FPE+oWuujwn41EUevbGksb6Jdlvq8K9XjH8Eyj/AFkWTj7y5U8b3i7w1p3ivRzp+qpJtWRZ4J4XMc1rMvKTROOUdT0I9wcgkHiNZsbrXLk+CfHTAtP/AKXoWv2ZWGUyw4Ocf8s7pOXygCuu/AUBlAB6jRXI/DvxHe6xaX+m+IIoLfxLo0wtdRihcMjkqGjnjGciORSCNwBBDLj5TXXUAFFFFABUV3bQXtrNa3kMU9tMhjlilUMkiEYKsDwQQcEGpaKAMrwv4e0vwrodvo+g2otNOtyxihDs+3cxZuWJJ5Ynk1q0UUAFcTaRRaN8XL5QAq+ItOS4XHea1bY5PuY5ofwjPpXbVwfxbA02w0fxUgAfw/fx3EzbST9lk/czjj0STf8A9sxQBL4HRdG8V+LPD7SMQ10NZtVZgcQ3Od4A7YnjnP8AwMetdvXA+P2GheJ/DXi2M4t45f7J1Bu32e4ZQjk+iTCP8Hau+oAKKKKACiiigArP16F7jRdTgiOJJLWRF+pVgK0KTHJPqMUAeHeHLm0l+FXwevLhVbS7e+tFuCVyiOIJoo2bsAJzHyejYrt/isFU+EJ4uL1PENmsDD72GJWUD2MRkz7CsP4WaRZf2H4t+HutW8FxaaVqE0SWr5IayuP30J/8ecZHQpweK2V8H6Z4X3eIdV1jW9Ug0SCW4to9QuhKloojO5lAUFm2ZG5yxwTzQBV8PPaz/Evxl4mjmhsdH0+3TTLqXzQkVzPGBJLNLzjMSlYwx5HzgnAAEmn674s8bwNeeFRY6D4dkVxa6jqVs9xc3i/Lsmjt9yCOM/OQXZiw2nYAawtY0SXSv2e44NZhnuWAg1PW41O2SVGuUuLxeCP4TKOo44r2BGV0VkOVYZB9RQB55a+F/iHbyBm+I1rcr3W48PRYP/fEq1qyWfj0EeVr3hhh33aJOv8A7dmuvooA4e5h+JStttr3wfIvHzyWdyhPqdolP5Zqxa2fj9oybrXfC0T56R6LcOMfU3S/yrsKKAOKj8N+MLnUZZ9T8dyQ2xQKltpGkwQBW7sWn89jn0yKdB8PNNZJBrGqeItaaWQvJ9u1WYRSAnOxoImSEp227MEcEGuzooAoaLoul6Fata6Jptlp1szFzFaQLChY8E7VAGeBz7VgeOvCI14w6jpzQw61ao0Smdd0F5bt/rLS5XB3QuPYlDhgDghuuooA8i8L6jq2ngDwxbXLGGRBqHg3U5gLqxjH7tnspnYKYsgFQxMTBSEaM5WtfUbTwz8WI9IWe61Czv8ARbuHUn05wLe7t5AMqs8TqWCnPUcHqrEc11Xijwxp/iJbWS68631CzZns9QtW8u4tWYYYxvg8EcFSCrDhgRXFeI7WezsLT/hYWnSa3HZtiDxFosTwXVoCqh5ZEjYSQ5x8zQllIB3Kg4oAu618HvCepWywwW9zpq/2uNakNnLzLcAEfNvDYXk/KuAO2Oa09T8CJeS6kbXxDr+nW2pFmurW2njaN9ww23zI3Meec7CvUms/Rr7xNHYw33h/U9K8beH3RmjmeZbe8OD90SRqYZW4ZcFYcEAM3U1csPiZ4dk1BNN1mW48O6s27bZa1F9mZ8PsGyQkxSZPTy3bIP1wAdB4W8P6b4W0Cz0XRLcW+n2ibY0ySeSSSSepJJJPqa1aKKAA9K+EPhFpR1fx94Ot3vpiZ9QW6eFmUqVi3THjGeTGPzr7quriC0tpbm7mjgt4UMkksjBVRQMliTwAB3NfHP7LllazfFOzGyH7dYW13NM0fzANkRYDcgjEhxg16GBqKnTrXerjbe27W3f07akSV2j6N8YJqGi+OdN8VQ6XdavpsVhLp9xDZLvuLbfIj+ckfWQHYFYL8wwCAeRW5pHjbwzq0qwWOuWDXZ62kkoiuEPo0T4dT7EA1y1loMXjLxN4sm1jUdbWLT9TWxtbe11Ka1ijQWsDk7YmXLFpHOTnqKi1f4f6nHIscD6Z4r0puDYeKR5kkPvFciN3/B1b/erzyz1CivGZ/AV5Yo02keFBpUqjOdB8UzwufZUeJYj9GwKteE/EXidHvEsrifxAtgwW90fVoUs9WtQfulWT9zMGAJB+UNjh85FAHrlFZXhfX7HxLo8WpaY0nkuWR45kMcsMikq8cinlXUggj+nNatABRRXN+MPFUXh82lnbWsmo65fsUsdPhIDykdWYnhI143OenucAgGrrms6doOnvfazewWVonBkmcKCeyjuWPYDJPYVx7a54s8VFo/C+m/2BphyP7W1mA+c4+YZhtMhuoUhpSvB+6a5Gx07Vta8V3Jt57XWPFNiwju9buoidO0V2wTBZw5+eZQQSTyON7AnZXZr8OYblSdb8S+KdTkfmQNqcltGx/wCucGxQPagDmvEWl2Gk6hbWStceNvHV0/mWkGr3HmQ2nrcvEoEcESdmVAxPyqSTx1WlfDvSipufFap4n1eUHzrrU4xKi5+8sMTZSJOSNqjp1Lda3PDPhfRfDFvLDoOnQWaytulZAS8p9Xc5Zj7kmtmgDym50Kf7VrPw+v7y5udI1TT5L3Rbu5laSa0eN1DRGQnc/lu8MiE8gEgk7RV/wLq82ueE9OvrtDHelDFdxlduyeMlJVwemHVq1PH8os9f8DXgO0jWTase5SW2nXb9NwQ/gKw/C8Caf4n8bacjOVXVvtiK38KzwRSHHt5hlr4njrCRq4GNfrB/g9H+NjpwsrSsdNXC+Hte8v49XdrFAwsLrTk057kD5WvYt1wI8+ohkc/h7V0XirXYPDujSXs0bzyllhtraIZkuZnO1IkHdmJA9uT0BqsfAl/YfDWK0sZoZvFdvcjWRdNws1/v3v6fKwLReyNXh8CZfOdeeNl8MVZebe/3L80a4qdlymnb+Tonxcu0cqi+JNPSWLJA3T2pKuPdjHLGR7RN6V29ef6wT8QfAem674XYw6xZyrf2Cz5QxXMeVe3lGRjI8yJh7k9hXU+EtetvE3h+01WzSWJJgQ8My7ZIZFJV43HZlYMp9xX6kcJr1i+LvDWn+K9FfTtUEqrvWaC4gfy57WZTlJonHKOp5B/A5BIO1RQB4Xd69qGg65BqutSl/EfhtRaa8sULRjU9Hkb5L5I1V8+UxEjBMbSJlJAIz7mjK6K6MGVhkEHIIrjPiZ4Ym1qyt9T0mJZtb00OYreRlEV/A+BPZyhgVKSqMZI+VgrZGDnI+AniGDVfCM+lRMwbQ7g2McUzoZ0ttoe3WVU4V1jYRMOTvifJJBoA9LoqG8do7Sd0OGVGYH0IFcz4V16e5a4TU5d22PzUcqF+Ufe6D/PNAHWUVyXhnWb3UNamiuZP3BjaRI9gG3kY5xnoaZpd1rGpi+aLUhF9nbCqYEIbr3xx0oA7CisTw5q732kS3V4FUwswdgMAgAHP61jaN4gv5dWg+2v/AKHcsyxjaowc4HIGevFAHaVV1Swt9U0y70+9j8y1u4XgmT+8jKVYfkTVqigDzzwPbDxR8Mbrwz4jJmu7ITaFqBJJZmj+VZMnnLIY5Af9oGtr4a6tPqfheKDUZGfWNLdtN1Dd1M8Xyl/o42yD2cVm3k58MfE+GaUBNJ8TRpbs/ZL+JTs3c8eZENo94VHeofE6t4O8ZR+LYU/4kuorHZa2FwPJIO2C7Oey7ijnPClTj5KAPQaKAcjI6UUAFFFFABRRRQB5h8TUuvCPiaw+IWnxy3FnbwjT9ctowTmzLFhOoHVomJJ4OVJ6AE1f+Kt3DrPg7TNLsJ0nh8TXltZRyxOGV7eQ+ZIykdQYUfn3rvZoo54ZIZ40kikUo6OMqynggg9RXingnw7Np/xqu9Et755/DXhy2N/Y2svLWkt0NoiU90VFk255AfHPWgDsvi1rUH/CPXvhewkhuPEmuWz2dnYBsyFZQUaZgMlY0G9ix4+QjOeK7aytxaWVvbqSywxrGCepwMVxfizy2+KHgRbdHN+PtrysmeLUQYYPj+HzWgxnuBXdUAFFFFABRRRQAUUUUAFFFFABRRRQBx+r+ANNudafWtGu7/w/rUhBnu9LdUFzgOAJonVopeXJyyluBgjFZ+szeIrawurXxd4a07xZojfM7aXEPMKqAw32c7ENhgcbJHYkLhM16BRQB5V4X0bwXfX0sXgHxDqXh6+ilkluNNsbhoShPytvsLlWWMZxg+UvbBrqJdN8a28TJYeJNFuFQYjbUNHdpX/66PFOiZ91jUe1bWuaBo2vxRx67pOn6lHGSUW8tkmCE9SAwOKwLj4f2Ykgk0jWvEukSQtuQWuqyyRYx93yZjJFt9tmBQB86+LPEdzq/irVrf4lSzSPpd2bZbeO2kXTItv3XC5YFmDBt0hzhgBwK7L4LppJ+KNlcaKtiYpNJvEaS02YYiW2wCV645qv8VtHuvBXi+LVrm71XW7fW4fJeSSCIyG5iHyJiJEX5o93JA4Tk4HGd8KI7zT/AIpaDe3VlYaeNRkntTBbIN4BgkkzJIOGYmMdBgepr3YuM8vagl56a6Pqz6WLjPK2oJeemqs92/M908Jbrfxr44tHUL5t3bX8fuklrHFn/vq3f8q6+uGu3bTvjPYu7EQazoz249DLbS+Yo+u2eQ/8BNdzXhHzQVyfjjwzcao9rrHh+4Sy8UaaGNnO+fLmQ8tbzgfeifA91OGXkc9VI6xxs7nCqCxPsKqadqlnqJcWc4kKY3DaVI/MUAeZaZcNrer3mreEbhNC8booXWPDupNmOYqAAZFXnpt2XEeQVIyG6DdX4n6Tp8AHjCy1Lwzdg7HS+tXaEtgE7J0DRuOezA+wrZ1HRvDXjEJNe2Ntey2x2x3BjKTQnr8kgw6/8BIrD1LwPqWmW8194Q8R64NUhHmQ2up6hJeWs5HPlushLAN03BgVznnGCAPl+IY1eFI/Amj3+u3EuQlzJBJa2UXIG55pFGQM5xGHJx0Fcz/acOjXGqDStQtfE3xR1RBC/wBkXzIrIAgKpAJEFvGW3EOQXOSck8X7/VY/iHN4J0/ZNBpOpR3V/qdm+5WP2bZG1tJ0yBNKAwPB8vHQ16No+kabotoLXRtPs9PtQS3k2sKxJk9TtUAUAV/Cmg2fhjQLTSdO3mG3XBkkO6SVycvI57szEsT6mtaorqQxW00igFkQsM9OBWf4a1GbVNONxcLGr+YVwgIGBj1J9aANWiiigDgfi5/q/B5H3v8AhJbHH/fTZ/TNUtYvbLRfHnim/wBQuIrWzTTLC4nlkbCr89yuT+CqPfitb4jxC41XwLbn+PX0fH/XO2uJP/ZBWZaeG9O8SfFHxHqer2zXS6U9na28ckjGHzFi87e0edrMvnjaSCVzkYrzc3y5ZlhZYVytzW19Gn+hdOfJLmDwVot34i1mDxd4ghmtoIQw0bTJV2tArDBuJh/z1cZwP4EOPvE49IoorpwmEpYOjGhRVox/r7+5MpOTuzzrWHT4eeJ5dbVdnhbWpx/ahzhbC6OFS59Aj8LIT0IRv71L4gW48B67deJrGKS48N37iTWraJdzWrhQPtkajqMAeYBzgbxyGz393bQXlrNbXcMc9tMhjlilUMjqRgqwPBBHGDXndjdv8N71dI1dnbwXMdun6jK5caeScfZp2PSPJxG54AwhPANdIj0W3niubeKe2lSaCVQ8ckbBldSMggjggjvUlecSWV78OLxrnSIZ77wVK26406FGkl0tj1kt1GS0OeWiH3eWXjK13ek6nY6xp0N/pV3BeWUw3RzwOHRhnBwR75H1oAuVzfh3wbpnh7xL4i1rTmuFn1x4pLiFmXyo2TfzGAARuaR2bJOWYniukooAgvlLWVwqgljGwAA5PFcnpXh973RoFnMtpNHI+d0ZBZCBkYOK7OigDmNKs5YPF944t5EtvK2o+whf4eAenaqWg6JLctfi7e+tUZ+FQmMSA56gjmu0ooA5zxBatZaALHSraVvNbaRGpYgdSSffpWbq3h+/g0uAx3JuTbH93DHAAVyecEcnmu1ooAgsJnnsoZZY2jkZAWRhgg9xip6KKAMjxboFp4n0C60q+MiRzAMk0RxJDIpDJIh7MrAEH2rnfDniIXcreEfG8MUWvNHJDsnjAg1aIL80sOflYFeXj6rkgjHJ7mop7aC4eFp4IpWhfzIy6BijYI3LnocEjI9aAK2iaXbaLpVtptgJRaWy+XEssrSMq9l3MSSAOBk9AKvUUUAFFFFABRRRQAV5l4FYv8X/AIp3AQu0badCqjGTtti2Bn3avTa80+G3/JUfikD977bZfl9lXFAFr4UwtrsEnjvUZYJtR1uBFhjh+ZLC1UkrbhiMlgxYueMvxgBRXoNcJ8OGGn+IfGvh1fM8mx1IXtuG6LFdIJSF9vN8+u7oAKKKKACiiigAooooAKKKKAOY+I3jbSvAHhmXXNcFw9skiRLFbqrSSOx4ChiB0yeSOAaxbr4r6HD8L4fHkVrqVzozkBo4I0M0WX8s7lLgDDcHDHqK5X4r6Nr/AI0+LPhPRrC1kt9E0hTqs99dWUkto84PyIcMgcjA4Djh264IrL+Fvg7VLGH4hfDXxDZXH9h3Beewv0tHjtmEqgMIySQNpMZCbiQQ3oTQB6b4m+Imj6DN4YheO8vpfEcqxWCWaKxYEKd7bmXCgOuTz1qtD8S9Pvr7VodD0jWtZttKl8i8vLGGNoo5B95AGkV5CMc7Fbt615B8A/C3iq/8c6ddeN9Ku7O38Iaa2nWDXEDos0jSOA6FgAwCErkcYCGmeL/B5tn1bVvA9t4+8N+L552f+zrKKV7K4kLnLeaq+WEYjd8zgYGNnQUAe/XXjLw7Y2Gn3era1p2lx38Kz2639yluzqQDwHI6bhn0zU58UaB/bTaP/bmlf2suc2X2uPzxhdxzHndwoLdOnNS+GF1NPDelLr7RvrAtYheNHjaZtg3kY4+9npxWnQB5N8XtX8LeJvhxql/p/iLSLqTQpItSje3vkkCypkrGdrdZVEkag5yWyASK8PXxRetJoviBNKeLTdNv4b5rmO7jkzGj7ZAFQnPyFweeOa+ya+O9Sg1TQW17QLzSxd6Np089gNs4S4W2AzGWDYVsxMhyGB56Zr1ssnzxnQbaTXRX/RnuZPPnjUw0pNKS6K+v3N/cfRPxaIsNN0TxIhA/sPVILmRv+mEhMEv4BJS3/Aa7uvKvhLqdv8SvgbBaX0nmSSWcmk3hPLblTZuOf4mQo/8AwKuw+G2pTap4H0mW8Ytfww/ZLzcMEXMJMUwx/vo1eSeGb2of8eFz/wBcm/ka4DS0m0y0tdYt8tGHMc6+2f8AP44r0OaMSwvG2drqVOOvNUrPSba10x7Fd8kDZzvIJ5+goAxvABzZXZHeX+ldTWfo2kwaTDJHbPKyu24+YQT+gFaFAHh/h2VNH/aMv9HWMxwSi8uoSTkFrmK0lYD0y9tO34mvcK8T8dFLX4tw6nEAJrW80KMt3AnkvoGH4rKPyFe2UAQah/x4XP8A1yb+Rrk/CWtWFhpRhu5/Lk8wtjYx4wPQV2dFADIZEmiSWM5R1DKfUHpT6KhvLmCytJ7q7lSG2gRpZZXOFRFGSxPYAAmgDktauEvfij4b0wMpNhZ3WqyDupO2CPP1Es3/AHyag+D5a98P6lrzmUjXtUuNRjEgwRDkRQ/gYooz+NcbcXOo3/hfUtbiWWDXPHV1FpmlKw+a1scN5bEZ4Ii8+c+7gdq9i0nT7bSdLs9OsIxFaWkKQQxj+FFUKo/ICgC1RRRQAVFd20F5azW13DHPbTIY5IpVDK6kYKkHggjtUtFAHmyNqPwwg2zNcar4IRvllO6S60iPHRupmgU9/vovXcBkXJPDPl3beJvhzqFrby3x+0XFqW32GpZH3yF/1chwP3qZz/ErV3vXrXB33hO/8Nzzal8PDBAZH8260SditndHuY+vkSH1X5T/ABKeoANPwn4xg1q8m0rUbSXR/EVuoefTLlgXKdPMiYcSx5yN6/QgHiuprz9JvDvxIiNjqlpdab4h00+Z9nlbyL+wftLE6nlScYdSUboc8in6X4m1Pw5q1voXjoq4uZPJ07XEQJDdsfuxSgcRTH0+6/O3B+WgDvaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzTwH+5+M3xPhPHmHTLhR6g27Kf1SvS68000/Y/2iNag6DUfD1vdfUxTvGf0YUAanhuZLj4r+NvKHEFpptvIcfxgXEhH/fMqfnXb1wd2reHPivb3oQf2d4ogWzmYDHl3kCu8RJz0eLzF6dY19a7ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+U/jb4duH+MGsT2xF6k1rZ6i+mTuVhnIV4foGHkrjcCMnnsR9WV85/HLT9Rl+LtrJY6gbFJ9EQbxAsm/wAud9wG7gY81fzrsy9J4iKav/w3noehlaUsVCLV7329PPT7xnwe8ZJpXxHfS7mCe10/XraJx56FTFeKzoqsOgLom3PQlFxnOa9OtGHg74k3VtLti0PxTIJ7d+AsWoquJI+n/LVFVxk8sj9yK8w+GPg4+IdY8W2Or389znTLWOO72IkkEpmldHTaAAUaNWHf8K9O02QeOvC2p+G9ff7J4k0x1huni4aKdfmhvIhx8rFVkX8VOcGjH/7zP1Fmn+91NOp6FRXH+CfE9zeXlx4e8SRJaeKLBA8qLxHeQ5wLmH1Rj1HVG+U9iewrjOAKKKKAPCfEsbXnjHXLpXDrP4t0PTYwOcC3SOd/1kf8q92rw7w5B9p17w5Ch8wX/ivWtZmb/ZtzNAv6tFXuNABRRVLWdVsNE06bUNXvILKyhGXmncIq/ie/oO9AF2vN9SuH+IurjTrE48GWE+dSuyPl1GWNv+PZM9Ygw/eN0bGwfxU6Q6v8SLfZF9s0HwhI3zu6mK91OP0UcGCFvU/Ow6BAcmLVDH4luH8B+FYktvD1gq22sXcI2xxRAAGyix/y0ZeGIPyKf7xAABb8HO/i/wAWXHi85/sS2hfT9EU4xMpYGa6xjIDsionP3UJx89egVFa28Npaw21rEkNvCgjjjjUKqKBgAAdAAMYqWgAooooAKKKKACiiigDnfGvhOy8U2CLNuttTttz2GoQnZPaSkcMjDnHTK9GHBBrhfhl44TxvoR8M+P8AT47fW5lntJoZQDDf+UxSbYRwHUglk4IBDD5SCPXK8VtfDdpN8RfG/hC6b7OL9ofFGk3EfMttcH93LMh7FZVU47hiDkE0AdNpN5e+AdRh0fX7t7rwzcOsOmapOxaS3kJwttOe4/uSHrjaxzjPolcLoOpJ4mt9V8H+NrK3Or28Wy7gx+6vbduFuIu+1j1HVG4z0JPBt7d+HtZHgzXruS7kWIz6RfzAhru2U4Mbt0aaLIBI+8pVsZ3YAO6ooooAKKKKACiiigAooooAKKKKACiiigAooooAK808YH+zvjf4CvhwuoWt9pkrfRVlQfmrV6XXmfx6/wBB8P6F4hHyroWt2d7K3pEX8px9MSUAdb470N/EXha+sLeUwXuFms5x1huI2DxP+DqpPqMjvUngjWj4j8H6LrLoI5L60ineMHIR2UFl/A5FX9aF8dHvho5hGpGBxamfPliXadm7HO3OM+1ct8Hbm2bwBpunQpJDdaQv9mXsEpBeG5iAEgJXg5PzAjghge9AHa0UUUAFFFFABRRRQAUVkSeJNJjkZHusMpII8t+CPwrQs7uC9gE1rKskZ4yP5H0oAnoqh/a9j/aH2Lzx9pzt2bT1xnGcYq/QAUUUUAFFFFABXjv7R6tYaf4a1q0tJrq9h1H7EY4RueSGaNi6qO53RRkDqSuO9exVwHxjX/iXeF5B1j8S6YR+M6r/AOzVdOpKnNTjujSlVlRmqkHqtTn/ANm6e31TRPEetWx3Jd6oYY3z1iiijUcdvmLn/gVdl4z8MT391b674dmjsvFFihSCZx+7uYs5a2nA6xse/VD8y9waXwjh8vTfEcmP9f4j1N/yuXX/ANlruqKtR1Zuct27hWqyrVJVJbt3PPLe50j4jQLb3S3eheLdHkLmHeEvNOlIwWU9JImBHODG4xkZ4BF4v1XwiBbfES2LWiDCeILCBmtpBnGZ4xloG6ZPKZJww6V0vivwnpniaKA36TQ3lsxe1vrWQxXFs3qkg5HuDkHuDXGeIdd8U/DnSpL7W7/R9f0aLgTXUn2C8z2XCqyStwcBQhPoagzPRtK1Ow1eyS80q9tr60fO2a2lWRGx1wykg1brxC78M3vxF8u/j8C6X4VaZd0mo6mmb45/uxQlCD7yOD/s1qad8BvDS24j1/Udf14dWS+1GQR59kQrx7EmgDndD1m38Nw2fiFv9I0nw/q2taRqbxkO0SXF0syToBneqhYwwXJAZuDtIr09/iX4ISx+2HxboZg27htvYyx4zgKDuJ9sZ9qXRfhv4M0TadN8MaRE69JGtldx/wACYE/rXSRWFnDN50VpbpLjG9YwGx6ZxQB5jrvxL8RX0v2XwF4G1y/ZiB/aGo2xtLcKcfOiylGk4zwSn1rM0LR/GV5qUGoeI/Co1fU7c7oLnXNYihhhb1itreOREPox3P8A7Ve1Vy/iL4geEvDjyR6z4h022uE+9b+cHm/CNcufwFAHOa5Z/FXWbG4tLW88LaAsw2/aLZ57meMd9pZFUHHGccdsHBFjQfDvjXQdIg0/Sr/wlBbwg7UGmXLEknJZmNzlmJySxySSSavS+Nb6/iDeFfCmsamCRie7QadBg98z4kI91jaoU0jx/qP76+8T6Zo5PS107ThOE+ssp+b8EWgBo1H4i6YGe/0LQNbiDAAaXevbTbe5CTKUJ9vMFbHhfxnpfiC5lsUW60/WIV3zaZqEXk3KLnG7aeHT/bQsvvWFd6r4s8Fxm98SS2niDw9GC1zeWdqYLq0TqZGiDMsiD+LZhgOdpwa2/GPhbRPH3hxba/CyxSJ5tpewNiSEsPlkicdOCPYjg5FAHT0V4x4EsvGWh6TcJpOoHV7nSbh7HUNF1GU4dlCssltcNlk3xtG4RyyjeRlcV6P4V8XaV4la5gspJIdRtCFu9PukMVzbMRkB0PbnhhlT2JoA6CiiigAooooAK8z+IIOkfFT4e66hWKG5muNFun7yCWPfCn/fyPP416ZXnfxzjij8IWGrTf8AMG1nT9QX/gNyin/x12oA2/HXh+71S3t9R0CeO08SaaTJYzyDMcmfvwSgcmJwAD3BCsOVFbFlH/aen6Xd6vpsVvfoqXPkSFZjaTFCGCuOMgM67l6gnsa0aKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnviHof/CS+Bde0YKGe8s5Yo89pNp2H8GANdDRQBzvw614eKPAmg61vR5LyzjklKdBLtxIPwYMPwrK8MRPa/FTxvCshMFxb6dfbOyyMs0TH8Vt4/wAqx/gnjR5/F/g4lVXQtVd7WJR8sdpcjzolB78s/wCVaXxD0260Zrjxr4dMw1SyhQ31qrkx6haRlmaMoeA6hnKMBnJxyCRQB3tFQafeQahYW17ZyCS2uIlmicdGRgCD+IIqegAooooAKKKKAOA0q/n06TWpYbMXMe8eYS+AnLAZHcc/pWz4VWLTvDs14ZVkDZlYL0XA+79a1dO0e2sXuzGZJBdHMiyEEd+Bx7mqaeGbWO2uLeO4u1gnILIHXHByMcUAcS08RgF6J/8AiZ/afM24P3euc9Otem2Vwl3aQ3Ef3ZEDD29qibT4G0v7AQfI8vy+vOPX696NLsY9Os1toXkeNSSPMIJGeccAUAW6KKKACiiigArz/wCMOXt/CEA6y+JtPH/fLlz+iGvQK4n4itEda8DpP9xdZe4Y+gjsrps/gcUAJ8G7kXvgcXo6XWpalOPcNezkfoa7euL+C1qtp8J/Cir/AMtNPiuD7tIvmH9WNXfHHiZtDgtbHTIku/EWpsYdOtDnDPjmSTHIiQHczenA5IoAPF/ir+xbi10zS7NtV8Q3uTbWEcgTCA4aaVufLiXuxBycAAmuWuYdN8Jahba/47v313xbc749Ptba2Mhj4y0VnbjJHGA0h5PG5gDip5YV8AWCtbI/iDx3r0gj86UhXu5QMlmx/qreMc4HCjA5ZsnoPB/hQaPNNqurXJ1PxLdoqXeoOuPlHIiiXpHECeFHXq2TzQBTgvfHOtIXt9O0rw3ASdh1B2vrgjPG6KNkRCRz/rGpkPhLxPM7NqfxB1Ug9EsLG1t1H03RyN+tdxRQBxJ8C3jfe8c+Lj9J7cfygqA/DWOV9134u8Z3A7qdXeIH/v2FrvaKAOHk+FXg+4kjk1HTZ9SdOR/aN/cXY/FZZGB/Kul0bQNH0NWXRdJ0/Tlb7wtLZId312gVp0UAFFFFACOqujI6hkYYKkZBFeY+HfEOmfDeO48K+K9RjsLOyDTaRd3bbUuLMnKxhjwZIs7CnUqEYDnj0+kZFbG5QccjI6UAeUeHNN8TXuq63418O3f2WLV7oSR6NqkTJHcwRxRxJITjfBI3luwOGG1kyuRwmt614T8R3FrbeOLW88IeJYci2ubp/sssTbefs94vyOvzH5d3Pde1es1BfWdtf2sltfW8NzbSDa8UyB0YehB4NAHGWkfjXSbYNZajpPiy0OTGbs/Yrjb2/exq8chxx9xPrSHx1q1pbqdX8A+JoZujCy+z3ifgUl3EfVRVxvhl4GbOfCGgDIx8thEP5Diqn/CvY9ItyPBGsaj4flXJWHzWu7Q5OSDBKWCg/wDTMofegBLf4iS3Mmy28E+M3b/bsI4R+ckiirJ8Y6quS/gLxQFHcNZMfyFxVOHxvq2lD7N4t8K6sl4nH2nR7Zr61n/2k2ZdM/3XUY9T1oTX/G+rGS70PwzZWWnJ/q4tbuWgubn1ISNXEQ7Dfz6gUASRfFDQYWVdfg1bw4zSCNTrFjJBESen74Axf+P0z40JDq3wa8Ty20sc0J057uKWNgysEAkVgRwR8oOa2fCviWHxEt5ZX2nz6bq1phbzTrrazIGzhlI+WSNsHDDg4I4IIriviJ4Li8P+CfFt34XuDpmly6RftfaUq7raUm3kw8S5xC4bGdmFYdRnBoA9TspxdWcE69JY1cfiM1NWZ4WJPhjSCeps4c/98CtOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNPEEUmg/HDw5rCA/YtfspdGuTkBEmjzPC3uzASKPpXpTKHUqwBUjBB6EVw/xp0y61D4f31zpiI2q6S8erWRZc4lgcSYA9SoZf8AgVdP4a1i28Q+HtN1ixJ+zX1ulxGD1AZQcH3GcH6UAc58G4ntvh9Y2MhJOn3F3YLn+5BcyxKP++UFdrXA6ddXXg3xdHo1+yTaFrt3cT6fdbdrW907NM9tJ2YNmRkbg8FSDwT31ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkfxs1OO3u7tGcKbHwvqt4D3WV/KhiP1O6QV65XhXjgLrfi7Xo5LYzR3eq6P4aiYHqsb/AGy4/DaxB/3aAPUJ73T/AAH4EtGvC/2XTrWG1jjjXdJKwCokaL3ZjgAeprG8PWS+GdJ1jxr4ybbrV1Abi9YnzPsVuoLJaRY42oOuPvuSecjFXxNf2+s/GXwt4aY7xplrNrs6HlS4/cw59wXdvwU1b8Zsdf8AHPh3wsj4tYP+J5qIB5aOFwIIyMdGmw30hI70AT/D7Q7w3N34r8SwCPxFqqhRCW3fYLUHMdsp9vvORjLk9QBXbUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSOodGVhlWGCPagDg/BrQ+I/HOueLbX5tPS3j0WymBOJxFI7zSL6qXcID38pj0Iqz8arlbT4SeLpG/j0yeEfV0KD9WFY/wAPU1rQPEsngy1mtNQ8NaLaIftjwmOeAuWMVsSGKyMqAEthflK5GTVr47BLnwAdLLbZNV1GxsI/dnuY8j/vkNQB3OlwfZdNtLc/8sYUj/JQKs0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHnrXmPwgR/DeseKPAsoKW+lXX23SweAbK4LOqrnltjiRSfXAr06vMfivI/hfxH4a8dRgLZ2UjabqxUcm0nZQrk+kcgVsf7RoA0vjerR/DfUdQg2i70uSDUbd2AO2SGZHGPqAR9Ca7yuC+NJjuvBtvpDSMn9t6nZacGUZ+V50L/+OK9d7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDe3UNlZz3V1IsVvBG0sjscBVUZJJ9ABXjHgho/P8ACM+rMlrNNFqPjO/LPxGZfkj3k9AI7lh/2y9q7n4sz+b4Yj0OMv5/iG6j0hdgBIjlP75uf7sKyn8BXnniINr114lNmrpHrmpWvg+yeFcGO1h3PdsM8bcfaV4/uCgCbwnHcQ+LPCHjXU0aKfxVPfJLvx+6jmjje0iJAHSK1Qf7zH1rtPCcrXHxa8fNNgtbxadbRcciPy5JPyLSP+Va3xA8PS674RnstLKQajbGO605zwI7iFg8X0GVCn2JrhtC8Yafe/EfQ9R0m6gmuPENiLLVNJjkU3NhNAJJFkkQcgKTLE2SOSmM0AewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw3wl/ead4iupCftVzr+oNPk8gpMYkH4Rxxj6AVl/FPGqePPhtoBUsj6pJq0hXqgtYiy59AXdRWr4ZU6Z8TfFWk2iBtPuYLbWHI/5Y3EpkidfowgV/ru9ayvD3/E++OviXVV3G10DTodHiYHKPLI3nSke6jYpoA9NooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArP8AEGkWmv6Hf6TqKeZZ3sLwSqOu1hg49D3B9a0KKAPDYZ9RufhNdWF2v2zxR4D1CKSSNuGnW1kWSNwBknzLfgHuxNe22lxDeWsNzayLLbzIJI5FOQ6kZBHsQa8w8dgeCPiLpXjSP93ouq7NJ17HCJk4t7l+g+VjsLseFYAVpeB5W8JeIJ/BN8xFkd11oMrk4kt85e2BPVoSeBnPllT2NAHoVFFFABRRRQAUUUUAFFFFABRRRQAUUVneItYtPD+g3+r6i+yzsoWnkPchRnA9SegHckCgDzTxprUj+MdW1O1RZj4XsxZadGwyJ9WvMKidecKYl9vOarug6LDo/izwX4WWQzjRdKudSlkJOZLl2SLzTn+95tyfxqz4O8EGaw8O6prpkjvkmm1m7sSvyNfz4bc3qYgzIo7YB7Crnhgi++K/ja7KZ+xwWOmo/wBEedgP+/6/lQB3VV7eytbaeaa3tYIppjuleOMK0h9WI6/jViigAooooAKKKKACsLxlPLb6MXglkifzFG5GKnv3FbtY/iuyuL/STDaR+ZLvVtuQOPxoA0NOZn0+1ZyWYxKSTyScCuX8VXt5NqZtdOmlj+zQtLL5blc8Z5x7Y/OtWwudVijt4JdIKoiqjSfaUPAGM4rP0zw/c3E13dalLc2s8zn5YJQMqfUjPHt7UAbXh69+36RbzE5k27X/AN4cH/H8a0a57wvp95pdxeW80Z+yM26KTcDnt0znkY/KuhoAKKKKACiiigAooooAK57xr4lHhzT4Tb2kmoatey/ZtPsIjhriYgnBPRUABZnPCgE+gPQ1wHgFT4j8Ra14wum8yHz5dL0ld+5IraJ9kki/7UsqMSeu1EHagDQ8PWH/AAh3h3V9a8S3sc+pT79R1W7RSEXag+SMdRGirtUHnqepNUPgjp8lv4Fi1W7RE1DxBPJrd0EzgNcHeqjP91Ni/hWd8ZJX8QXug+ALJ28zW5xPqRjJBi0+IhpCSOV3sFQEjByRXpsUaQxJHEipGgCqqjAUDoAOwoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm+JdFs/Eegaho+px+ZZ3sLQSDuAR1HoR1B7EA15l4Z/tHxh4NufD2o3Qs/HvhO5WNbs84mQfubjHUxyx5DZHIZxjpXr9eYfEqIeD/FGm/EO23LaRBdO1yNej2jthJsd2jcqehJUkcAUAdb4I8Sp4k02UzQNZ6tZSm21Gxc/NbzjqPdCMMrdGUg+oHRVwnjO1u9Hvo/GvhmA3k0cKx6nZwcm/tAchkHQyx5Zk9QWXuMdfpGpWes6Xa6jplwlzZXUYlhlToykZB/+t2oAuUUUUAFFFFABRRRQAUUUUAFef+MD/wAJV420nwpF8+n2DR6xrBzwQrH7NAeDndIu8g4+WL/arrvEutWfhzQb7V9TfZaWkRlfHVsdFA7sTgAdyQKxvhzpV5Z6RPqetwrHr2sy/br9Rz5ZICxw59I41RPqCe9AHV1w3wul+1XXjW7x/rfEVxHn1EUcUP8A7TNdzXEfCGML4Z1CXvPreqSn/wADZh/SgDt6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxvFPiG18OWEdxcxXFzPPKsFtaWqB5rmQ9ERSQCcAkkkAAEkgCsH4XWF14U+HUNr4giWwWxa4lJklVikBkeRTIVJUMFb5sEjIJzVPwq8Hiz4ja14h82G6sNExpOmNG6ugkZFkuZQR/EdyR5B6Iw7mqXxJmPjTxJbfDrT5nW3dFvdfnibBitARtgyOjytjvkICcEGgCb4SpL4jv9X8f38DxvrBFtpaSD5otPjJ2cdVMjFpCMkcrXpVR20EVtbxQW8aRQRKESNBhVUDAAHYAVJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQahZ22o2NxZX0Mc9pcRtFLFIMq6MMEEehBqeigDzP4Tz3nh3UdT8AazK8r6UBPpNxK2WurBjhR7mI/If8AgNTyuPh14lMmzy/BmsTZkbP7vS7xj94/3IZTj2WQ54D1Y+LPhvUNTstP1/wyF/4Sjw/K11YhiQtwhGJbdvaRRjtyByOTWx4b1nRfiH4KS8hjFxpmoQtFPbTr8yH7rxOOzA5B/McYNAHS0VwfgrUbjw/qy+CtemaSaKNpNHvJP+Xy0XgIx7zRjAb+8MN3OO8oAKKKKACiiigAoorifG+t3d5fr4R8MTtHrl3HvuLxBldNticGVv8ApowyI17tyeFNAFSbZ458cLCpaTw54bm3ykHMd5f/AMK/7Sw4yef9Yy90Neg1neHdFsfDuiWek6TCIbK1QJGuck9ySe7E5JJ5JJNaNABXHfCb/kTm/wCwpqf/AKXT12NcR8IZQ3hrUou9vrmqRH/wMlP/ALNQB29FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBX1G+tdNsZ73ULiK2tIEMks0rBVRR1JJ6VwNppt/8Q5hqOutd2PhPJ+x6P8ANBJer08266NsPVYuBjBbPQPvUj8f+MnsWLv4Z8PTg3SceXfXwwyxn+8kPDMOhdlBB2Guj8b+LdM8G6KdR1ZpG3OIre2hXfNcyn7sca/xMf8A9dAGT458QW/gfw7bWHhvTraXWrxvsuj6TAgQSyeu1cYjQfMx4AA6jIqz8NvCA8J6K4vJ/t2vX7/adU1BuWuZz157Iv3VXgADpkmsr4f+EdQGs3HjHxqYpfFF4nlw28bbotMt+ogjPdv7z9zkDjJb0KgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry3xNpmr+AtevPFXhCxfUdHvpPO1vRYR+8Z8c3VuOnmYxuX+PHryPUqKAOOvItG+JfhKzv8ARNSQlXW70/UYAGe0uF+6xU9xnDI2MglTjNHg7xdNe3z6B4oto9M8VW6lngUnybxB/wAt7Zj95D3X7yHhumTm+JPh26apPr/gPUD4e8QSN5kyKubO/bk4uIRwScn5x8w3E8msLU/FlldwxaR8YfDc2hTRSKYNVQs9l5vRZIbpPmgc/MRuKkDqaAPYKK830o+K9Ns47jwvrGm+NdCYExfbLkR3QGOAtzGGSX/gSg+rGrj/ABBurRUXVfBHi23mI+YW9pHdoD7NC7ZH4CgDvKK4NPiDdXYddK8EeLbmYD5RPZpaIT7tM64/I01tL8Z+KWA12+i8M6UcE2ekzmW7lHHD3JUCMcdIxnn79AFnxN4tun1d/Dfg6CK/8QgKbiSTJttNRuQ87DqxHKxg7m68Dmtfwh4Ys/DFjNHbyTXV5dSGe8vrkhprqU/xOQB9ABgAAACrug6Jpvh/TlsdHs4rS2BLFUHLserMx5Zj3Ykk9zWjQAUUUUAFcN8LYjbT+NLU/wDLLxFcuB6CRIpv/aldzXCaBnSPix4msJd4h1m2g1a2JHyl41EEyg+oCwH/AIHQB3dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFBIAJJwB3oAK47xx4huo7u38NeGpYz4m1FdyMU3rYwZw9zIOwHIUH7z4HTOKeqeL77XbmTSvh7FFeTBtlxrUo3WNn/e2sP8AXyj+4pwCfmI5Fc6dXtfDM8/hr4dwHxL42umH9oX9w5kWFhkebezjpjDbYxzxgAZGQDf1jWdD+E3hPTtMtorq+vZSYrCwiPm3eoTk5Zj6ksxZnIwM+pAMfg3wbf3mtQ+MPHxjn8SlCtrZRtuttKjP8Ef96Qj70nc8DgZOh4F8CR6BczavrV7Jrnim6XbcancqMqvJ8qFekUYJPyr179sdpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJoo54XimjSSJwVZHGQwPUEdxT6KAPOtS+EXh83sl/4an1HwtqDnc0ui3BgRz23xcxke20Zoh034maKka22u6B4kiB+YajaPZTbe2HiLKT9UFei0UAeanx34x05pW174aamLaPjzdJv4L5n9xH8jY/CiL4x6FFEZNb0fxVoSf3tR0WdR+aBhXpVFAHnFh8b/hzezeVF4oto3zj/SYZYAPxdQK6zSPFvhzWpvJ0fX9Jv5uuy1vI5W/JSTWtcW8NxG0dxDHLG3BV1DA/ga5PVfhf4G1WGSO88J6L+85Z4rRIX/77QBh+dAHY0V51D8JNF02GOPwvqviLw8sZ3KlhqkrR5945S6H6YqGXSvihosjSaZ4h0bxLb5z5Gq2f2SUD0WSH5SfcqKAPS65nx1oN5q1rZXuiTpba7pU32qyeQZSQ7Srwyd9kikqSOQcNyVArmI/ixHpEiweP/DureF5CdpupE+02RJOBiePIGfcCvQ9L1Ky1ayjvNLvLe8tJPuTW8iyI30YHFAGV4N8TW/ifTHmSGWzvrd/IvbGf/W2swHKN69chhwwII61v1y3ifwgup6gusaPfTaN4jji8pL+AB1kTkiOaM/LImSevI/hIrJi8d3WgMLb4haW+lkHaNWtVabT5eg3Fx80OfSQAD+8etAHf0VX0++tNRtEutPuoLq2kGUmgkEiN9CODVigAooooAKKKDwOaACiuY1jx94S0YsupeI9KhlBx5IuVeUn0CKSxPsBWY3xDN8WTwz4Y8Raw2PllNp9jgP8A20uCnH0BoA7qmTSxwQvLPIkcSKWd3OFUDqST0FcOYviHrJ+e40TwxbHtCrahcgf7zbI1P/AWpbzwBoDx/b/GV7d679m/fPJrF1/oyYHLGBdsAGP9igBLj4j2d/NJaeCLC48VXqNtZ7NglnEeD89037voeib2/wBmsrxVpu/TZdV+LHiK2s9CjHzaTZSNFaseflkk4kuCf7oCg4+4ajk+IdzrzHSPhLpEWpiH902q3CmHTLUDjAYDMpHHyoPfOK1NB+G1udSt9b8a3z+J/EUJzFcXSBYLXpxDAPkXoDuILZGc0AYdi3iPx9p0dp4bgk8E+CAuyK5WIJfXcXAxDGMC3QjdhjliNpAANeieFPDWkeE9Hi0vw/YxWdmnO1OS7d2ZjyzH1PNbFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABAIIIyD2rzvW/hTo8l82q+E55/CevH/l80oBI5PaWD/VyLnkggEnvXolFAHl8XjbxF4MVoviXpnm6fH93xBpETSwFcdZ4Rl4jxyQCuTxivQdD1nTde02K/0W+t76yk+7NBIHX6cdD6g8ir5GRg9K891r4T+H7nUpNV0GS+8M605y15o0xg8w5ziSPlHBPJyuT60AamqfDjwtqF618ulrYaiwIN5pkr2Uxz1JeIqW/4FmqTeCNbtIVTRvH/AIigC9r2O2vB9MvHvP4tVW3s/idoaIF1Tw/4qhUkv9rt2064b2DR74/zUVE3j3xfYs39tfDPVlQdH0y+gvQR9Mof0oA0U8P+OUUKfHVo/wDtPoaZ/SUD9KanhTxhLJm9+Il4sfdLPSrWL9XVzWf/AMLbgTi58FePIG9G0V2/VWIo/wCFuWrcQeDfHczeiaI4/mQKANKX4efapVfUvF3i+7A6oNS+zKfqIFjp8fws8F/axdXWhxahcD/lpqU0l6f/ACMzVlf8LF8R3g/4k3w08SSt2+3yQWQ/8ec/yqwt/wDE/U1jNvonhnQF/j+3Xst8/wCCxqi/+PUAdvpelafpNv5GlWFpZQdfLtoVjX8lAFY3i3x34Y8IpnxFrdnZSHBEJbfMwPQiNcuR7gVzD/DvxHrDn/hLPiHrNzb7twttIhTTUx3RmXc7Ken3hXReEvh54T8JP5mgaHaW1zzm5YGWc56jzXJfHtnFAHPXPjTxb4hxH4D8JyxWzkqNV8QE2kK9DuWD/WuCOhwtFj8K4tTvYdS+ImrXXim/jYSJbTDyrCBu2y3X5TjkZbOR1Fel0UANijSGJIoUWONFCqijAUDoAOwp1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic of the parasternal short-axis echocardiographic view shows the location of the membranous septum (blue), the infundibular septum (yellow), atrioventricular septum (pink), and infundibular defect (I) and membranous defect (M).",
"    <div class=\"footnotes\">",
"     Ao: aorta; LA: left atrium; LV: left ventricle; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8323=[""].join("\n");
var outline_f8_8_8323=null;
var title_f8_8_8324="Carditis CPC Light";
var content_f8_8_8324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a biopsy specimen from the erythematous area of the distal esophagus. The specimen contains cardiac type mucosa with marked chronic inflammation (mononuclear cell infiltrate) diagnostic of chronic carditis. No goblet cells were identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8324=[""].join("\n");
var outline_f8_8_8324=null;
var title_f8_8_8325="Vinorelbine: Patient drug information";
var content_f8_8_8325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vinorelbine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     see \"Vinorelbine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Navelbine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Navelbine&reg;;",
"     </li>",
"     <li>",
"      Vinorelbine Injection, USP;",
"     </li>",
"     <li>",
"      Vinorelbine Tartrate for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vinorelbine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some side effects may happen up to 2 weeks after the shot. Report them to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11144 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8325=[""].join("\n");
var outline_f8_8_8325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234356\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234357\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031481\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031483\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031482\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031487\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031488\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031490\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031485\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031492\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=related_link\">",
"      Vinorelbine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8326="Varicella-zoster immune globulin (human): Drug information";
var content_f8_8_8326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Varicella-zoster immune globulin (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/47/1781?source=see_link\">",
"    see \"Varicella-zoster immune globulin (human): Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/7/41076?source=see_link\">",
"    see \"Varicella-zoster immune globulin (human): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16317530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Varizig&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5088784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VariZIG&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5088788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5091379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     I.M.: Administer a single dose based on body weight. Dose may be repeated for high-risk patients with additional exposure &gt;3 weeks after initial administration. The minimum dose is 62.5 int. units and the maximum dose is 625 int. units:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &le;2 kg: 62.5 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2.1-10 kg: 125 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10.1-20 kg: 250 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     20.1-30 kg: 375 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     30.1-40 kg: 500 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;40.1 kg: 625 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The U.S. Food and Drug Administration (FDA) allows for administration to begin within 10 days after exposure; however, drug should be administered as soon as possible (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Prevention or reduction of maternal infection:",
"     </b>",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     I.M., I.V.: 125 units/10 kg (minimum dose: 125 units; maximum dose: 625 units). Administer within 96 hours of exposure.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5091378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/47/1781?source=see_link\">",
"      see \"Varicella-zoster immune globulin (human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     I.M.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5091380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     I.M.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16317957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varizig&reg;: 125 units [contains polysorbate 80; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5088786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5091381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     For I.M. administration. Administer into deltoid muscle or anterolateral aspect of upper thigh; avoid gluteal region. Do not use &gt;3 mL per injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     For I.M. or I.V. administration. Bring to room temperature prior to use. Should be given as soon as possible following exposure; efficacy has not been established for use &gt;96 hours following exposure. For I.M. injection, administer into deltoid muscle or anterolateral aspect of upper thigh; avoid gluteal region. For I.V. administration, inject over 3-5 minutes. Pre-existing I.V. lines should be flushed with normal saline prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5088789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Postexposure prophylaxis of varicella in high-risk individuals. High-risk groups include:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Immunocompromised children and adults",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Newborns of mothers with varicella shortly before or after delivery",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Premature infants",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Neonates and infants &lt;1 year of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Adults without evidence of immunity",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     - Pregnant women",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     In pregnant women, for the prevention or reduction in severity of maternal infection within 4 days of exposure to the varicella zoster virus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends varicella-zoster immune globulin (VZIG) for the passive immunization of patients who are at a greater risk of complications following significant exposure to varicella and do not have evidence of immunity (postexposure prophylaxis). Guidelines restrict administration to those patients meeting the following criteria (CDC, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunocompromised patients without evidence of immunity, including those with neoplastic disease (eg, leukemia or lymphoma); primary or acquired immunodeficiency; immunosuppressive therapy (including steroid therapy equivalent to prednisone &ge;2 mg/kg or 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Newborn of mother who had onset of varicella (chickenpox) within 5 days before delivery or within 48 hours after delivery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Premature infants (&ge;28 weeks gestation) who were exposed during the neonatal period and whose mother has no evidence of immunity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Premature infants (&lt;28 weeks gestation or &le;1000 g) regardless of maternal history and who were exposed during the neonatal period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnant women without evidence of immunity who have been exposed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Significant exposure includes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous household contact",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Face-to-face indoor contact (&gt;5 minutes or &gt;1 hour depending on reference)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hospital contact (sharing a room with an infectious patient or face-to-face contact with an infectious staff member or patient)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5088782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Varicella virus vaccine has been given in error (instead of the indicated varicella immune globulin) to pregnant women exposed to varicella.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5091359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      U.S. labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%), chills (2%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site pain (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: DVT, serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Central nervous system: Headache (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site pain (17% to 47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Cardiovascular: Flushing (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (&le;5%), fever (&le;5%), pain (&le;5%), chills (&le;2%), fatigue (&le;2%), insomnia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (&le;5%), dermatitis (&le;2%), erythematous rash (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2% to 5%), dysgeusia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site bruising, itching, or tenderness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Neck pain (&le;5%), myalgia (&le;2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5090534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     History of anaphylaxis or other severe reaction associated with past human immune globulin administration; IgA deficiency",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Additional contraindications (not in US labeling): Hypersensitivity to any component of the formulation; patients with evidence of immunity to varicella zoster virus (ie, with previous varicella infection or vaccination)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5090535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions:",
"     <b>",
"      [Canadian Boxed Warning]: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1:1000) should be available. Reactions can occur in patients with IgA deficiency or hypersensitivity reactions to human globulin.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary edema: Noncardiogenic pulmonary edema has been reported with intravenous administration of immune globulin. Monitor for symptoms of transfusion-related acute lung injury (TRALI) including severe respiratory distress, hypoxemia, fever, and pulmonary edema which typically occur within 1-6 hours after administration. Use caution with preexisting respiratory conditions. Per Canadian labeling, I.M. administration may be preferred in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia,  nephrotoxic medications, and in the elderly due to risk of renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients with cardiovascular risk factors, history of atherosclerosis, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known hyperviscosity disorders. Per Canadian labeling, I.M. administration may be preferred in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma:",
"     <b>",
"      [Canadian Boxed Warnings]: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk.",
"     </b>",
"     Infections thought to be transmitted by this product should be reported to the manufacturer (Cangene Corporation 800-768-2304)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Varicella zoster immune globulin should be administered as soon as possible following exposure (within 96 hours, preferred) to reduce the severity of varicella. There is no evidence which shows therapy will reduce the incidence of chickenpox infection after exposure to varicella zoster virus, or that it will effect established varicella zoster virus infections. According to the U.S. CDC guidelines, healthy and immunocompromised patients (except bone marrow transplant recipients [BMT]) with positive history of varicella infection are considered immune. BMT patients who had varicella infection",
"     <i>",
"      prior",
"     </i>",
"     to transplant are",
"     <b>",
"      not",
"     </b>",
"     considered immune. BMT patients who develop varicella infection",
"     <i>",
"      after",
"     </i>",
"     transplant",
"     <b>",
"      are",
"     </b>",
"     considered immune. Patients who are fully vaccinated, but later became immunocompromised should be monitored closely; treatment with VZIG is not indicated, but other therapy may be needed if disease occurs (CDC, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5091362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16317535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5088791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Endogenous immune globulins cross the placenta. Clinical use of other immunoglobulins suggest that there are no adverse effects on the fetus. Women who do not have evidence of immunity to varicella may be at increased risk of complications if infected during pregnancy. Varicella infection in the mother can also lead to intrauterine infection in the fetus. VZIG is primarily used to prevent maternal complications, not fetal infection (CDC, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5090533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16317538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if this preparation is excreted into breast milk; endogenous immune globulins can be found in breast milk (Agarwal, 2011). The manufacturer recommends that caution be used if administered to breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (VariZIG Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 unit (1): $780.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5091384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for adverse effects for 20 minutes following administration; baseline assessment of blood viscosity in patients at risk for hyperviscosity; signs and symptoms of varicella infection for 28 days after VZIG administration (CDC, 2007)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Varitect (HK, TH, TW);",
"     </li>",
"     <li>",
"      Vazigam (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5091369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antibodies obtained from pooled human plasma of individuals with high titers of varicella-zoster provide passive immunity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5091371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &ge;6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized in the reticuloendothelial system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: I.V.: 18-24 days; I.M.: 24-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: I.V.: &lt;3 hours; I.M.: 2-7 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agarwal S, Karmaus W, Davis S, et al, \"Immune Markers in Breast Milk and Fetal and Maternal Body Fluids: A Systematic Review of Perinatal Concentrations,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      ,  2011, 27(2):171-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/21678611/pubmed\" id=\"21678611\" target=\"_blank\">",
"        21678611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:212",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/22456121/pubmed\" id=\"22456121\" target=\"_blank\">",
"        22456121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Prevention of Varicella, Recommendations of the Advisory Committee on Immunization Practices (ACIP), &rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR4);1-40. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/17585291/pubmed\" id=\"17585291\" target=\"_blank\">",
"        17585291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen A, Moschopoulos P, Stiehm RE, et al, \"Congenital Varicella Syndrome: The Evidence for Secondary Prevention With Varicella-Zoster Immune Globulin,\"",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2011, 183(2):204-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/21262937/pubmed\" id=\"21262937\" target=\"_blank\">",
"        21262937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamont RF, Sobel JD, Carrington D, et al, \"Varicella-Zoster Virus (Chickenpox) Infection in Pregnancy,\"",
"      <i>",
"       BJOG",
"      </i>",
"      , 2011, 118(10):1155-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/21585641/pubmed\" id=\"21585641\" target=\"_blank\">",
"        21585641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sendelbach DM and Sanchez PJ, \"Varicella, Influenza: Not Necessary to Separate Mother and Infant,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012 , 130(2):e464. 22855925.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8326/abstract-text/22855925/pubmed\" id=\"22855925\" target=\"_blank\">",
"        22855925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9442 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8326=[""].join("\n");
var outline_f8_8_8326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317530\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088788\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091379\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091378\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091380\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317957\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088786\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091381\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088789\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088782\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091359\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5090534\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5090535\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300209\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091362\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317535\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088791\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5090533\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317538\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570491\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091384\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539992\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091369\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5091371\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/7/41076?source=related_link\">",
"      Varicella-zoster immune globulin (human): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/47/1781?source=related_link\">",
"      Varicella-zoster immune globulin (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8327="Epidemiology and pathogenesis of acute rheumatic fever";
var content_f8_8_8327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of acute rheumatic fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Allan Gibofsky, MD, JD, FACP, FCLM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     John B Zabriskie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8327/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/8/8327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever (ARF) is a delayed, nonsuppurative sequela of a pharyngeal infection with the group A streptococcus (GAS). Following the initial pharyngitis, a latent period of two to three weeks occurs before the first signs or symptoms of ARF appear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/1\">",
"     1",
"    </a>",
"    ]. The disease presents with various manifestations that may include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of ARF are reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link\">",
"     \"Treatment and prevention of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing areas of the world, acute rheumatic fever (ARF) and rheumatic heart disease are estimated to affect nearly 20 million people and are the leading causes of cardiovascular death during the first five decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/2\">",
"     2",
"    </a>",
"    ]. Rheumatic fever can occur at any age, although most cases occur in children 5 to 15 years of age. Worldwide, there are 470,000 new cases of rheumatic fever and 233,000 deaths attributable to rheumatic fever or rheumatic heart disease each year; most occur in developing countries and among indigenous groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The mean incidence of ARF is 19 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States and other developed countries, the incidence of ARF is much lower at 2 to 14 cases per 100,000; this is probably due to improved hygienic standards and routine use of antibiotics for acute pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Many cases that do occur are part of localized outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During epidemics in the mid 1900s, as many as 3 percent of untreated acute streptococcal sore throats were followed by rheumatic fever; in endemic infections, the incidence of rheumatic fever is substantially less [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatogenic strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation in some studies that only a few M serotypes (types 3, 5, 6, 14, 18, 19, 24, and 29) were implicated in outbreaks of rheumatic fever in the United States suggested a particular \"rheumatogenic\" potential of certain strains of GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/7,14-16\">",
"     7,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To address the \"rheumatogenic\" potential of GAS, a serologic surveillance study compared the M types of GAS recovered from children in Chicago with acute pharyngitis during the time period 1961 to 1968 to the GAS strains recovered from Chicago children and children from across the United States in the time period 2000 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/15\">",
"     15",
"    </a>",
"    ]. Rheumatogenic strains (eg, types 3, 5, 6, 14, 18, 19, and 29) were less prevalent among the latter isolates (10.6 versus 49.7 percent in the earlier time period) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors hypothesized that the marked decrease in the incidence of ARF in the United States correlates with the replacement of rheumatogenic types by nonrheumatogenic types. However, an accompanying editorial noted that although the prevalence of rheumatogenic strains decreased two- to fivefold, the reduction in the incidence of ARF over the same period was &ge;20-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, a shift in the prevalence of rheumatogenic M type GAS strains does not appear to fully explain the decrease in ARF.",
"   </p>",
"   <p>",
"    Our own series, gathered over a 20-year period, has produced different results. We isolated a large number of different M serotypes, including six strains that were nontypable. In addition, several different M types were isolated from the patients seen during a mid-1980s outbreak of ARF in Utah; these strains were both mucoid and non-mucoid in character [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, M serotypes different from those in the United States have been associated with ARF in Trinidad and Hawaii [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the issue of potential \"rheumatogenic\" strains remains unresolved. A streptococcal strain capable of causing a well-documented pharyngitis almost always is potentially capable of causing rheumatic fever, although some exceptions have been recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/22\">",
"     22",
"    </a>",
"    ]. The lack of specific rheumatogenic strains also may explain the relatively high risk of recurrent disease with new streptococcal infections, in contrast to poststreptococcal glomerulonephritis, in which only a few \"nephritogenic\" strains appear to be capable of inducing the disease (eg, type 12 with pharyngitis and type 49 with impetigo), and recurrent disease is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenic mechanisms that lead to the development of acute rheumatic fever (ARF) remain incompletely understood. Clearly streptococcal pharyngeal infection is required, and genetic susceptibility may be present. On the other hand, evidence is sparse that toxins produced by the streptococcus are important.",
"   </p>",
"   <p>",
"    Within this framework, molecular mimicry is thought to play an important role in the initiation of the tissue injury (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Molecular mimicry'",
"    </a>",
"    below). However, the factors responsible for perpetuation of the process remain unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of the streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of evidence for the direct involvement of GAS in the affected tissues of patients with ARF, significant epidemiologic and immunologic evidence indirectly implicates the GAS in the initiation of disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outbreaks of rheumatic fever closely follow epidemics of streptococcal pharyngitis or scarlet fever with associated pharyngitis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adequate treatment of a documented streptococcal pharyngitis markedly reduces the incidence of subsequent rheumatic fever [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Appropriate antimicrobial prophylaxis prevents the recurrence of disease in patients who have had ARF [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/14,27\">",
"       14,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most patients with ARF have elevated antibody titers to at least one of three antistreptococcal antibodies (streptolysin \"O\", hyaluronidase, and streptokinase), whether or not they recall an antecedent sore throat [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the high sensitivity of antistreptococcal antibodies for the documentation of streptococcal infection, the rate of isolation of GAS from the oropharynx of patients with ARF is extremely low, even in populations that generally do not have access to microbial antibiotics. The clinical documentation of an antecedent pharyngitis also appears to have an age-related variability. One study, for example, noted that the recollection of pharyngitis approached 70 percent in older children and young adults versus only 20 percent in younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, a high index of suspicion of ARF is important, particularly in children or young adults presenting with signs of arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carditis, even in the absence of a documented episode of pharyngitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Importance of pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal pharyngitis is the only streptococcal infection that has been associated with ARF. As an example, there have been many documented outbreaks of impetigo that can cause glomerulonephritis but almost never ARF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/24,29\">",
"     24,29",
"    </a>",
"    ]. In addition, a study of patients in Trinidad with ARF or acute glomerulonephritis (AGN) diagnosed during an outbreak of scabies and secondary impetigo found that the streptococcal strains colonizing the skin in patients with impetigo were different from those associated with rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/29\">",
"     29",
"    </a>",
"    ]. The presence of impetigo was associated with AGN, but did not influence the incidence of ARF.",
"   </p>",
"   <p>",
"    In communities of aboriginal Australians, pharyngeal carriage of GAS is uncommon although rates of ARF are high [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/30\">",
"     30",
"    </a>",
"    ]. Such findings have led to the hypothesis that ARF may arise from GAS pyoderma or from pharyngitis due to non-group A streptococcal strains that inherited certain group A streptococcal antigens or enzymes that are important for initiating ARF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/30\">",
"     30",
"    </a>",
"    ]. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Predisposing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial genetic factors may be an important determinant of the site of GAS infection. Five chromosome patterns of emm genes, which code for M and M-like surface proteins, have been recognized and labeled A-E. Pharyngeal strains typically have patterns A-C, whereas almost all impetigo strains show D and E patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rheumatogenic strains'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another factor affecting localization to the pharynx may be CD44, a hyaluronic acid binding protein that appears to act as a pharyngeal receptor for GAS. After intranasal inoculation, GAS colonize the oropharynx in wild-type mice but not transgenic mice that do not express CD44 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few theories have tried to explain why ARF is only associated with streptococcal pharyngitis, but the exact explanation remains obscure. GAS fall into two main classes based upon differences in the C repeat regions of the M protein [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/33\">",
"     33",
"    </a>",
"    ]. One class is associated with streptococcal pharyngeal infection; the other (with some exceptions) belongs to strains commonly associated with impetigo. Thus, the particular strain of streptococcus may be crucial in initiating the disease process. The pharyngeal site of infection, with its large repository of lymphoid tissue, also may be important in the initiation of the abnormal host response to those antigens crossreactive with target organs.",
"   </p>",
"   <p>",
"    Impetigo strains do colonize the pharynx. However, they do not appear to elicit as strong an immunologic response to the M protein moiety as the pharyngeal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This observation may prove to be an important factor, especially in light of the known cross-reaction between various streptococcal structures and mammalian proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of molecular mimicry, antibodies directed against GAS antigens crossreact with host antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. In addition to the role of antibody, observations suggest a role for cellular immunity in molecular mimicry in ARF. A study of human heart-intralesional T cell clones found that 63 percent of patients reacted with meromyosin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore many of these clones cross-reacted with myosin, valve-derived proteins, as well as streptococcal M5 peptides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal M protein and N-acetyl-beta-D-glucosamine (NABG, the immunodominant carbohydrate antigen of GAS) share epitopes with myosin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/37,38,40\">",
"     37,38,40",
"    </a>",
"    ]. Rodents immunized with recombinant streptococcal M protein type 6 develop both valvulitis and focal cardiac myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential clinical significance of these observations was illustrated in a study in which monoclonal antibodies were generated from tonsillar or peripheral blood lymphocytes of patients infected with GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/39\">",
"     39",
"    </a>",
"    ]. Some of these antibodies crossreacted with myosin and certain other proteins. In addition, antimyosin antibodies purified from patients with ARF crossreacted with GAS and M protein. Similar antibodies were present in much lower concentrations in some normal subjects.",
"   </p>",
"   <p>",
"    In a later report, a monoclonal antibody isolated from a patient with rheumatic carditis was directed against myosin and NABG [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/40\">",
"     40",
"    </a>",
"    ]. The antibody was cytotoxic for human endothelial cell lines and reacted with human valvular endothelium; this reactivity was inhibited by myosin&gt;laminin&gt;NABG. The reactivity with the extracellular matrix protein laminin may explain the reactivity against the valve surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular mimicry may also be involved in the development of Sydenham chorea. In an animal model, monoclonal antibodies that caused chorea bound to both NABG and mammalian lysoganglioside [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/43\">",
"     43",
"    </a>",
"    ]. Exposure of cultured human neuronal cells to either monoclonal antibodies or serum from patients with chorea led to induction of",
"    <span class=\"nowrap\">",
"     calcium/calmodulin",
"    </span>",
"    protein kinase. Exposure to serum from patients following streptococcal infection that was not complicated by chorea did not have this effect on neuronal cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=see_link\">",
"     \"Sydenham chorea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept that rheumatic fever might be the result of a host genetic predisposition has intrigued investigators for more than 100 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/44\">",
"     44",
"    </a>",
"    ]. During that time, suggestions have included the theory that the disease is transmitted in an autosomal dominant fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/45\">",
"     45",
"    </a>",
"    ], in an autosomal recessive fashion with limited penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/46\">",
"     46",
"    </a>",
"    ], or via genes related to determinants of blood group secretor status [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renewed interest in the genetics of rheumatic fever occurred with the recognition that gene products of the human MHC were associated with certain clinical diseases. Several studies have reported genetic associations with ARF; some appear to be MHC-related, others are non-MHC-related.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using an alloserum from a multiparous donor, an increased frequency of a B cell alloantigen that was not MHC-related was reported in several genetically distinct and ethnically diverse populations of individuals with ARF [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, monoclonal antibodies were generated by immunizing mice with B cells from patients with rheumatic fever. One of these antibodies,",
"      <span class=\"nowrap\">",
"       D8/17,",
"      </span>",
"      was found to identify a marker expressed on increased numbers (&gt;20 percent) of B cells in 100 percent of patients with ARF of diverse ethnic origins [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/49\">",
"       49",
"      </a>",
"      ]. The percentage of",
"      <span class=\"nowrap\">",
"       D8/17+",
"      </span>",
"      B cells ranged from 4 to 6 percent in approximately 90 to 95 percent of nonaffected normal subjects. In contrast, the number of",
"      <span class=\"nowrap\">",
"       D8/17+",
"      </span>",
"      B cells was one standard deviation above normal (10 to 12 percent) in 4 to 7 percent of subjects. Thus, this marker might identify a population of rheumatic fever-susceptible individuals. The antigen defined by this monoclonal antibody showed no association with or linkage to any known MHC allele, nor did it appear to be related to B cell activation antigens.",
"     </li>",
"     <li>",
"      An increased frequency of the classic MHC class II alleles, HLA-DR4 and DR2, has been noted in Caucasian and black patients with rheumatic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/50\">",
"       50",
"      </a>",
"      ]. Other studies have implicated DR1 and DRW6 as susceptibility factors in South African black patients with rheumatic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/51\">",
"       51",
"      </a>",
"      ] and a close association with HLA-DR7 and DW53 has been noted in ARF patients in Brazil [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8327/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These apparently differing results concerning HLA antigens and ARF susceptibility have led to speculation that the reported associations might be of genes close to, but not identical to, the ARF susceptibility gene. Alternatively, and more likely, susceptibility to ARF is polygenic, and the",
"    <span class=\"nowrap\">",
"     D8/17",
"    </span>",
"    antigen might be associated with only one of the genes conferring susceptibility; whereas another might be the MHC complex encoding for DR antigens. Although the exact explanation remains to be determined, the presence of an increased percentage of",
"    <span class=\"nowrap\">",
"     D8/17+",
"    </span>",
"    B cells appears to identify a population at special risk of contracting ARF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10703183\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute rheumatic fever (ARF) is a delayed, nonsuppurative sequela of a pharyngeal infection with the group A streptococcus (GAS). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of ARF occur in children 5 to 15 years of age. ARF is more common in developing than developed countries. Certain strains of GAS may have greater rheumatogenic potential. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenic mechanisms that lead to the development of acute rheumatic fever (ARF) remain incompletely understood. Streptococcal pharyngeal infection is required, although evidence is sparse that toxins produced by the streptococcus are important. Molecular mimicry, due to activation of autoreactive B and T cells by GAS antigens, is thought to play an important role in the initiation of the tissue injury. Genetic susceptibility may also be a factor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/1\">",
"      RAMMELKAMP CH Jr, STOLZER BL. The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/2\">",
"      Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/3\">",
"      Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med 2007; 357:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/4\">",
"      Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart 2008; 94:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/5\">",
"      Miyake CY, Gauvreau K, Tani LY, et al. Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics 2007; 120:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/6\">",
"      Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 1985; 72:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/7\">",
"      Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/8\">",
"      Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/9\">",
"      Hoffman TM, Rhodes LA, Pyles LA, et al. Childhood acute rheumatic fever: a comparison of recent resurgence areas to cases in West Virginia. W V Med J 1997; 93:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/10\">",
"      Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994; 124:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/11\">",
"      Westlake RM, Graham TP, Edwards KM. An outbreak of acute rheumatic fever in Tennessee. Pediatr Infect Dis J 1990; 9:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/12\">",
"      Hosier DM, Craenen JM, Teske DW, Wheller JJ. Resurgence of acute rheumatic fever. Am J Dis Child 1987; 141:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/13\">",
"      Siegel AC, Johnson EE, Stollerman GH. Controlled studies of streptococcal pharyngitis in a pediatric population, 1: factors related to the attack rate of rheumatic fever. N Engl J Med 1961; 265:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/14\">",
"      Markowitz M, Gerber MA. Rheumatic fever: recent outbreaks of an old disease. Conn Med 1987; 51:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/15\">",
"      Shulman ST, Stollerman G, Beall B, et al. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis 2006; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/16\">",
"      Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/17\">",
"      Lee GM, Wessels MR. Changing epidemiology of acute rheumatic fever in the United States. Clin Infect Dis 2006; 42:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/18\">",
"      Kaplan EL, Johnson DR, Cleary PP. Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. J Infect Dis 1989; 159:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/19\">",
"      Read SE, Reid HF, Fischetti VA, et al. Serial studies on the cellular immune response to streptococcal antigens in acute and convalescent rheumatic fever patients in Trinidad. J Clin Immunol 1986; 6:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/20\">",
"      Potter EV, Vincente JB, Mayon-WHite RT, et al. Skin infections and immunoglobulin A in serum, sweat, and saliva of patients recovered from poststreptococcal acute glomerulonephritis or acute rheumatic fever and their siblings. Am J Epidemiol 1982; 115:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/21\">",
"      Erdem G, Mizumoto C, Esaki D, et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis 2007; 45:e20.",
"     </a>",
"    </li>",
"    <li>",
"     Whitnack E, Bisno L. Rheumatic fever and other immunologically-mediated cardiac diseases. In: Clinical immunology, Parker C (Ed), WB Saunders, Philadelphia 1980. Vol 2, p.894.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/23\">",
"      STETSON CA, RAMMELKAMP CH Jr, KRAUSE RM, et al. Epidemic acute nephritis: studies on etiology, natural history and prevention. Medicine (Baltimore) 1955; 34:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/24\">",
"      Anthony BF, Kaplan EL, Wannamaker LW, et al. Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract. J Clin Invest 1969; 48:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/25\">",
"      Kaplan EL, Bisno AL. Antecedent streptococcal infection in acute rheumatic fever. Clin Infect Dis 2006; 43:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/26\">",
"      DENNY FW, WANNAMAKER LW, BRINK WR, et al. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J Am Med Assoc 1950; 143:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/27\">",
"      Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/28\">",
"      STOLLERMAN GH, LEWIS AJ, SCHULTZ I, TARANTA A. Relationship of immune response to group A streptococci to the course of acute, chronic and recurrent rheumatic fever. Am J Med 1956; 20:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/29\">",
"      Potter EV, Svartman M, Mohammed I, et al. Tropical acute rheumatic fever and associated streptococcal infections compared with concurrent acute glomerulonephritis. J Pediatr 1978; 92:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/30\">",
"      McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/31\">",
"      Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis 1996; 173:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/32\">",
"      Cywes C, Stamenkovic I, Wessels MR. CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest 2000; 106:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/33\">",
"      Bessen D, Jones KF, Fischetti VA. Evidence for two distinct classes of streptococcal M protein and their relationship to rheumatic fever. J Exp Med 1989; 169:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/34\">",
"      Kaplan EL, Anthony BF, Chapman SS, et al. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970; 49:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/35\">",
"      Bisno AL, Nelson KE. Type-specific opsonic antibodies in streptococcal pyoderma. Infect Immun 1974; 10:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/36\">",
"      van de Rijn I, Zabriskie JB, McCarty M. Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen. J Exp Med 1977; 146:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/37\">",
"      Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 1985; 162:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/38\">",
"      Cunningham MW, McCormack JM, Fenderson PG, et al. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol 1989; 143:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/39\">",
"      Cunningham MW, McCormack JM, Talaber LR, et al. Human monoclonal antibodies reactive with antigens of the group A Streptococcus and human heart. J Immunol 1988; 141:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/40\">",
"      Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000; 106:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/41\">",
"      Fa&eacute; KC, da Silva DD, Oshiro SE, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 2006; 176:5662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/42\">",
"      Quinn A, Kosanke S, Fischetti VA, et al. Induction of autoimmune valvular heart disease by recombinant streptococcal m protein. Infect Immun 2001; 69:4072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/43\">",
"      Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/44\">",
"      Cheadle WB. Harvean lectures on the various manifestations of the rheumatic state as exemplified in childhood and early life. Lancet 1889; 1:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/45\">",
"      Wilson MG, Schweitzr MD, Lubschez R. The familial epidemiology of rheumatic fever. J Pediatr 1943; 44:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/46\">",
"      Taranta A, Torosdag S, Metrakos JD, et al. Rheumatic fever in monozygotic and dizygotic twins. Circulation 1959; 20:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/47\">",
"      GLYNN LE, HOLBOROW EJ. Relation between blood groups, secretor status and susceptibility to rheumatic fever. Arthritis Rheum 1961; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/48\">",
"      Patarroyo ME, Winchester RJ, Vejerano A, et al. Association of a B-cell alloantigen with susceptibility to rheumatic fever. Nature 1979; 278:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/49\">",
"      Khanna AK, Buskirk DR, Williams RC Jr, et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest 1989; 83:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/50\">",
"      Ayoub EM, Barrett DJ, Maclaren NK, Krischer JP. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest 1986; 77:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/51\">",
"      Maharaj B, Hammond MG, Appadoo B, et al. HLA-A, B, DR, and DQ antigens in black patients with severe chronic rheumatic heart disease. Circulation 1987; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8327/abstract/52\">",
"      Guilherme L, Weidebach W, Kiss MH, et al. Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation 1991; 83:1995.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3151 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8327=[""].join("\n");
var outline_f8_8_8327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10703183\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatogenic strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of the streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Importance of pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10703183\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=related_link\">",
"      Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8328="Cytotoxic chemotherapy for metastatic melanoma";
var content_f8_8_8328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytotoxic chemotherapy for metastatic melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8328/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/8/8328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H100464857\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage. In that setting, surgical excision is curative in most cases, and patients at high-risk of developing metastatic disease may benefit from adjuvant therapy with interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with stage IV disease require systemic treatment (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). For patients with extracranial metastatic melanoma, cytotoxic chemotherapy historically was widely used in patients who were not candidates for therapy with high-dose interleukin-2 (IL-2), although this approach was never demonstrated to improve survival. The clinical role of cytotoxic chemotherapy administered as a single agent, in combination chemotherapy regimens, or in combination with biological agents (interleukin [IL]-2, interferon alfa [IFNa]) will be reviewed here.",
"   </p>",
"   <p>",
"    An overview of the management of advanced melanoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274871397\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY FOR DISSEMINATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches that have been shown to provide clinically important benefit for patients with disseminated melanoma in appropriately selected patients include immunotherapy with high-dose interleukin-2 (IL-2), immunotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , a monoclonal antibody targeting CTLA-4, and inhibition of the MAP kinase pathway with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    in patients whose tumors contain a V600 mutation in the BRAF gene. Cytotoxic chemotherapy does not have an established role in the initial management of patients with advanced melanoma.",
"   </p>",
"   <p>",
"    The factors influencing the choice of therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464864\">",
"    <span class=\"h1\">",
"     SINGLE AGENT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used agents for the treatment of advanced melanoma are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    and its prodrug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . Other agents that may have demonstrated at least some activity include the nitrosoureas, platinum compounds, vinca alkaloids, and taxanes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464871\">",
"    <span class=\"h2\">",
"     Dacarbazine and temozolomide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464879\">",
"    <span class=\"h3\">",
"     Dacarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     Dacarbazine",
"    </a>",
"    is the only cytotoxic drug approved in the United States for the treatment of patients with metastatic melanoma. However, there are no phase III trials that have demonstrated a survival benefit for dacarbazine compared with a \"no treatment\" control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/2\">",
"     2",
"    </a>",
"    ]. Dacarbazine is generally considered to be the most active single agent in patients with metastatic melanoma with a response rate of 8 to 20 percent. The vast majority of responses are only partial and the median response duration is four to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Long-term follow-up of patients treated with dacarbazine indicates that less than 2 percent of patients can be anticipated to survive six years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     Dacarbazine",
"    </a>",
"    is generally well tolerated, with the major side effect being nausea and vomiting. Dacarbazine administration requires good venous access, because of the potential for chemical phlebitis. Bone marrow suppression is usually only modest, and alopecia and fatigue are minimal, allowing most patients to maintain relatively normal function while receiving therapy.",
"   </p>",
"   <p>",
"    Typical schedules for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    are 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously for five days or 850 mg to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously over one hour every two to four weeks. Response rates and response duration do not appear to be affected by the administration schedule. The availability of powerful antiemetic agents permits the more convenient one day every three to four weeks schedule to be administered in an outpatient setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464886\">",
"    <span class=\"h3\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is an analog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    that is chemically degraded at physiologic pH to MTIC, the active metabolite of dacarbazine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast to dacarbazine, temozolomide does not require metabolic activation. Unlike dacarbazine, temozolomide is orally absorbed and can cross the blood brain barrier and may have some activity in brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link&amp;anchor=H14#H14\">",
"     \"Systemic therapy for brain metastases\", section on 'Melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of brain metastases in melanoma\", section on 'Systemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    has been compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in two randomized trials. In a phase III that included 305 patients with metastatic melanoma, treatment with temozolomide was associated with nonsignificant improvements in overall survival and progression-free survival compared to dacarbazine (median 7.7 versus 6.4 months and 1.9 months versus 1.5 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/7\">",
"     7",
"    </a>",
"    ]. Similarly, in a trial conducted by the EORTC in 859 patients with metastatic melanoma, there was no difference in overall or progression free survival (median 9.1 versus 9.4 months and 2.3 versus 2.2 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various experimental approaches to improve the activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    have not been successful, and the clinical data have not been sufficiently compelling to achieve FDA approval for the treatment of metastatic melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100474841\">",
"    <span class=\"h2\">",
"     Fotemustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrosoureas fotemustine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU), and semustine (methyl CCNU) all have produced overall response rates of 13 to 18 percent in patients with metastatic melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ]. Alopecia is more severe with these agents than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , and hematologic toxicity, particularly thrombocytopenia, is more prolonged.",
"   </p>",
"   <p>",
"    In a phase III trial, 229 patients with advanced disease, with or without brain metastases, were randomly assigned to fotemustine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/9\">",
"     9",
"    </a>",
"    ]. The objective response rate was twice as high with fotemustine compared with dacarbazine (15 versus 7 percent), but the median time to progression (1.9 and 1.8 months, respectively) and median survival (7.3 and 5.6 months, respectively) were not significantly different. Among patients without brain metastases, those randomly assigned to fotemustine had a lower risk of cerebral progression compared to dacarbazine (18 versus 23 percent) and a significantly longer time to the development of brain metastases (22.7 versus 7.2 months). This finding requires independent confirmation.",
"   </p>",
"   <p>",
"    There have been some encouraging responses when fotemustine was administered via the hepatic artery to patients with isolated liver metastases from primary uveal melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/10\">",
"     10",
"    </a>",
"    ]. The EORTC is currently conducting a randomized phase III trial comparing intrahepatic artery administration with intravenous fotemustine in this patient population (NCT00110123) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link&amp;anchor=H25#H25\">",
"     \"Ocular melanoma\", section on 'Hepatic artery infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although fotemustine is considered first-line therapy in some European countries, it is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464901\">",
"    <span class=\"h2\">",
"     Platinum compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    have shown only modest activity in patients with metastatic melanoma. Single agent cisplatin has been tested at doses up to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with response rates ranging from 0 to 53 percent (mean 15 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/3\">",
"     3",
"    </a>",
"    ]. Single arm studies have provided evidence for some dose dependency. In one study, for example, single-agent cisplatin was given at doses up to 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    , a thiol derivative with protective effects on bone marrow and renal tissue. Tumor responses were noted in 53 percent of patients, but all were partial and the median response duration was only four months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized phase II trial conducted by the Eastern Cooperative Oncology Group (ECOG) compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    to a lower dose of cisplatin alone (120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    Although both regimens showed activity, each had unacceptable renal, gastrointestinal, and ototoxicity, and amifostine failed to improve the clinical activity of cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    has been less extensively tested [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/13\">",
"     13",
"    </a>",
"    ], and its activity compared with other single agents is uncertain. These agents have been studied primarily in biochemotherapy combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464915\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microtubule toxins, such as vinca alkaloids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/14\">",
"     14",
"    </a>",
"    ], and agents that interfere with microtubule disassembly, such as the taxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], have shown only modest activity in patients with metastatic melanoma. These agents have been studied primarily in combinations.",
"   </p>",
"   <p>",
"    The nanoparticle albumin-bound formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel) was evaluated in a phase II study of 74 patients with metastatic melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/17\">",
"     17",
"    </a>",
"    ]. The response rates in chemotherapy-na&iuml;ve and previously treated patients were 22 and 3 percent, respectively. Nab-paclitaxel is currently being compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in a randomized phase III trial in previously untreated patients with metastatic disease (NCT00864253) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464922\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single agent activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    and its analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    have led to their use in combination with a variety of other agents. Initial studies suggested that such combinations may increase the response rate and possibly survival, compared with single agent dacarbazine or temozolomide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/19-24\">",
"     19-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, phase III trials have not confirmed a survival advantage compared to single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . The lack of improvement in survival is illustrated by results from a multicenter trial in which 240 patients were randomly assigned to either dacarbazine or a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , dacarbazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (CDBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the response rate with CDBT was marginally improved (19 versus 10 percent compared to dacarbazine alone, p = 0.09), median survival was seven months on both treatment arms. Toxicity (myelosuppression, nausea, vomiting, fatigue) was more severe with the combination regimen.",
"   </p>",
"   <p>",
"    In summary, there is at present no evidence to indicate that combination chemotherapy is more effective than single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    for patients with metastatic melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464929\">",
"    <span class=\"h1\">",
"     BIOCHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy with interferon alfa (IFNa) or interleukin (IL)-2 has activity in some patients with metastatic melanoma. These observations led to their evaluation in combination with cytotoxic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464936\">",
"    <span class=\"h2\">",
"     IFNa regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining cytotoxic chemotherapy with IFNa has been compared to chemotherapy alone in at least 11 randomized trials. This approach is illustrated by the two largest of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ECOG trial 3690, 271 patients were randomly assigned to one of four treatment arms:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      alone, dacarbazine with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , dacarbazine with IFNa, or dacarbazine with the combination of tamoxifen plus IFNa [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/26\">",
"       26",
"      </a>",
"      ]. The overall response rate was 18 percent, median time to treatment failure was 2.6 months, and median survival was 9.1 months. There were no significant differences in response rate, time to treatment failure, or overall survival that could be attributed to the addition of IFNa, tamoxifen, or the combination of these two agents to dacarbazine.",
"     </li>",
"     <li>",
"      A phase III trial from the Dermatologic Cooperative Oncology Group randomly assigned 282 patients to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      plus IFNa or temozolomide alone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/27\">",
"       27",
"      </a>",
"      ]. The addition of IFNa was associated with a significant increase in response rate (24 versus 13 percent), although the difference in survival was not significant (9.7 versus 8.4 months with temozolomide alone). Grade 3 or 4 leucopenia and thrombocytopenia were significantly more common with the regimen containing IFNa (20 versus 4 and 23 versus 4 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464943\">",
"    <span class=\"h2\">",
"     IL-2 regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies combined IL-2 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    . These combinations produced considerable toxicity, while yielding response rates in the range of only 13 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/3,28,29\">",
"     3,28,29",
"    </a>",
"    ]. Subsequent studies combined IL-2 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alone or in combination with other chemotherapy agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/30-37\">",
"     30-37",
"    </a>",
"    ]. These regimens produced higher response rates, often with an associated increase in toxicity. These results provided the basis for a number of phase III trials.",
"   </p>",
"   <p>",
"    Several large randomized phase III trials comparing biochemotherapy to",
"    <span class=\"nowrap\">",
"     IL-2/IFNa",
"    </span>",
"    or chemotherapy alone have been completed. The spectrum of trials that have failed to show a statistically significant survival benefit for biochemotherapy includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IFNa plus IL-2 with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (EORTC) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      with or without IL-2 and IFNa (National Cancer Institute Surgery Branch) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ) compared to the same chemotherapy regimen followed by outpatient IL-2 and IFNa (Italy) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      , plus IFNa compared to the same regimen with decrescendo IL-2 (EORTC) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (CVD) with or without IL-2 plus IFNa (Intergroup trial E3695) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two systematic reviews of the literature, which identified 18 trials that included over 2600 patients, compared biochemotherapy to chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Despite a higher response rate, no difference in survival was identified.",
"   </p>",
"   <p>",
"    The achievement of durable complete responses with IL-2 immunotherapy depends upon the use of high doses of IL-2. Integration of IL-2 into biochemotherapy regimens requires attenuation of IL-2 dose intensity that probably leads to the loss of its immunotherapeutic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose-dependency of IL-2 is supported by the results of a phase II study, in which high-dose bolus IL-2 was given to patients who had progressed on or after treatment with an IL-2 biochemotherapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/47\">",
"     47",
"    </a>",
"    ]. Complete responses to treatment with high-dose bolus IL-2 were observed in 4 of 26 patients (15 percent), all of whom had failed to respond to the original IL-2-containing biochemotherapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464950\">",
"    <span class=\"h2\">",
"     Clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of these trials, biochemotherapy, defined as any regimen containing a combination of one or more cytotoxic agents plus IL-2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IFNa cannot be considered a standard of care.",
"   </p>",
"   <p>",
"    Maintenance biotherapy may improve progression-free and overall survival. In a phase II, multicenter study, 133 patients were treated with induction chemotherapy combined with IL-2, IFNa, and granulocyte macrophage colony-stimulating factor (GM-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients who were progression-free at completion of induction were placed on maintenance therapy with IL-2 plus GM-CSF. The median progression-free and overall survival durations were 9 and 14 months, respectively. At a median follow-up of 30 months, 20 percent of patients remained alive, including 12 (9 percent) who were disease-free. However, 39 percent of patients progressed in the central nervous system (CNS), and in 40 percent of these, the CNS was the first or only site of progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100464957\">",
"    <span class=\"h2\">",
"     Future applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to reduce the incidence of central nervous system relapse associated with biochemotherapy regimens have focused on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    , which is absorbed orally and has significant central nervous system penetration. While substitution of temozolomide for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in biochemotherapy regimens appeared to reduce the incidence of initial CNS relapse, this benefit did not translate into increases in either time to progression or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have focused on moving biochemotherapy into the neoadjuvant or adjuvant setting. In addition to a lower tumor burden and associated immune suppression and treatment resistance, these earlier disease settings offer the potential advantage of a lower likelihood of early central nervous system involvement.",
"   </p>",
"   <p>",
"    As an example, an intergroup phase III trial compared the modified M. D. Anderson biochemotherapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/50\">",
"     50",
"    </a>",
"    ] to high-dose IFNa following resection of disease involving multiple or palpable regional lymph nodes (stage IIIB or IIIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8328/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients receiving biochemotherapy had a significantly improved progression-free survival at five years compared with high dose IFN (47 versus 39 percent, HR 0.76, 95%CI 0.58-0.98). However, the overall five-year survival was identical for both arms (56 percent, HR 1.02, 95%CI 0.76-1.37). Therefore the acute toxicity of biochemotherapy was substituted for the chronic toxicity of 12 months of IFN, without any benefit in overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100475599\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose interleukin-2 (IL-2),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (an anti-CTLA4 monoclonal antibody), and BRAF inhibition are the preferred modalities for the initial systemic treatment of patients with advanced melanoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"       \"Overview of the management of advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Single agent cytotoxic chemotherapy induces partial remissions in 10 to 20 percent of patients, but such remissions are generally of short duration, and therapy has not been shown to prolong survival. Cytotoxic chemotherapy should be restricted to patients who are not candidates for treatment with high-dose IL-2,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      and those have progressed after optimal treatment with other options. Active agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      , and fotemustine. (See",
"      <a class=\"local\" href=\"#H100464864\">",
"       'Single agent chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Combination chemotherapy regimens have not been demonstrated to have more activity than single agent chemotherapy and are associated with increased toxicity. (See",
"      <a class=\"local\" href=\"#H100464922\">",
"       'Combination chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combining chemotherapy with immunotherapy utilizing IL-2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interferon has not increased survival in multiple phase III trials. The use of biochemotherapy cannot be routinely recommended. (See",
"      <a class=\"local\" href=\"#H100464929\">",
"       'Biochemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/1\">",
"      Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/2\">",
"      Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; :CD001215.",
"     </a>",
"    </li>",
"    <li>",
"     Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Molecular Diagnosis, Prevention &amp; Therapy of Melanoma, Kirkwood JK (Ed), Marcel Dekker, New York 1997. p.219.",
"    </li>",
"    <li>",
"     Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Cutaneous Melanoma, 2nd, Balch, Houghton, Milton, et al (Eds), JB Lippincott Company, Philadelphia  p.498.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/5\">",
"      Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984; 53:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/6\">",
"      Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M &amp; B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/7\">",
"      Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/8\">",
"      Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/9\">",
"      Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/10\">",
"      Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on August 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/12\">",
"      Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/13\">",
"      Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987; 71:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/14\">",
"      Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1984; 2:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/15\">",
"      Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/16\">",
"      Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011; 22:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/17\">",
"      Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116:155.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on September 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/19\">",
"      Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/20\">",
"      McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/21\">",
"      Margolin KA, Liu PY, Flaherty LE, et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998; 16:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/22\">",
"      Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/23\">",
"      Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/24\">",
"      Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/25\">",
"      Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/26\">",
"      Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/27\">",
"      Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23:9001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/28\">",
"      Stoter G, Aamdal S, Rodenhuis S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991; 9:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/29\">",
"      Dummer R, Gore ME, Hancock BW, et al. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer 1995; 75:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/30\">",
"      Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/31\">",
"      Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/32\">",
"      Demchak PA, Mier JW, Robert NJ, et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/33\">",
"      Atkins MB, O'Boyle KR, Sosman JA, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/34\">",
"      Antoine EC, Benhammouda A, Bernard A, et al. Salp&ecirc;tri&egrave;re Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997; 3 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/35\">",
"      Legha SS, Ring S, Eton O, et al. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     Mousseau M, Khayat D, Benhammouda A, et al. Feasibility study of chemo-immunotherapy (Ch-IM) with cisplatin (CDDP) interleukin-2 (IL-2) and interferon alpha 2a (IFNa) on 14 melanoma brain metastases patients (pts) (abstract). Proc Am Soc Clin Oncol 1997; 16:1773a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/37\">",
"      Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/38\">",
"      Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/39\">",
"      Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/40\">",
"      Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/41\">",
"      Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23:6747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/42\">",
"      Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/43\">",
"      Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/44\">",
"      Sasse AD, Sasse EC, Clark LG, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; :CD005413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/45\">",
"      Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/46\">",
"      McDermott DF, Atkins MB. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J Clin Oncol 2007; 25:3791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/47\">",
"      Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/48\">",
"      O'Day SJ, Atkins MB, Boasberg P, et al. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009; 27:6207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/49\">",
"      Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8328/abstract/50\">",
"      McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6:2201.",
"     </a>",
"    </li>",
"    <li>",
"     Flaherty LE, Moon, J, Atkins MB, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol 30, 2012 (suppl; abstr 8504).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15406 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8328=[""].join("\n");
var outline_f8_8_8328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H100475599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100464857\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274871397\">",
"      CHOICE OF THERAPY FOR DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100464864\">",
"      SINGLE AGENT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464871\">",
"      Dacarbazine and temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100464879\">",
"      - Dacarbazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100464886\">",
"      - Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100474841\">",
"      Fotemustine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464901\">",
"      Platinum compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464915\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100464922\">",
"      COMBINATION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100464929\">",
"      BIOCHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464936\">",
"      IFNa regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464943\">",
"      IL-2 regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464950\">",
"      Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100464957\">",
"      Future applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100475599\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15406\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15406|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=related_link\">",
"      Ocular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8329="Lorazepam: Drug information";
var content_f8_8_8329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lorazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19669?source=see_link\">",
"    see \"Lorazepam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"    see \"Lorazepam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Lorazepam Intensol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lorazepam&reg;;",
"     </li>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Dom-Lorazepam;",
"     </li>",
"     <li>",
"      Lorazepam Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Lorazem;",
"     </li>",
"     <li>",
"      Nu-Loraz;",
"     </li>",
"     <li>",
"      PHL-Lorazepam;",
"     </li>",
"     <li>",
"      PMS-Lorazepam;",
"     </li>",
"     <li>",
"      PRO-Lorazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     Oral, I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     May be administered sublingually; not a labeled route): 0.5-2 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety, sedation, and procedural amnesia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-10 mg/day in 2-3 divided doses; usual dose: 2-6 mg/day in divided doses or 1-2 mg 1 hour before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 0.05 mg/kg administered 2 hours before surgery (maximum: 4 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.044 mg/kg 15-20 minutes before surgery (usual dose: 2 mg; maximum: 4 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: 2-4 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.: 4 mg/dose slow I.V. (maximum rate: 2 mg/minute); may repeat in 10-15 minutes; usual maximum dose: 8 mg. May be given I.M, but I.V. preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rapid tranquilization of agitated patient (unlabeled use):",
"     </b>",
"     Oral, I.M.: 1-2 mg administered every 30-60 minutes; may be administered with an antipsychotic (eg, haloperidol) (Battaglia, 2005; De Fruyt, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Average total dose for tranquilization: 4-8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Agitation in the ICU patient (unlabeled use):",
"     </b>",
"     I.V.: Loading dose: 0.02-0.04 mg/kg (maximum single dose: 2 mg); Maintenance: 0.02-0.06 mg/kg every 2-6 hours as needed",
"     <b>",
"      or",
"     </b>",
"     0.01-0.1 mg/kg/hour; maximum dose: &le;10 mg/hour (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Alcohol withdrawal syndrome (unlabeled use):",
"     </b>",
"     Oral: 2 mg every 6 hours for 4 doses, then 1 mg every  6 hours for 8 additional doses (Mayo-Smith, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Alcohol withdrawal delirium (unlabeled use)",
"     </b>",
"     (Mayo-Smith, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 1-4 mg every 5-15 minutes until calm, then every hour as needed to maintain light somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 1-4 mg every 30-60 minutes until calm, then every hour as needed to maintain light somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for lorazepam with concomitant medications:",
"     </b>",
"     <i>",
"      Probenecid or valproic acid:",
"     </i>",
"     Reduce lorazepam dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"      see \"Lorazepam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     Children 2-15 years (unlabeled use): I.V.: 0.05 mg/kg (up to 2 mg/dose) prior to chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety, sedation, and procedural amnesia:",
"     </b>",
"     Infants and Children (unlabeled except for oral use in children &gt;12 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: Usual: 0.05 mg/kg/dose (range: 0.02-0.09 mg/kg) every 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Usual: 0.05 mg/kg/dose (range: 0.02-0.09 mg/kg) every 4-8 hours; may use smaller doses (eg, 0.01-0.03 mg/kg) and repeat every 20 minutes, as needed to titrate to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants and Children (unlabeled use):",
"     </i>",
"     I.V.: 0.05-0.1 mg/kg (maximum: 4 mg/dose) slow I.V.  (maximum rate: 2 mg/minute); may repeat every 10-15 minutes as needed (Hegenbarth, 2008; Sabo-Graham, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for lorazepam with concomitant medications:",
"     </b>",
"     <i>",
"      Probenecid or valproic acid:",
"     </i>",
"     Reduce lorazepam dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anxiety, sedation, and procedural amnesia:",
"     </b>",
"     Oral: Initial: 1-2 mg/day in divided doses; Beers Criteria: Avoid maintenance doses &gt;3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Other indications:",
"     </b>",
"     Refer to adult dosing. Dose selection should generally be on the low end of the dosage range (ie, initial dose not to exceed 2 mg).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4413000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Risk of propylene glycol toxicity.  Monitor closely if using for prolonged periods or at high doses.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4413001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dose reduction necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol 400, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 2 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorazepam Intensol&trade;: 2 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 1 mg, 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F189975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F189901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Should be administered deep into the muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Do not exceed 2 mg/minute or 0.05 mg/kg over 2-5 minutes. Continuous infusion solutions should have an in-line filter and the solution should be checked frequently for possible precipitation. Avoid intra-arterial administration. Monitor I.V. site for extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Lorazepam oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with liquid (eg, water, juice, soda, soda-like beverage) or semisolid food (eg, applesauce, pudding), and stir for a few seconds to blend completely. The prepared mixture should be administered immediately.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F189981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, albumin, allopurinol, amifostine, amikacin, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, atracurium, bivalirudin, bumetanide, caspofungin, cefepime, cefotaxime, ciprofloxacin, cisatracurium, cisplatin, cladribine, clonidine, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, epinephrine, erythromycin lactobionate, etomidate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, fosphenytoin, furosemide, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, labetalol, levofloxacin, linezolid, melphalan, methadone, methotrexate, metronidazole, micafungin, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, oxaliplatin, paclitaxel, palonosetron, pancuronium, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, ranitidine, remifentanil, sulfamethoxazole/trimethoprim, tacrolimus, teniposide, thiotepa, vancomycin, vecuronium, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, aztreonam, caffeine citrate, floxacillin, gallium nitrate, idarubicin, imipenem/cilastatin, ondansetron, pantoprazole, sargramostim, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Foscarnet, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aripiprazole, cimetidine, dimenhydrinate, haloperidol, hydromorphone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, pantoprazole, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Management of anxiety disorders or short-term (&le;4 months) relief of the symptoms of anxiety, anxiety associated with depressive symptoms, or insomnia due to anxiety or transient stress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Status epilepticus, amnesia, sedation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F189969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol detoxification; psychogenic catatonia; partial complex seizures; agitation (I.V.); antiemetic for chemotherapy; rapid tranquilization of the agitated patient",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LORazepam may be confused with ALPRAZolam, clonazePAM, diazepam, KlonoPIN&reg;, Lovaza&reg;, temazepam, zolpidem",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Ativan&reg; may be confused with Ambien&reg;, Atarax&reg;, Atgam&reg;, Avitene&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injection dosage form contains propylene glycol. Monitor for toxicity when administering continuous lorazepam infusions.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Akathisia, amnesia, ataxia, confusion, depression, disorientation, dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Changes in appetite, nausea, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea, hyperventilation, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% or frequency not defined (Limited to important or life-threatening): Asthenia, blood dyscrasias, disinhibition, euphoria, fatigue, increased salivation, menstrual irregularities, physical and psychological dependence (with prolonged use), reflex slowing, polyethylene glycol or propylene glycol poisoning (prolonged I.V. infusion), suicidal ideation, seizure, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lorazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); acute narrow-angle glaucoma; sleep apnea (parenteral); intra-arterial injection of parenteral formulation; severe respiratory insufficiency (except during mechanical ventilation)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse, alcoholism, or significant personality disorders; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use. Risk of dependence increases with higher dosage and longer duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dose adjustment may be needed. May worsen hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use caution in patients with depression, particularly if suicidal risk may be present. Pre-existing depression may emerge or worsen during therapy. Not recommended for use in primary depressive or psychotic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease, including COPD or sleep apnea. Benzodiazepines may cause significant respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group, avoid use for treatment of insomnia, agitation, or delirium.  (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyethylene glycol: Parenteral formulation contains polyethylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol: Parenteral formulation contains propylene glycol (PG). May be associated with dose-related toxicity and can occur &ge;48 hours after initiation of lorazepam. Limited data suggest increased risk of PG accumulation at doses of &ge;6 mg/hour for 48 hours or more (Nelson, 2008). Monitor for signs of toxicity which may include acute renal failure, lactic acidosis, and/or osmol gap. May consider using enteral delivery of lorazepam tablets to decrease the risk of PG toxicity (Lugo, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F189921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal studies. Lorazepam and its metabolite cross the human placenta. Teratogenic effects in humans have been observed with some benzodiazepines (including lorazepam); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (including lorazepam). Elimination of lorazepam in the newborn infant is slow; following",
"     <i>",
"      in utero",
"     </i>",
"     exposure, term infants may excrete lorazepam for up to 8 days.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F189909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (LORazepam Intensol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (30 mL): $48.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (LORazepam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (30 mL): $39.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ativan Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $2.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (LORazepam Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $0.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $3.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ativan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $447.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $597.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $952.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (LORazepam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $67.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $88.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $128.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clinical signs of propylene glycol toxicity (for continuous high-dose and/or long duration intravenous use): Serum creatinine, BUN, serum lactate, osmol gap",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Critically-ill patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F189897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 50-240 ng/mL (SI: 156-746 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abinol (CN);",
"     </li>",
"     <li>",
"      Ansilor (PT);",
"     </li>",
"     <li>",
"      Anta (TH);",
"     </li>",
"     <li>",
"      Anxira (TH);",
"     </li>",
"     <li>",
"      Anzepam (TW);",
"     </li>",
"     <li>",
"      Aplacasse (AR);",
"     </li>",
"     <li>",
"      Aripax (GR);",
"     </li>",
"     <li>",
"      Ativan (AU, BF, BJ, CI, CO, CR, DO, EC, ET, GB, GH, GM, GN, GT, HN, IE, IN, KE, KP, LR, MA, ML, MR, MU, MW, MX, NE, NG, NI, NZ, PA, PE, PH, PK, SC, SD, SG, SL, SN, SV, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Bonatranquan (DE);",
"     </li>",
"     <li>",
"      Control (IT);",
"     </li>",
"     <li>",
"      Emotival (AR);",
"     </li>",
"     <li>",
"      Larpose (IN);",
"     </li>",
"     <li>",
"      Laubeel (DE);",
"     </li>",
"     <li>",
"      Lauracalm (LU);",
"     </li>",
"     <li>",
"      Lonza (TH);",
"     </li>",
"     <li>",
"      Lopam (TW);",
"     </li>",
"     <li>",
"      Lora (CL);",
"     </li>",
"     <li>",
"      Lorabenz (DK);",
"     </li>",
"     <li>",
"      Lorafen (PL);",
"     </li>",
"     <li>",
"      Loram (HR);",
"     </li>",
"     <li>",
"      Lorans (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Loravan (KP);",
"     </li>",
"     <li>",
"      Lorax (BR);",
"     </li>",
"     <li>",
"      Lorazep (TH);",
"     </li>",
"     <li>",
"      Lorazepam-Efeka (LU);",
"     </li>",
"     <li>",
"      Lorazepam-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Lorazin (TW);",
"     </li>",
"     <li>",
"      Lorenin (PT);",
"     </li>",
"     <li>",
"      Loridem (BE, LU);",
"     </li>",
"     <li>",
"      Lorivan (IL);",
"     </li>",
"     <li>",
"      Lorsilan (HR);",
"     </li>",
"     <li>",
"      Lozicum (HK);",
"     </li>",
"     <li>",
"      Merlit (AT, RU);",
"     </li>",
"     <li>",
"      Merlopam (ID);",
"     </li>",
"     <li>",
"      Nervistop L (AR);",
"     </li>",
"     <li>",
"      Neuropam (TW);",
"     </li>",
"     <li>",
"      Novhepar (GR);",
"     </li>",
"     <li>",
"      Orfidal (ES);",
"     </li>",
"     <li>",
"      Psicopax (PY);",
"     </li>",
"     <li>",
"      Renaquil (ID);",
"     </li>",
"     <li>",
"      Sedatival (AR);",
"     </li>",
"     <li>",
"      Sidenar (AR);",
"     </li>",
"     <li>",
"      Silence (HK, TW);",
"     </li>",
"     <li>",
"      Stapam (TW);",
"     </li>",
"     <li>",
"      Tavor (BG, CZ, DE, GR, IT);",
"     </li>",
"     <li>",
"      Temesta (AT, BE, CH, DK, FI, FR, LU, NL, SE);",
"     </li>",
"     <li>",
"      Titus (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Tranqipam (ZA);",
"     </li>",
"     <li>",
"      Trapax (AR);",
"     </li>",
"     <li>",
"      Trapex (IN);",
"     </li>",
"     <li>",
"      Vigiten (LU);",
"     </li>",
"     <li>",
"      Zora (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnosis: I.M.: 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: I.V.: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anticonvulsant: I.V.: 5 minutes, oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.M.: Prompt",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Neonates: 0.76 L/kg, Adults: 1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85%; free fraction may be significantly higher in elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: 40.2 hours; Older children: 10.5 hours; Adults: 12.9 hours; Elderly: 15.9 hours; End-stage renal disease: 32-70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces (minimal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abernethy DR, Greenblatt DJ, Ameer B, et al, &ldquo;Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,&rdquo;",
"      <i>",
"       J Pharmacol Exp Ther",
"      </i>",
"      , 1985, 234(2):345-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/4020675/pubmed\" id=\"4020675\" target=\"_blank\">",
"        4020675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alldredge BK, Gelb AM, Isaacs SM, et al, &ldquo;A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(9):631-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/11547716/pubmed\" id=\"11547716\" target=\"_blank\">",
"        11547716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ameer B and Greenblatt DJ, &ldquo;Lorazepam: A Review of Its Clinical Pharmacological Properties and Therapeutic Uses,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1981, 21(3):162-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/6114848/pubmed\" id=\"6114848\" target=\"_blank\">",
"        6114848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GD, Gidal BE, Kantor ED, et al, &ldquo;Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1994, 35(1):221-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/8112251/pubmed\" id=\"8112251\" target=\"_blank\">",
"        8112251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arroliga AC, Shehab N, McCarthy K, et al, &ldquo;Relationship of Continuous Infusion Lorazepam to Serum Propylene Glycol Concentration in Critically Ill Adults,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(8):1709-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/15286548/pubmed\" id=\"15286548\" target=\"_blank\">",
"        15286548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barnes BJ, Gerst C, Smith JR, et al, &ldquo;Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(1):23-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/16422667/pubmed\" id=\"16422667\" target=\"_blank\">",
"        16422667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Battaglia J, \"Pharmacological Management of Acute Agitation,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(9):1207-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/15916448/pubmed\" id=\"15916448\" target=\"_blank\">",
"        15916448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bishop JF, Olver IN, Wolf MM, et al, &ldquo;Lorazepam: A Randomized, Double-Blind, Crossover Study of a New Antiemetic in Patients Receiving Cytotoxic Chemotherapy and Prochlorperazine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1984, 2(5):691-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/6374058/pubmed\" id=\"6374058\" target=\"_blank\">",
"        6374058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleck TB, Seizures, Stroke, and Other Neurologic Emergencies. In: Zimmerman JL, Roberts PR, eds.",
"      <i>",
"       Multidisciplinary Critical Care Review",
"      </i>",
"      , Des Plains, IL: Society of Critical Care Medicine; 2003:325-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar AU, Esparza L, Natale R, et al, &ldquo;Lorazepam-Enhancement of the Antiemetic Efficacy of Dexamethasone and Promethazine. A Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1994, 17(5):417-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/8092114/pubmed\" id=\"8092114\" target=\"_blank\">",
"        8092114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, Sage TA, Tunget C, et al, &ldquo;Delayed Onset Lorazepam Poisoning Successfully Reversed by Flumazenil in a Child: Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1995, 11(1):32-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/7739960/pubmed\" id=\"7739960\" target=\"_blank\">",
"        7739960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crawford TO, Mitchell WG, and Snodgrass SR, &ldquo;Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1987, 37(2):190-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/3808299/pubmed\" id=\"3808299\" target=\"_blank\">",
"        3808299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Fruyt J and Demyttenaere K, \"Rapid Tranquilization: New Approaches in the Emergency Treatment of Behavioral Disturbances,\"",
"      <i>",
"       Eur Psychiatry",
"      </i>",
"      , 2004, 19(5):243-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/15276655/pubmed\" id=\"15276655\" target=\"_blank\">",
"        15276655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deshmukh A, Wittert W, Schnitzler E, et al, &ldquo;Lorazepam in the Treatment of Refractory Neonatal Seizures: A Pilot Study,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1986, 140(10):1042-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/3752014/pubmed\" id=\"3752014\" target=\"_blank\">",
"        3752014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Divoll M and Greenblatt DJ, &ldquo;Effect of Age and Sex on Lorazepam Protein Binding,&rdquo;",
"      <i>",
"       J Pharm Pharmacol",
"      </i>",
"      , 1982, 34(2):122-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/6121874/pubmed\" id=\"6121874\" target=\"_blank\">",
"        6121874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraser AD and Bryan W, &ldquo;Evaluation of the Abbott TDx&reg; Serum Benzodiazepine Immunoassay for the Analysis of Lorazepam, Adinazolam, and N-Desmethyladinazolam,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(5):281-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/7500613/pubmed\" id=\"7500613\" target=\"_blank\">",
"        7500613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenblatt DJ, Allen MD, Locniskar A, et al, &ldquo;Lorazepam Kinetics in the Elderly,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):103-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/36252/pubmed\" id=\"36252\" target=\"_blank\">",
"        36252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guterman B, Sebastian P, and Sodha N, &ldquo;Recovery From Alpha Coma After Lorazepam Overdose,&rdquo;",
"      <i>",
"       Clin Electroencephalogr",
"      </i>",
"      , 1981, 12(4):205-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/6121636/pubmed\" id=\"6121636\" target=\"_blank\">",
"        6121636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hayman M, Seidl EC, Ali M, et al, &ldquo;Acute Tubular Necrosis Associated With Propylene Glycol From Concomitant Administration of Intravenous Lorazepam and Trimethoprim-sulfamethoxazole,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(9):1190-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/14524651/pubmed\" id=\"14524651\" target=\"_blank\">",
"        14524651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henry DW, Burwinkle JW, and Klutman NE, &ldquo;Determination of Sedative and Amnestic Doses of Lorazepam in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(8):625-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/1934919/pubmed\" id=\"1934919\" target=\"_blank\">",
"        1934919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalviainen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lapierre YD and Labelle A, &ldquo;Manic-Like Reaction Induced by Lorazepam Withdrawal,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1987, 32(8):697-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/3690487/pubmed\" id=\"3690487\" target=\"_blank\">",
"        3690487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laszlo J, Clark RA, Hanson DC, et al, &ldquo;Lorazepam in Cancer Patients Treated With Cisplatin: A Drug Having Antiemetic, Amnesic, and Anxiolytic Effects,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1985, 3(6):864-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/4040158/pubmed\" id=\"4040158\" target=\"_blank\">",
"        4040158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SA, Lee JK, Heo K, &ldquo;Coma Probably Induced by Lorazepam-Valproate Interaction,&rdquo;",
"      <i>",
"       Seizure",
"      </i>",
"      , 2002, 11(2):124-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/11945099/pubmed\" id=\"11945099\" target=\"_blank\">",
"        11945099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee DS, Wong HA, and Knoppert DC, &ldquo;Myoclonus Associated With Lorazepam Therapy in Very-Low-Birth-Weight Infants,&rdquo;",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 1994, 66(6):311-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/7727612/pubmed\" id=\"7727612\" target=\"_blank\">",
"        7727612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lheureux P and Askenasi R, &ldquo;Specific Treatment of Benzodiazepine Overdose,&rdquo;",
"      <i>",
"       Hum Toxicol",
"      </i>",
"      , 1988, 7(2):165-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/3132418/pubmed\" id=\"3132418\" target=\"_blank\">",
"        3132418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lugo RA, Chester EA, Cash J, et al, &ldquo;A Cost Analysis of Enterally Administered Lorazepam in the Pediatric Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(2):417-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/10075070/pubmed\" id=\"10075070\" target=\"_blank\">",
"        10075070",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malik IA, Khan WA, Qazilbash M, et al, &ldquo;Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin. A Prospective Randomized Trial,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1995, 18(2):170-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/7900711/pubmed\" id=\"7900711\" target=\"_blank\">",
"        7900711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manno EM, &ldquo;New Management Strategies in the Treatment of Status Epilepticus,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2003, 78(4):508-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/12683704/pubmed\" id=\"12683704\" target=\"_blank\">",
"        12683704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(4):657-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/7699551/pubmed\" id=\"7699551\" target=\"_blank\">",
"        7699551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayo-Smith MF, \"Pharmacological Management of Alcohol Withdrawal. A Meta-analysis and Evidence-Based Practice Guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 278(2):144-51",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/9214531/pubmed\" id=\"9214531\" target=\"_blank\">",
"        9214531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayo-Smith MF, Beecher LH, Fischer TL, et al, \"Management of Alcohol Withdrawal Delirium. An Evidence-Based Practice Guideline,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2004, 164(13):1405-12; published erratum appears in",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2004, 164(18):2068.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/15249349/pubmed\" id=\"15249349\" target=\"_blank\">",
"        15249349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDermott CA, Kowalczyk AL, Schnitzler ER, et al, &ldquo;Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(3):479-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/1538303/pubmed\" id=\"1538303\" target=\"_blank\">",
"        1538303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelsen JL, Haas, CE, Habtemariam B, et al, &ldquo;A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients,&rdquo;",
"      <i>",
"       J Intens Care Med",
"      </i>",
"      , 2008, 23(3):184-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/18543419/pubmed\" id=\"18543419\" target=\"_blank\">",
"        18543419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pandharipande PP, Pun BT, Herr DL, et al, &ldquo;Effect of Sedation With Dexmedetomidine Vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients: The MENDS Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(22):2644-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/1807336/pubmed\" id=\"1807336\" target=\"_blank\">",
"        1807336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabo-Graham T and Seay AR, &ldquo;Management of Status Epilepticus in Children,&rdquo;",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 1998, 19(9):306-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/9745313/pubmed\" id=\"9745313\" target=\"_blank\">",
"        9745313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samara EE, Granneman RG, Witt GF, et al, &ldquo;Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1997, 37(5):442-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/9156377/pubmed\" id=\"9156377\" target=\"_blank\">",
"        9156377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stanford GK and Pine RH, &ldquo;Postburn Delirium Associated With Use of Intravenous Lorazepam,&rdquo;",
"      <i>",
"       J Burn Care Rehabil",
"      </i>",
"      , 1988, 9(2):160-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/3360819/pubmed\" id=\"3360819\" target=\"_blank\">",
"        3360819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(7):854-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/8340986/pubmed\" id=\"8340986\" target=\"_blank\">",
"        8340986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treiman DM, Meyers PD, Walton NY, et al, &ldquo;A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(12):792-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/9738086/pubmed\" id=\"9738086\" target=\"_blank\">",
"        9738086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uchaipichat V, Mackenzie PI, Guo XH, et al, &ldquo;Human UDP-Glucuronosyltransferases: Isoform Selectivity and Kinetics of 4-Methylumbelliferone and 1-Naphthol Glucuronidation, Effects of Organic Solvents, and Inhibition by Diclofenac and Probenecid,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2004, 32(4):413-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/15039294/pubmed\" id=\"15039294\" target=\"_blank\">",
"        15039294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vlachos P, Kentarchou P, Poulosa L, et al, &ldquo;Lorazepam Poisoning,&rdquo;",
"      <i>",
"       Toxicol Lett",
"      </i>",
"      , 1978, 2:109-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Moltke LL, Manis M, Harmatz JS, et al, &ldquo;Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,&rdquo;",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1993, 14(2):119-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/8453022/pubmed\" id=\"8453022\" target=\"_blank\">",
"        8453022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiley J and Wiley C, &ldquo;Benzodiazepine Ingestions in Children,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):520.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaucher NE, Fish JT, Smith HW, et al, &ldquo;Propylene Glycol-Associated Renal Toxicity From Lorazepam Infusion,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(9):1094-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/8/8329/abstract-text/14524641/pubmed\" id=\"14524641\" target=\"_blank\">",
"        14524641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9573 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8329=[""].join("\n");
var outline_f8_8_8329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189926\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189927\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189973\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189931\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189951\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189932\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4413000\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4413001\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189896\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189880\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189975\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189901\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189981\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189900\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189969\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189983\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189971\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189904\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189884\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299616\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189889\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189921\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189891\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189908\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189937\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189909\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189907\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189893\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189897\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189910\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189883\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189903\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19669?source=related_link\">",
"      Lorazepam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=related_link\">",
"      Lorazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8330="Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome";
var content_f8_8_8330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8330/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8330/contributors\">",
"     J Quentin Clemens, MD, FACS, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8330/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/8/8330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/8/8330/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/8/8330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28423471\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bladder pain can be a debilitating condition that impacts quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pathophysiology of chronic bladder pain is not well understood and it is likely that such symptoms represent more than one underlying etiology. Interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    is a diagnosis that applies to patients with chronic bladder pain in the absence of other etiologies of the symptoms. Identification of patients who meet diagnostic criteria for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    allows for treatment with the goal of providing symptomatic relief. This condition often coexists with other chronic pain syndromes (eg, fibromyalgia, irritable bowel syndrome).",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, and diagnosis of interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome will be discussed here. Management of this condition is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4802765\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bladder pain in the absence of an identifiable etiology has historically been called interstitial cystitis. This term is a misnomer, however, since there is no clear evidence that bladder inflammation (cystitis) is involved in the etiology or pathophysiology of the condition, nor is there evidence that the condition is associated with abnormalities of the interstices of the bladder.",
"   </p>",
"   <p>",
"    The current understanding is that patients with these symptoms have a chronic pain condition of the bladder, analogous to other poorly understood chronic pain conditions such as fibromyalgia or irritable bowel syndrome. As such, there has been a movement to rename the condition painful bladder syndrome or bladder pain syndrome. However, considerable previous efforts have been devoted to recognizing &ldquo;interstitial cystitis&rdquo; as a legitimate, disabling medical condition and, therefore, the term has been retained in contemporary use in order to maintain continuity. This topic review will use the term &ldquo;interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome.&rdquo;",
"   </p>",
"   <p>",
"    The definition of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H13715198\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28423485\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    have varied, which had made establishing the prevalence difficult.",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptoms are present in many patients that have not been given an official diagnosis of this condition, suggesting that the prevalence has been underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence studies for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    have used one of three methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-report studies (survey participants were asked if they have been diagnosed with the condition) have estimated the prevalence to be approximately 850 per 100,000 women and 60 per 100,000 men [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical billing data have been queried to determine the prevalence of physician-diagnosed",
"      <span class=\"nowrap\">",
"       IC/BPS,",
"      </span>",
"      based on the ICD-9 code 595.1 (&ldquo;interstitial cystitis&rdquo;), yielding estimates of 197 per 100,000 women, and 41 per 100,000 men [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptom surveys have been conducted, in which respondents were asked to complete a questionnaire regarding",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      symptoms. The most comprehensive study of this type is the RAND Interstitial Cystitis Epidemiology (RICE) study [",
"      <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/7\">",
"       7",
"      </a>",
"      ]. These investigators conducted a two-stage survey of approximately 150,000 United States households to identify and interview women with",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      symptoms. Using two validated",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      case definitions (high sensitivity definition and high specificity definition), they concluded that between 2.7 and 6.5 percent of United States women have symptoms consistent with a diagnosis of",
"      <span class=\"nowrap\">",
"       IC/BPS.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is most commonly diagnosed in the fourth decade or later, but symptoms have been recognized in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    occurs approximately five times more commonly in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/4\">",
"     4",
"    </a>",
"    ]. Other risk factors are not well established. The few studies which have examined",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    prevalence patterns suggest that no large differences exist, but these data are very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/12\">",
"     12",
"    </a>",
"    ]. A greater concordance of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    among monozygotic twin pairs than among dizygotic twin pairs suggests a genetic susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    often coexists with other chronic pain conditions (eg, fibromyalgia, irritable bowel syndrome). (See",
"    <a class=\"local\" href=\"#H318782\">",
"     'Coexisting conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28423492\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little known about the etiology and pathogenesis of interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS).",
"    </span>",
"    Ongoing and future research will likely demonstrate that patients currently grouped together under the umbrella diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    actually suffer from several different conditions with distinct etiologies.",
"   </p>",
"   <p>",
"    It is accepted that any of several inciting factors may lead to the clinical manifestation of",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    and several pathogenetic mechanisms have been proposed to explain the clinical phenomena.",
"   </p>",
"   <p>",
"    There are no consistent triggering events for",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    Most patients cannot identify a preceding event, while others developed symptoms after an apparently uncomplicated urinary tract infection, surgical procedure, or pelvic trauma, such as a fall onto the coccyx. Surveys of patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    suggest that certain foods and beverages, such as caffeine, alcoholic beverages, citrus fruits, tomatoes, and spicy foods, may worsen symptoms in some patients, although this is highly variable from patient to patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in which patients underwent bladder biopsy have documented that patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    have urothelial abnormalities. Importantly, it is not known whether these urothelial abnormalities are secondary to another process that is not yet recognized.",
"   </p>",
"   <p>",
"    Urothelial abnormalities in patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    include: altered bladder epithelial expression of HLA Class I and II antigens, decreased expression of uroplakin and chondroitin sulfate, altered cytokeratin profile (towards a profile more typical of squamous cells), and altered integrity of the glycosaminoglycan (GAG) layer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. A defect in Tamm-Horsfall protein has been found in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, the expression of interleukin-6 and P2X3 ATP receptors is increased, and activation of the NFkB gene is enhanced.",
"   </p>",
"   <p>",
"    The GAG layer of the bladder normally coats the urothelial surface and renders it impermeable to solutes, and, therefore, defects in this layer may allow urinary irritants to penetrate the urothelium and activate the underlying nerve and muscle tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/24\">",
"     24",
"    </a>",
"    ]. This process may promote further tissue damage, pain, and hypersensitivity. Bladder mast cells may also play a role in the propagation of ongoing bladder damage after an initial insult [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiproliferative factor (APF) may also have a pathogenetic role in the generation of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptoms. APF is a lipoglycopeptide that is produced by the urothelium of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    patients, but not by patients without",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/27\">",
"     27",
"    </a>",
"    ]. APF may affect urothelial activity through altered production of growth factors and other proteins involved in urothelial growth and function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic upregulation of pain sensation likely plays a role in",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    Central sensitization and increased activation of bladder sensory neurons during normal bladder filling may result in bladder pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This increased sensitivity may be present in the bladder itself, or may be due to increased activity and new pathways within the central nervous system. Animal models suggest that hypersensitivity in bowel and other pelvic organs may be responsible for sensitization of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/31\">",
"     31",
"    </a>",
"    ]. Similar alterations in neural pathways may be responsible for the suprapubic tenderness that is present in",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/32\">",
"     32",
"    </a>",
"    ]. It is also possible that the increase in visceral (bladder) sensitivity is secondary to a primary somatic injury that has sensitized central pathways that overlap with afferents from the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28423499\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    is typically characterized by bladder discomfort, often associated with bladder filling, as well as pelvic tenderness on examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2089812\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, all patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    have persistent unpleasant sensations that are attributable to the bladder. The characteristics of these sensations are variable, but the most consistent feature is an increase in discomfort with bladder filling and a relief with voiding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This symptom pattern is found in most, but not all, patients with",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    The distribution of symptoms at time of diagnosis is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef56872 \" href=\"UTD.htm?39/53/40795\">",
"     table 1",
"    </a>",
"    ). The American Urological Association definition of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    requires that the duration of symptoms is at least six weeks. (See",
"    <a class=\"local\" href=\"#H13715198\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The character of the unpleasant sensation varies across patients and across time in individual patients. Some patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    complain of bladder pain, while others describe the sensations as &ldquo;pressure&rdquo; or &ldquo;discomfort.&rdquo; Some patients describe bladder spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/34\">",
"     34",
"    </a>",
"    ]. The character of symptoms may vary from one day to the next in a single patient. The severity of pain ranges from mild pressure to severe, debilitating pain.",
"   </p>",
"   <p>",
"    The location of the pain or discomfort is usually described as being suprapubic or urethral, although patterns such as unilateral lower abdominal pain or low back pain with bladder filling are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. Isolated urethral pain is uncommon; most patients cannot differentiate between urethral and bladder pain.",
"   </p>",
"   <p>",
"    Regarding the onset of the symptoms, the majority of patients describe symptoms that are of gradual onset, with worsening of discomfort, urgency and frequency over a period of months. A smaller subset of patients describes symptoms that are abrupt and severe from their onset, with some patients able to name the exact date on which symptoms began.",
"   </p>",
"   <p>",
"    Most patients cannot identify a triggering event, but some developed symptoms after an apparently uncomplicated urinary tract infection or surgical procedure, or after a trauma, such as a fall onto the coccyx. Exacerbation of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptoms may occur after intake of certain foods or drinks, during stress, after certain activities (eg, exercise, sexual intercourse, prolonged sitting), or during the luteal phase of the menstrual cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/15,36,37\">",
"     15,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional urinary symptoms, including urinary frequency, urgency, and nocturia, often accompany the discomfort or pain. A consistent feature of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is that the bothersome sensations are worsened by bladder filling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relieved by emptying. Thus, increased urinary frequency may arise because the pain of bladder filling is partially or completely relieved by voiding, so patients prefer to maintain low bladder volumes.",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is not commonly associated with urinary incontinence.",
"   </p>",
"   <p>",
"    To further clarify the etiology of nonspecific urinary symptoms, it is useful to ask patients why they void frequently to help distinguish",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    from other causes of urinary frequency. As an example, patients with overactive bladder syndrome may void frequently to avoid urinary urge incontinence, whereas in",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    they void frequently to avoid discomfort. Patients with severe",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    may void as many as 60 times per day, with associated disruption of daytime activities and sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients may describe sitting on a toilet for hours at a time in order to let urine dribble from their bladders more or less continuously so that bladders remain as empty as possible and pain is minimized.",
"   </p>",
"   <p>",
"    Many patients experience disruption of home and work life due to chronic pain, urinary frequency, and fatigue, predictably resulting in some degree of worsening of quality of life. In surveys, 50 percent of patients reported being unable to work full-time, 75 percent described dyspareunia, 70 percent reported sleep disturbance, and 90 percent reported that",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    affected their daily activities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other chronic pain symptoms (eg, irritable bowel syndrome, vulvodynia, fibromyalgia) are present in many patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/39\">",
"     39",
"    </a>",
"    ]. They may also describe exacerbation of their",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptoms during times when other pain symptoms are at their worst. Pain associated with these conditions should be differentiated from",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    pain, whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of generalized vulvodynia\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link&amp;anchor=H3#H3\">",
"      \"Clinical manifestations and diagnosis of fibromyalgia in adults\", section on 'Symptoms'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H318782\">",
"    <span class=\"h2\">",
"     Coexisting conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IC/BPS",
"    is often associated with other conditions, particularly chronic pain conditions (eg, vulvodynia, irritable bowel syndrome, fibromyalgia,). A diagnosis of one of these conditions makes the diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    more likely, but at the same time makes it difficult, since bladder or perivesical pain is also a feature of some of these conditions.",
"   </p>",
"   <p>",
"    Vulvodynia coexists with interstitial",
"    <span class=\"nowrap\">",
"     cystitis/painful",
"    </span>",
"    bladder syndrome in many women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. As an example, one study of 122 women found that 80 percent of those with vulvodynia also had symptomatic interstitial",
"    <span class=\"nowrap\">",
"     cystitis/painful",
"    </span>",
"    bladder syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/44\">",
"     44",
"    </a>",
"    ]. It is uncertain whether this represents referred pain between the bladder and vulva or a shared pathogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=see_link&amp;anchor=H4268195#H4268195\">",
"     \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\", section on 'Interstitial cystitis/painful bladder syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sexual concerns are common in women with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. This is likely due primarily to coexisting vulvodynia and resultant dyspareunia, as well as bladder-specific symptoms during sexual activity. As an example, a questionnaire study of 985 women with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    who had sexual partners found that 88 percent reported a general sexual dysfunction symptom (eg, low libido, difficulty with arousal) and 90 percent reported a sexual symptom specifically associated with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    (eg, bladder pain during sex, urge to urinate during sex) within the past four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H7#H7\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other gynecologic conditions that have been found to be common in women with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    include dysmenorrhea and endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to women, men with pelvic pain often have concomitant sexual dysfunction, as with men with chronic prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many conditions associated with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    involve chronic pain or psychiatric illness. The frequency of conditions or history that are commonly found in men and women with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    was reported by a case-control study, including: gastritis (12-fold more likely in patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    than controls); child abuse (9-fold); fibromyalgia (3-fold); anxiety disorder (3-fold); headache (3-fold); esophageal reflux (2-fold); unspecified back disorder (2-fold); and depression (2-fold) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/39,46-48\">",
"     39,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2089857\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable tenderness of the abdominal wall, hip girdle, pelvic floor, bladder base, and urethra is almost universally present in patients with",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    This is likely due to sensitization of afferent nerve fibers in the dermomyotomes (thoracolumbar and sacral) to which the bladder refers. In males, scrotal and penile tenderness may be present. Patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    may experience allodynia (perception of non-noxious stimuli, such as light touch, as being noxious or painful), as with other patients with chronic pain.",
"   </p>",
"   <p>",
"    Many patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    exhibit tenderness or tightness of the pelvic floor muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These abnormalities can be easily identified by palpation of the levator muscles on pelvic examination in women or on rectal examination in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H12621847#H12621847\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Physical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167450\">",
"    <span class=\"h2\">",
"     Urine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    patient will have an unremarkable urinalysis and sterile urine culture. Many patients will have had multiple negative urine cultures since their symptoms of dysuria and frequency often mimic bacterial cystitis. An occasional positive urine culture does not exclude a diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    since the risk of urinary tract infection is the same as in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31166172\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the diagnostic evaluation for interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    is to identify characteristic features and exclude other conditions (see",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    below). The evaluation includes eliciting a history of symptoms and associated conditions, physical examination, and urine testing.",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    does not have any characteristic findings on imaging studies. Cystoscopy is not required to make the diagnosis, but may be used for some patients to exclude other etiologies or identify bladder lesions associated with",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31166218\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should elicit the characteristics of the pain or discomfort (eg, location, duration, relationship to bladder filling or emptying).",
"   </p>",
"   <p>",
"    A voiding and fluid intake log can be helpful to document the frequent, low volume voiding pattern that is characteristic of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    and any relationship of fluid intake to symptoms (",
"    <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Validated symptom scales have been developed to assess",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptom severity and to monitor clinical progress after diagnosis, but these are not helpful in distinguishing",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    from other conditions and are typically used only by specialists for a focused visit regarding",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    or for research. Two such scales are the IC Symptom and Problem Index and the Genitourinary Pain Index [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The IC Symptom and Problem Index is a tandem questionnaire that assesses the severity of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    symptoms and their associated bother. The Genitourinary Pain Index can be used to determine the severity of urologic pain symptoms (including",
"    <span class=\"nowrap\">",
"     IC/BPS)",
"    </span>",
"    in men or women.",
"   </p>",
"   <p>",
"    Element of the medical history related to the bladder should be elicited, including recurrent urinary tract infections or prior pelvic trauma, surgery, or radiation.",
"   </p>",
"   <p>",
"    Clinical manifestations that suggest conditions other than",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    should be identified and evaluated as appropriate (eg, fever, urinary incontinence). (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31166979\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough physical examination of patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is of critical importance in making a diagnosis and to exclude other conditions that may be causing or contributing to the symptoms, such as urethral diverticula, urogenital prolapse, and urogenital cancer. (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exquisite tenderness may make it impossible to perform an adequate digital rectal examination or, in women, an adequate pelvic examination. In this situation, for patients who meet diagnostic criteria for",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    clinicians may choose to begin empiric treatment and to defer full examination until symptoms have either improved to the point where examination is possible or until symptoms have failed to respond to usual therapies and evaluation for other etiologies requires examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167125\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167184\">",
"    <span class=\"h3\">",
"     Urine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis with microscopy should be performed in all patients with suspected",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    to exclude infection and hematuria. A urine culture should be performed if the urinalysis results suggest urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the urine for chlamydia, which can cause dysuria, is reserved for patients at risk of sexually transmitted infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H11#H11\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Dysuria-pyuria syndrome due to urethritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=see_link&amp;anchor=H5248350#H5248350\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\", section on 'Urethritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hematuria is present, urine cytology and cystoscopy are required to exclude urinary tract malignancy or other pathology. Up to 33 percent of patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    have gross hematuria, and a prevalence as high as 41 percent has been reported when microscopic hematuria is included [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/34,53\">",
"     34,53",
"    </a>",
"    ]. There are few available data regarding the rate of urinary tract malignancy in patients with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    and patients with hematuria, and the risk is likely similar to the general population (12.7 percent of patients with hematuria in a study from a hematuria clinic) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H319447\">",
"     'Role of cystoscopy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A postvoid residual urine volume should be measured, either using a catheter (usually avoided due to associated pain) or by ultrasound. Urinary retention due to bladder outlet obstruction or neurologic dysfunction may result in bladder pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167237\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiproliferative factor (APF) and other biomarkers requires further validation; they are not currently used in clinical settings. Several serum biomarkers are being considered for potential use in diagnosing",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    The most promising marker is APF, which may be involved in the pathogenesis of",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    In a study in which urine from 219 patients with symptomatic IC was compared with that from 324 controls without IC, the sensitivity and specificity of APF for a diagnosis of IC was 94 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28423492\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167645\">",
"    <span class=\"h2\">",
"     Tests not routinely recommended",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167654\">",
"    <span class=\"h3\">",
"     Potassium sensitivity test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potassium sensitivity test has been proposed by some researchers as useful for diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/56\">",
"     56",
"    </a>",
"    ], but is not recommended for routine use since its results are nonspecific for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, the test can be extremely painful to the patients, and there is no consistent evidence that the results provide additional information to guide treatment above and beyond the standard diagnostic tests listed above.",
"   </p>",
"   <p>",
"    During this test, 40 mL of sterile water is instilled into the bladder via a catheter, and note is made of any associated pain. The bladder is drained and then filled with 40 mL of 0.4 M",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ; a finding of increased pain during this second fill is considered indicative of bladder hypersensitivity and suggestive of",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167662\">",
"    <span class=\"h3\">",
"     Instillation of lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    into the bladder has been described as an &ldquo;anesthetic bladder challenge.&rdquo; With this test, improvement of symptoms after lidocaine instillation is considered suggestive of the presence of",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    However, as with the potassium sensitivity test, data are lacking to correlate these test results with treatment response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31167670\">",
"    <span class=\"h3\">",
"     Urodynamic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urodynamic testing has a limited role in the diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    There are no standard urodynamic criteria for the diagnosis of the condition, and the testing may cause significant patient discomfort. However, in certain patients in whom there is clinical uncertainty about the diagnosis, urodynamic testing can be helpful as part of the diagnostic process. As an example, urodynamic testing may help to guide therapy in patients with bladder pain symptoms who also have urinary incontinence or have evidence of poor bladder emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13715198\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    is a clinical diagnosis based upon the presence of characteristic symptoms, typically characterized by bladder discomfort associated with bladder filling, and the exclusion of other etiologies of the symptoms. (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The American Urological Association guidelines use the following definition for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      is an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination findings contribute to the clinical picture, but are not necessary to make the diagnosis. Urinalysis, urine culture, and a postvoid residual are performed to exclude other etiologies. Cystoscopy is not required to make the diagnosis, but may add information regarding the presence of intravesical findings consistent with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may be indicated to exclude other conditions. (See",
"    <a class=\"local\" href=\"#H2089857\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31167125\">",
"     'Laboratory tests'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H319447\">",
"     'Role of cystoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The definition and diagnostic criteria for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    have varied widely over the past few decades (",
"    <a class=\"graphic graphic_table graphicRef66969 \" href=\"UTD.htm?33/16/34060\">",
"     table 2",
"    </a>",
"    ). It is likely that refinement of terminology will continue to occur as the understanding of this condition increases.",
"   </p>",
"   <p>",
"    Before 2002,",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    was defined in research settings according to the criteria of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), using the so-called &ldquo;NIDDK criteria&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef66969 \" href=\"UTD.htm?33/16/34060\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/58\">",
"     58",
"    </a>",
"    ]. The NIDDK criteria were soon recognized as being too restrictive for general use, which led to the development of less restrictive definitions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13715206\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    includes other conditions that result in chronic bladder pain or discomfort.",
"   </p>",
"   <p>",
"    Excluding malignancy is the main priority in the evaluation of patients with bladder pain. Bladder pain with or without hematuria is a common presentation of bladder cancer. Urethral cancer is rare, but may also present with urethral or bladder pain with or without hematuria. In addition, hematuria may be a sign of malignancy in other parts of the urinary tract. The absence of a mass on physical examination does not reliably exclude urinary tract cancer. Thus, all patients undergoing evaluation for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    who have hematuria and those without hematuria who have risk factors for bladder cancer should undergo evaluation with urine cytology and cystoscopy to exclude malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=see_link\">",
"     \"Urethral cancer in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=see_link\">",
"     \"Urethral cancer in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital tract cancers may also cause",
"    <span class=\"nowrap\">",
"     suprapubic/perivesical",
"    </span>",
"    pain, as well as other urinary symptoms due to the presence of a pelvic mass and pressure on or invasion into the bladder. Appropriate evaluation should be performed for gynecologic or prostate cancers, depending upon physical examination findings and risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benign pelvic masses may cause bladder discomfort and urinary symptoms. In women, uterine leiomyomas are a common condition that may cause bladder pressure or pain. Physical examination findings consistent with a pelvic mass should be further evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H5287048#H5287048\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Bulk-related symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravesical pathology may result in bladder pain or discomfort, such as a bladder stone or other foreign object. Risk factors for bladder stones include chronic bladder catheterization, ureteral stents, renal transplantation, and some medications (eg, fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Patients with a history of pelvic surgery may have erosion of suture material or surgical mesh into the bladder wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link&amp;anchor=H34#H34\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\", section on 'Graft erosion or extrusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urethral diverticulum is another potential etiology of bladder pain or discomfort. Patients with this condition typically have postvoid dribbling of urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link\">",
"     \"Urethral diverticulum in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with urinary retention due to bladder outlet obstruction or neurologic dysfunction may experience bladder pain. A postvoid residual is used to evaluate for urinary retention. (See",
"    <a class=\"local\" href=\"#H31167184\">",
"     'Urine tests'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary symptoms such as dysuria, frequency, or urgency may be the result of acute cystitis or urethritis. Fever is not part of the symptoms of",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    and patients with fever should be evaluated for an infectious etiology of their symptoms. Fever is also absent in most patients with cystitis and urethritis, and patients with chronic urinary tract infection or urethritis may have chronic intermittent symptoms that mimic",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    Urinalysis and culture should be performed to exclude bacterial cystitis. Chlamydial or gonococcal urethritis may be suspected in patients at risk of sexual transmitted diseases, and urine testing or urethral culture should be performed. (See",
"    <a class=\"local\" href=\"#H31167184\">",
"     'Urine tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with overactive bladder syndrome may present with urinary urgency, but typically do not have bladder pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conditions that do not typically present with bladder pain and therefore are not part of the differential diagnosis for",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    include: urogenital fistula in women and benign prostatic hyperplasia in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319447\">",
"    <span class=\"h1\">",
"     ROLE OF CYSTOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is not required to make the diagnosis of interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS),",
"    </span>",
"    and is typically performed if other conditions are suspected initially or to further exclude other diagnoses if patients do not respond to treatment with oral medications. In addition, for patients who do not respond to initial therapy, cystoscopic treatment with hydrodistention or fulguration of intravesical lesions associated with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H12621896#H12621896\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Third-line therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H284358#H284358\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Oral medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319796\">",
"    <span class=\"h2\">",
"     Excluding other etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    who have hematuria should undergo cystoscopy and urinary cytology to exclude bladder malignancy. Bladder biopsy should be performed if there are findings suggestive of malignancy. (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who fail to respond to initial treatment for",
"    <span class=\"nowrap\">",
"     IC/BPS,",
"    </span>",
"    cystoscopic examination also allows identification of an intravesical foreign body or structural lesion (eg, bladder stone, erosion of surgical mesh). (See",
"    <a class=\"local\" href=\"#H13715206\">",
"     'Differential diagnosis'",
"    </a>",
"    <span class=\"nowrap\">",
"     above.)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10805495\">",
"    <span class=\"h2\">",
"     Identification of characteristic bladder lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IC/BPS",
"    is associated with several characteristic intravesical lesions. The diagnostic value of cystoscopy in",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    is the identification of the small subset of patients who have not responded to oral medications and who have Hunner lesions that will respond to cystoscopic treatment. Findings of other characteristic lesions are helpful only to support the diagnosis of",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H12621896#H12621896\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Third-line therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link&amp;anchor=H284358#H284358\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\", section on 'Oral medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intravesical findings associated with",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hunner lesions (reddened lesions on the bladder mucosa with attached fibrin deposits; typically bleed after hydrodistention)",
"     </li>",
"     <li>",
"      Glomerulations (petechial red areas)",
"     </li>",
"     <li>",
"      Increased numbers of mast cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To identify Hunner lesions or glomerulations, cystoscopy is performed with direct visualization before and after hydrodistention and biopsies are taken of suspected lesions. Increased numbers of mast cells are not associated with a visual finding, but may be found on biopsy. For hydrodistention, patients are placed under anesthesia and the bladder is filled with water or saline until 70 to 80 cm of water pressure is reached, usually at a bladder volume that is far greater than an awake patient can tolerate. This bladder dilation is maintained for several minutes, then the dilating fluid is released and the bladder is refilled. During this second bladder fill, the bladder epithelium is examined cystoscopically for characteristic findings of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    and biopsies are performed at these sites.",
"   </p>",
"   <p>",
"    In some regions of the world, and historically in the United States, cystoscopy with bladder biopsy and hydrodistention are part of the routine evaluation of patients with suspected",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. The cystoscopic findings are used to classify patients into subgroups based upon the presence or absence of intravesical findings associated with",
"    <span class=\"nowrap\">",
"     IC/BPS.",
"    </span>",
"    There is no evidence that subclassification of",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    patients in this manner provides meaningful information about prognosis or treatment response. Data suggest that some of the findings on biopsy may be due to the hydrodistention procedure itself [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, confirmation of these lesions requires deep muscle biopsies, which carry the risk of bladder perforation.",
"   </p>",
"   <p>",
"    Evaluation with cystoscopy identifies Hunner lesions in only 5 to 10 percent of patients. For this subset of patients, fulguration of the lesions may help alleviate symptoms.",
"   </p>",
"   <p>",
"    Glomerulations are of limited diagnostic value, since they are a nonspecific finding (eg, one study found glomerulations in 45 percent of healthy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/65\">",
"     65",
"    </a>",
"    ]) and their presence does not correlate well with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/8/8330/abstract/64\">",
"     64",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501884\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial diagnostic evaluation of most patients with interstitial",
"    <span class=\"nowrap\">",
"     cystitis/bladder",
"    </span>",
"    pain syndrome",
"    <span class=\"nowrap\">",
"     (IC/BPS)",
"    </span>",
"    may be performed by a primary care clinician. Certain patients with bladder pain symptoms warrant referral to a specialist for additional diagnostic testing, including patients with the following symptoms or characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Complex symptoms (eg, pain and urinary incontinence)",
"     </li>",
"     <li>",
"      Incomplete bladder emptying",
"     </li>",
"     <li>",
"      A neurologic disorder that may affect bladder function",
"     </li>",
"     <li>",
"      Prior pelvic radiation",
"     </li>",
"     <li>",
"      Prior pelvic surgery",
"     </li>",
"     <li>",
"      Have not responded to initial treatment with oral medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specialists with expertise in",
"    <span class=\"nowrap\">",
"     IC/BPS",
"    </span>",
"    include urologists and urogynecologists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th&nbsp;to 6th&nbsp;grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th&nbsp;to 12th&nbsp;grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/11/20658?source=see_link\">",
"       \"Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"       \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/22/17764?source=see_link\">",
"       \"Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28423605\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial",
"      <span class=\"nowrap\">",
"       cystitis/bladder",
"      </span>",
"      pain syndrome",
"      <span class=\"nowrap\">",
"       (IC/BPS)",
"      </span>",
"      is defined as an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes. (See",
"      <a class=\"local\" href=\"#H13715198\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      is more common in women than in men. (See",
"      <a class=\"local\" href=\"#H28423485\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristics of the bladder pain or discomfort in patients with",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      are variable, but the most consistent feature is an increase in discomfort with bladder filling and a relief with voiding. (See",
"      <a class=\"local\" href=\"#H2089812\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common physical examination findings include widespread tenderness of the abdominal wall, hip girdle, buttocks, thighs, and pelvic floor, as well as tenderness of the bladder base",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urethra. (See",
"      <a class=\"local\" href=\"#H2089857\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinalysis with microscopy should be performed in all patients to exclude significant hematuria and infection. Urine culture can be obtained if the urinalysis results are suspicious for infection. Cystoscopy, hydrodistention, bladder biopsy, and potassium sensitivity testing are not necessary for diagnosis of",
"      <span class=\"nowrap\">",
"       IC/BPS.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13715198\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H319447\">",
"       'Role of cystoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      is a clinical diagnosis based upon the presence of characteristic symptoms and the exclusion of other etiologies of the symptoms. Physical examination findings contribute to the clinical picture, but are not necessary to make the diagnosis. Urinalysis, urine culture, and postvoid residual are essential to exclude other etiologies. Cystoscopy is not required to make the diagnosis, but may add information regarding the presence of intravesical findings consistent with",
"      <span class=\"nowrap\">",
"       IC/BPS",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      may be indicated to exclude other conditions. (See",
"      <a class=\"local\" href=\"#H13715198\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/1\">",
"      Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am 1994; 21:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/2\">",
"      Konkle KS, Berry SH, Elliott MN, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol 2012; 187:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/3\">",
"      Parsons CL, Tatsis V. Prevalence of interstitial cystitis in young women. Urology 2004; 64:866.",
"     </a>",
"    </li>",
"    <li>",
"     Clemens JQ, Joyce GF, Wise M, Payne C. Interstitial Cystitis and Painful Bladder Syndrome. In: Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Litwin MS, Saigal CS (Eds), Washington, DC 2007. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/5\">",
"      Payne CK, Joyce GF, Wise M, et al. Interstitial cystitis and painful bladder syndrome. J Urol 2007; 177:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/6\">",
"      Clemens JQ, Meenan RT, Rosetti MC, et al. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol 2005; 173:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/7\">",
"      Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011; 186:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/8\">",
"      Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn 1975; 64:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/9\">",
"      Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients. J Urol 1993; 149:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/10\">",
"      Simon LJ, Landis JR, Erickson DR, Nyberg LM. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology 1997; 49:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/11\">",
"      Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011; 185:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/12\">",
"      Clemens JQ, Link CL, Eggers PW, et al. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol 2007; 177:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/13\">",
"      Warren JW, Keay SK, Meyers D, Xu J. Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs. Urology 2001; 57:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/14\">",
"      Tunitsky E, Barber MD, Jeppson PC, et al. Bladder pain syndrome/interstitial cystitis in twin sisters. J Urol 2012; 187:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/15\">",
"      Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int 2012; 109:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/16\">",
"      Slobodov G, Feloney M, Gran C, et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol 2004; 171:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/17\">",
"      Graham E, Chai TC. Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis. Curr Urol Rep 2006; 7:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/18\">",
"      Hurst RE, Roy JB, Min KW, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology 1996; 48:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/19\">",
"      Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol 1997; 158:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/20\">",
"      Erickson DR, Herb N, Ordille S, et al. A new direct test of bladder permeability. J Urol 2000; 164:419.",
"     </a>",
"    </li>",
"    <li>",
"     Hohlbrugger, G. Dinsintegrity of the vesical block-urine barrier in interstitial cystitis: a vicious circle. In: Interstitial Cystitis, Sant, GR (Eds), Lippincott-Raven, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/22\">",
"      Hurst RE, Moldwin RM, Mulholland SG. Bladder defense molecules, urothelial differentiation, urinary biomarkers, and interstitial cystitis. Urology 2007; 69:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/23\">",
"      Parsons CL, Stein P, Zupkas P, et al. Defective Tamm-Horsfall protein in patients with interstitial cystitis. J Urol 2007; 178:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/24\">",
"      Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 2007; 69:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/25\">",
"      Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/26\">",
"      Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/27\">",
"      Keay S, Takeda M, Tamaki M, Hanno P. Current and future directions in diagnostic markers in interstitial cystitis. Int J Urol 2003; 10 Suppl:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/28\">",
"      Keay S, Zhang CO, Shoenfelt JL, Chai TC. Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis. Urology 2003; 61:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/29\">",
"      Wesselmann U. Interstitial cystitis: a chronic visceral pain syndrome. Urology 2001; 57:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/30\">",
"      Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007; 69:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/31\">",
"      Ustinova EE, Fraser MO, Pezzone MA. Colonic irritation in the rat sensitizes urinary bladder afferents to mechanical and chemical stimuli: an afferent origin of pelvic organ cross-sensitization. Am J Physiol Renal Physiol 2006; 290:F1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/32\">",
"      Lilius HG, Oravisto KJ, Valtonen EJ. Origin of pain in interstitial cystitis. Effect of ultrasound treatment on the concomitant levator ani spasm syndrome. Scand J Urol Nephrol 1973; 7:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/33\">",
"      Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007; 177:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/34\">",
"      Teichman JM, Parsons CL. Contemporary clinical presentation of interstitial cystitis. Urology 2007; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/35\">",
"      FitzGerald MP, Brensinger C, Brubaker L, et al. What is the pain of interstitial cystitis like? Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/36\">",
"      Rothrock NE, Lutgendorf SK, Kreder KJ, et al. Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology 2001; 57:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/37\">",
"      Powell-Boone T, Ness TJ, Cannon R, et al. Menstrual cycle affects bladder pain sensation in subjects with interstitial cystitis. J Urol 2005; 174:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/38\">",
"      Tsai CF, Ouyang WC, Tsai SJ, et al. Risk factors for poor sleep quality among patients with interstitial cystitis in Taiwan. Neurourol Urodyn 2010; 29:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/39\">",
"      Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, et al. Case-control study of medical comorbidities in women with interstitial cystitis. J Urol 2008; 179:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/40\">",
"      McCormack WM. Two urogenital sinus syndromes. Interstitial cystitis and focal vulvitis. J Reprod Med 1990; 35:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/41\">",
"      Fitzpatrick CC, DeLancey JO, Elkins TE, McGuire EJ. Vulvar vestibulitis and interstitial cystitis: a disorder of urogenital sinus-derived epithelium? Obstet Gynecol 1993; 81:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/42\">",
"      Tarr G, Selo-Ojeme DO, Onwude JL. Coexistence of vulvar vestibulitis and interstitial cystitis. Acta Obstet Gynecol Scand 2003; 82:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/43\">",
"      Gardella B, Porru D, Nappi RE, et al. Interstitial cystitis is associated with vulvodynia and sexual dysfunction--a case-control study. J Sex Med 2011; 8:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/44\">",
"      Kahn BS, Tatro C, Parsons CL, Willems JJ. Prevalence of interstitial cystitis in vulvodynia patients detected by bladder potassium sensitivity. J Sex Med 2010; 7:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/45\">",
"      Bogart LM, Suttorp MJ, Elliott MN, et al. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology 2011; 77:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/46\">",
"      Nickel JC, Tripp DA, Pontari M, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol 2010; 184:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/47\">",
"      Buffington CA. Comorbidity of interstitial cystitis with other unexplained clinical conditions. J Urol 2004; 172:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/48\">",
"      Rodr&iacute;guez MA, Afari N, Buchwald DS, National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2009; 182:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/49\">",
"      Peters KM, Carrico DJ, Kalinowski SE, et al. Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. Urology 2007; 70:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/50\">",
"      Bassaly R, Tidwell N, Bertolino S, et al. Myofascial pain and pelvic floor dysfunction in patients with interstitial cystitis. Int Urogynecol J 2011; 22:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/51\">",
"      O'Leary MP, Sant GR, Fowler FJ Jr, et al. The interstitial cystitis symptom index and problem index. Urology 1997; 49:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/52\">",
"      Clemens JQ, Calhoun EA, Litwin MS, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology 2009; 74:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/53\">",
"      Gomes CM, S&aacute;nchez-Ortiz RF, Harris C, et al. Significance of hematuria in patients with interstitial cystitis: review of radiographic and endoscopic findings. Urology 2001; 57:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/54\">",
"      Stanford EJ, Mattox TF, Parsons JK, McMurphy C. Prevalence of benign microscopic hematuria among women with interstitial cystitis: implications for evaluation of genitourinary malignancy. Urology 2006; 67:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/55\">",
"      Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/56\">",
"      Parsons CL. Argument for the use of the potassium sensitivity test in the diagnosis of interstitial cystitis. For. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/57\">",
"      Hanno P. Is the potassium sensitivity test a valid and useful test for the diagnosis of interstitial cystitis? Against. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:428.",
"     </a>",
"    </li>",
"    <li>",
"     Wein AJ, Hanno PM, Gillenwater JY. Interstitial Cystitis: An Introduction to the Problem. In: Interstitial Cystitis: Current Concepts, anno PM, Staskin DR, Krane RJ, Wein AJ (Eds), Springer-Verlag, London 1990. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/59\">",
"      Schwartz BF, Stoller ML. The vesical calculus. Urol Clin North Am 2000; 27:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/60\">",
"      Yudkoff BL, Linsenmeyer TA, Oakley A, Kirshblum S. Urolithiasis associated with indinavir in a patient with spinal cord injury. J Spinal Cord Med 2004; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/61\">",
"      Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2005; 66:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/62\">",
"      Fall M, Peeker R. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2006; 68:236; author reply 236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/63\">",
"      van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008; 53:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/64\">",
"      Tomaszewski JE, Landis JR, Russack V, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology 2001; 57:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/8/8330/abstract/65\">",
"      Parsons CL, Greenberger M, Gabal L, et al. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol 1998; 159:1862.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8085 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8330=[""].join("\n");
var outline_f8_8_8330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28423605\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28423471\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4802765\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28423485\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28423492\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28423499\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2089812\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H318782\">",
"      Coexisting conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2089857\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31167450\">",
"      Urine tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31166172\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31166218\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31166979\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31167125\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31167184\">",
"      - Urine tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31167237\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31167645\">",
"      Tests not routinely recommended",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31167654\">",
"      - Potassium sensitivity test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31167662\">",
"      - Instillation of lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31167670\">",
"      - Urodynamic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13715198\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13715206\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H319447\">",
"      ROLE OF CYSTOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H319796\">",
"      Excluding other etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10805495\">",
"      Identification of characteristic bladder lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1501884\">",
"      INDICATIONS FOR REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28423605\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/8085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/8085|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/30/4591\" title=\"figure 1\">",
"      Voiding diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/8085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/53/40795\" title=\"table 1\">",
"      IC BPS clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/16/34060\" title=\"table 2\">",
"      Criteria for PBS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=related_link\">",
"      Chronic prostatitis/chronic pelvic pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=related_link\">",
"      Clinical manifestations and diagnosis of generalized vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=related_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/11/20658?source=related_link\">",
"      Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=related_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/22/17764?source=related_link\">",
"      Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=related_link\">",
"      Urethral cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=related_link\">",
"      Urethral cancer in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_8_8331="Evaluation bronchiectasis 3";
var content_f8_8_8331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-3",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specific examples",
"      </td>",
"      <td class=\"subtitle1\">",
"       Diagnostic tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Childhood infections",
"      </td>",
"      <td>",
"       Pertussis; measles",
"      </td>",
"      <td>",
"       History of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial infections",
"      </td>",
"      <td>",
"       Infections due to Staphylococcus aureus, Klebsiella, Pseudomonas aeruginosa",
"      </td>",
"      <td>",
"       History of infection; sputum culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Viral infections",
"      </td>",
"      <td>",
"       Infections due to adenovirus (particularly types 7 and 21), influenza, herpes simplex",
"      </td>",
"      <td>",
"       History/serologic evidence of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other infections",
"      </td>",
"      <td>",
"       Fungal (histoplasmosis); Mycobacterium tuberculosis, nontuberculous mycobacteria; possibly mycoplasma",
"      </td>",
"      <td>",
"       Fungal culture; AFB smear and mycobacterial culture",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFB: acid-fast bacilli.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8331=[""].join("\n");
var outline_f8_8_8331=null;
var title_f8_8_8332="Support nonsupport dx MSA";
var content_f8_8_8332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features supporting (red flags) and not supporting a diagnosis of MSA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Supporting features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orofacial dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disproportionate antecollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Camptocormia (severe anterior flexion of the spine) and/or Pisa syndrome (severe lateral flexion of the spine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contractures of hands or feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inspiratory sighs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe dysphonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe dysarthria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        New or increased snoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cold hands and feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pathologic laughter or crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jerky, myoclonic postural/action tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nonsupporting features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Classic pill-rolling rest tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clinically significant neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hallucinations not induced by drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onset after age 75 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history of ataxia or parkinsonism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dementia (on DSM-IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White matter lesions suggesting multiple sclerosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSA: multiple system atrophy; y: year; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.",
"    </div>",
"    <div class=\"reference\">",
"     Gilman, S, Wenning, GK, Low, PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8332=[""].join("\n");
var outline_f8_8_8332=null;
var title_f8_8_8333="Causes spontaneous pneumothorax";
var content_f8_8_8333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of spontaneous pneumothorax",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Primary pneumothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Asthenic body habitus/subpleural blebs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drug use",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cigarette smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Snorting cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Smoking marijuana",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Increased transpulmonary pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valsalva maneuver",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diving, military flying",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary pneumothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Airway disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic obstructive pulmonary disease (COPD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pneumocystis carinii (jirovecii)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Necrotizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Congenital lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital pulmonary adenomatous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital lobar emphysema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Langerhans'-cell granulomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Marfan's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ehlers-Danlos syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Polymyositis or dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Metastatic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Airway obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Foreign body aspiration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Thoracic endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Catamenial pneumothorax",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8333=[""].join("\n");
var outline_f8_8_8333=null;
var title_f8_8_8334="Assessment of the red eye";
var content_f8_8_8334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of the red eye",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acuity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Foreign body sensation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Photophobia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Discharge",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardinal feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treat/refer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Lids/lashes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stye/hordeoleum",
"       </td>",
"       <td>",
"        Nl",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Tender",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chalazion",
"       </td>",
"       <td>",
"        Nl",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Nontender",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blepharitis",
"       </td>",
"       <td>",
"        Nl",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Dry crusting",
"       </td>",
"       <td>",
"        Chronic",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Conjunctiva",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"7\" rowspan=\"1\">",
"        Conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bacterial",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nl",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        Mucopurulent",
"       </td>",
"       <td class=\"sublist_other\">",
"        Discharge all day",
"       </td>",
"       <td class=\"sublist_other\">",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Viral",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Mucoserous",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        None/URI",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Allergic",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Mucoserous",
"       </td>",
"       <td class=\"sublist_other\">",
"        Itching",
"       </td>",
"       <td class=\"sublist_other\">",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Non-specific (toxic or dry eye syndrome)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nl",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        Watery",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Episcleritis",
"       </td>",
"       <td>",
"        Nl",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Sectoral injection, dull ache",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subconjunctival hemorrhage",
"       </td>",
"       <td>",
"        Nl",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Extravasated &nbsp;blood",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Cornea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abrasion",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Watery",
"       </td>",
"       <td>",
"        History/trauma defect revealed by fluorescein",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contact lens overwear",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Watery",
"       </td>",
"       <td>",
"        History",
"       </td>",
"       <td>",
"        Treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreign body",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Mucoserous",
"       </td>",
"       <td>",
"        History/trauma",
"       </td>",
"       <td>",
"        Treat initially by attempt to remove by irrigation or swab; refer if still present after 24 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"7\" rowspan=\"1\">",
"        Infectious keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bacterial",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nl or down",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        Muco-purulent",
"       </td>",
"       <td class=\"sublist_other\">",
"        White spot on cornea spots stains w/fluorescein",
"       </td>",
"       <td class=\"sublist_other\">",
"        Refer, same day/ emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Viral",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nl or down",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        Watery",
"       </td>",
"       <td class=\"sublist_other\">",
"        Gray, branching opacity dendrite; dendrite revealed w/fluorescein",
"       </td>",
"       <td class=\"sublist_other\">",
"        Refer, 1 to 2 days/ urgent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Anterior chamber/iris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iritis",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        None/watery",
"       </td>",
"       <td>",
"        Miotic pupil",
"       </td>",
"       <td>",
"        Refer, 1 to 2 days/urgent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyphema",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        None/watery",
"       </td>",
"       <td>",
"        RBC \"level\"",
"       </td>",
"       <td>",
"        Refer, same day/emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypopyon",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        None/purulent",
"       </td>",
"       <td>",
"        WBC \"level\"",
"       </td>",
"       <td>",
"        Refer, same day/emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Iris/lens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angle closure",
"       </td>",
"       <td>",
"        Nl or down",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        None/watery",
"       </td>",
"       <td>",
"        Fixed, mid-dilated pupil",
"       </td>",
"       <td>",
"        Refer, same day/emergent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8334=[""].join("\n");
var outline_f8_8_8334=null;
var title_f8_8_8335="Mechanism of HCO3 reabsorption";
var content_f8_8_8335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 669px\">",
"   <div class=\"ttl\">",
"    Mechanisms of bicarbonate reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 649px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Major cellular and luminal events in bicarbonate reabsorption in proximal tubules (left panel) and collecting tubules (right panel). Intracellular H2O dissociates into H",
"    <sup>",
"     +",
"    </sup>",
"    and OH",
"    <sup>",
"     -",
"    </sup>",
"    ions, and the latter combines with CO2 to form HCO3",
"    <sup>",
"     -",
"    </sup>",
"    via a reaction catalyzed by carbonic anhydrase (CA). In the proximal tubule, the steep electrochemical gradient for sodium, created by Na-K-ATPase, allows H",
"    <sup>",
"     +",
"    </sup>",
"    ions to be secreted into the lumen in exchange for sodium via the Na",
"    <sup>",
"     +",
"    </sup>",
"    -H",
"    <sup>",
"     +",
"    </sup>",
"    exchanger. The HCO3",
"    <sup>",
"     -",
"    </sup>",
"    ions which are generated in these cells move into the peritubular capillary primarily via a Na",
"    <sup>",
"     +",
"    </sup>",
"    -3HCO3",
"    <sup>",
"     -",
"    </sup>",
"    cotransporter. The H",
"    <sup>",
"     +",
"    </sup>",
"    ions, which enter the proximal tubule lumen, combine with filtered HCO3",
"    <sup>",
"     -",
"    </sup>",
"    to form carbonic acid (H2CO3). The dissociation of the carbonic acid is facilitated by intraluminal CA which is tethered to the membrane. The CO2 and H2O which form are passively reabsorbed. Secretion of H",
"    <sup>",
"     +",
"    </sup>",
"    is matched by equimolar addition of HCO3",
"    <sup>",
"     -",
"    </sup>",
"    to the extracellular fluid. Note that HCO3",
"    <sup>",
"     -",
"    </sup>",
"    ions which enter the peritubular capillaries are not actually the filtered ions; however, the net effect is to reclaim filtered HCO3 and return it to the circulation.",
"    <br>",
"     <br>",
"      In the type A intercalated cells of the distal convoluted connecting and collecting tubules, H",
"      <sup>",
"       +",
"      </sup>",
"      and HCO3",
"      <sup>",
"       -",
"      </sup>",
"      are generated by a similar intracellular process catalyzed by CA (right panel). However, the pumps and transporters which move these ions into the lumen and peritubular capillary differ from those in proximal tubule cells. An H",
"      <sup>",
"       +",
"      </sup>",
"      -ATPase pump in the luminal membrane drives H",
"      <sup>",
"       +",
"      </sup>",
"      secretion, and, driven by their electrochemical concentration gradients, cellular bicarbonate enters the peritublar capillary in exchange for extracelluar chloride via a Cl",
"      <sup>",
"       -",
"      </sup>",
"      -HCO3",
"      <sup>",
"       -",
"      </sup>",
"      exchanger in the basolateral membrane (AE-1 or Anion Exchanger-1). Some of the secreted H",
"      <sup>",
"       +",
"      </sup>",
"      ions combine with bicarbonate ions in the tubular lumen, completing the process of reclaiming filtered bicarbonate, which began in the proximal tubule. Some of the secreted H",
"      <sup>",
"       +",
"      </sup>",
"      ions combine with NH3 to form NH4 and with HPO4",
"      <sup>",
"       -",
"      </sup>",
"      2 to form H2 PO4",
"      <sup>",
"       -",
"      </sup>",
"      , generating new HCO3",
"      <sup>",
"       -",
"      </sup>",
"      (beyond that which was filtered) for transport to the peritubular capillaries. The type A intercalated cells also have H",
"      <sup>",
"       +",
"      </sup>",
"      -K",
"      <sup>",
"       +",
"      </sup>",
"      -ATPase pumps in the luminal membrane that are involved in both acid secretion and, perhaps more importantly, K",
"      <sup>",
"       +",
"      </sup>",
"      reabsorption (not shown).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_8_8335=[""].join("\n");
var outline_f8_8_8335=null;
